1.8 - **"-relin" versus "-relix"** — 1.8 - **"-tide" stem** — 1.8 - ****"98% / 99% purity by HPLC"**** — 37.5 (science), 37.6 - ****"AI has revolutionized drug discovery"**** — 37.6 - **"AI has revolutionized drug discovery" (claim form) ⚠️** — ch35 §35.8 - ****"disclosing all substance use to a tre → Appendix L — Index
"AI has revolutionized drug discovery"
37.6 - **"disclosing all substance use to a treating clinician improves care"** — 37.6, 37.5 (In the Clinic callout), 37.8 (safety callout) - **"immune modulation"** — 37.5 (infectious) - **"it isn't on the banned list"** — 37.6; FR Tier 3 - **"it's approved in [another country]"** — 37.6 - **"it's → Index contributions — Chapter 37
"Antimicrobial peptide" vs. "host defense peptide"
the chapter introduces both and uses AMP as the primary term, noting that HDP is preferred where immunomodulation is the focus. Later chapters should follow the same convention. 2. **"Peptide antibiotic"** is used for the approved agents (colistin, daptomycin, vancomycin, etc.) and describes **compo → Continuity — Chapter 25
"approved peptide drugs"
recommend the master index route that phrase here rather than to Ch 37, with a *see also* to Ch 37's master table. - The **six functional boxes** taxonomy originates here and recurs in Ch 37. Suggest a single index entry ("functional taxonomy of approved peptide drugs") pointing at both, with 29.10 → Index entries — Chapter 29
"approximately 0.2"
deliberately hedged. ⚠️ **Verify exact HR and CI against the paper before final print.** - Chapter states long-term follow-up **did not demonstrate a statistically significant OS benefit**, affected by crossover. Verify against the published final OS analysis. - Also cite: the long-term overall surv → Bibliography notes — Chapter 27
"Binding was never the bottleneck."
**The general rule:** *a technology that improves one stage of a pipeline improves the whole pipeline only if that stage was the constraint.* This is intended to be portable and quotable; Chapter 36 and the closing chapters may reuse it verbatim. - **Origin carries no evidentiary weight whatsoever.* → Continuity — Chapter 35
"Breadth of use is not breadth of approval"
coined here; reusable. 7. **Case reports as a harm-detection instrument** now has a full worked application (§24.6) that later gray-market chapters can cite. → Continuity notes — Chapter 24
"cataloged" (§39.4, question 2)
house style is American; consider *cataloged*. Only spelling variant found. 2. **Peri-operative currency (§39.2, reason 3).** Written to age well — it states that guidance began in 2023, has been revised, and has moved from a blanket hold toward individualized assessment, without naming an interval. → Continuity Record — Chapter 39: Talking to Your Doctor About Peptides
a paraphrased popular claim, set against the real evidence - **"Read this study"** — interpret an abstract: design, population, endpoint, limitation - **"Compare the evidence"** — two peptides, one indication, one standard applied to both - **"Identify the red flags"** — an unreliable source, dissec → How to Use This Book
"food noise"
the persistent, > intrusive, background preoccupation with food. Not hunger exactly, and not appetite in the simple > sense. The mental *loop*: planning the next meal, thinking about what is in the kitchen, the > effortful negotiation with oneself that some people conduct many times a day. > > Patie → Chapter 7: The Incretin System: GLP-1, GIP, and How Your Gut Tells Your Brain You're Full
the evidence exists and is negative. A strictly stronger claim than the above. *Ch 28's nesiritide is the canonical instance.* → Glossary contributions — Chapter 39
not a technical term. It creates an impression of centrality that licenses the rest of the argument without asserting anything checkable. 2. **"Restoring your levels to where they were at 25"** — the age-adjusted-versus-youthful reference range move (§14.4). Comparing a 55-year-old to a 25-year-old' → Chapter 14 — Worked Solutions
"Nobody knows"
a fact about the *world*. The trial has not been run. This is ❌, kind: evidence absent. It is compatible with the compound working spectacularly. It licenses nothing, but it forecloses nothing either, and it identifies precisely what would resolve it: the trial nobody ran. → Chapter 40: Your Peptide Evidence Dossier — Putting It All Together
"not approved" has five distinct meanings
never submitted, submitted and rejected, approved elsewhere only, used off-label, or not regulated as a drug at all. Have students assign compounds to those five bins from their own dossiers. The exercise collapses the category, and "never submitted" and "submitted and rejected" sitting in different → Where Students Get Stuck
a category term borrowing credibility from insulin and semaglutide, exactly > as Chapter 1 warned. It carries no evidentiary weight whatsoever. > > **"Physician-supervised"** — true, and irrelevant to whether the claim is supported. Supervision > addresses safety monitoring, not efficacy. It is a re → Chapter 14: Growth Hormone — What It Does, How It Declines, and the Science of the "Youth Hormone"
self-reported, subjective, unblinded. Expectation drives this directly. - **"Improvement"** is undefined. Improvement in what, measured how, by how much? - **"Clinical study"** is not a protected term and does not imply randomization, blinding, or registration. - **87% is a proportion of responders* → Answers — Chapter 5
"roughly half or more, varying by load"
stated as a range, never a percentage - incretin effect **substantially reduced** in T2D — direction only, no figure → Continuity notes — Chapter 7
"Smart insulin"
glucose-responsive insulin that self-regulates its activity according to surrounding glucose — would be the genuine solution, since it would restore glucose-dependence to a molecule that lacks it. It has been pursued for decades. **As of this writing it remains investigational, and it is rated 🔬.** → Chapter 11: Insulin: The Original Peptide Drug — 100 Years of Saving Lives
"The female Viagra" is wrong three times
wrong about mechanism, wrong about the target complaint, and wrong about magnitude. The third error does the most damage, because it sets up an expectation the drug cannot meet. - A response problem can be an early sign of vascular disease elsewhere, which is why treating it purely as a bedroom issu → Chapter 24 — Key Takeaways
"The same active ingredient"
sometimes true of the molecule, and silent about identity, purity, concentration accuracy, sterility, and stability, which is where the documented harm has actually been (Chapters 19 and 34). - **"Compounded"** — a real and long-standing pharmacy practice, invoked so as to imply the assurances of an → Chapter 42: The Creator Economy and the Peptide Pipeline
that is a distinction worth naming aloud for the whole room, because it is the difference between epistemology and ethics, and this book is careful about which one it is doing at any moment. → Instructor notes — Chapter 31
"what would change your mind about this?"
the same question field 12 asks. A student who can answer it is a specific skeptic and should score well. A student who cannot, and who deflects the question repeatedly, is holding a position immune to evidence, and that is scored *Insufficient* on criterion 4 no matter how accurate their objections → Rubric — Participation and Discussion
"What would change your mind?"
the repair move for a category dismissal, and the same question Field 12 of the Evidence Dossier asks. Informative in all three of its usual answers. → Glossary contributions — Chapter 39
strongest and the only real one; then **(3) approved elsewhere, not here** — ambiguous, and worth almost nothing until you know which story applies; then **(1) never submitted**, **(4) approved but not for this use**, and **(5) not a drug at all**, which carry no signal about the molecule at all. De → Chapter 38 — Answers to selected exercises
(3) Approved elsewhere
thymosin alpha-1 (Chapter 18) is this book's standing example. **(5) Not a drug at all** covers three genuinely different regimes, which §G.8 separates. → Appendix G — Regulatory and Legal Quick Reference
(a) A patient deciding whether to start
**treatment-regimen.** They are deciding whether to be prescribed the drug, and the probability that they will be among those who stop is part of what they are deciding about. Giving them the efficacy figure conditions on an outcome they cannot guarantee. → Answers — Chapter 9
(A) Studied and disappointing
someone looked and the answer was unfavorable. The most informative state. - **(B) Not studied** — tells you about funding, incentives, and regulatory status; nothing about efficacy. - **(C) Studied in a different molecule** — a parent, a different route, a different species. **The most dangerous st → Chapter 18 — Key Takeaways
(Checked.)
[ ] No fabricated statistic appears in the chapter or its files; all numeric claims in Chapter 40 are restatements of figures already established in Appendix C. **(Checked.)** → Bibliography contributions — Chapter 40
(d) A marketing department
the **efficacy** figure, because it is larger. This is not a criticism; it is a prediction, and it is why an unnamed figure should be assumed to be this one. → Answers — Chapter 9
Cardiovascular death alone and heart failure hospitalization alone both moved in the same direction - All-cause mortality **17.0 versus 19.8 percent**, hazard ratio **0.84** - More symptomatic hypotension; less cough, less hyperkalemia, less renal impairment than enalapril - Angioedema uncommon in b → Case Study 28.2 — PARADIGM-HF: Why Preserving the Peptide Beat Supplying It
1. Claim specificity
every rating attaches to a claim with a **population** and an **endpoint** (Rule 1) | Every claim names a population and an endpoint precisely enough that a reader could tell whether a given trial tested it. Populations are the ones actually studied, not silently broadened. | Population and endpoint → Rubric — The Peptide Evidence Dossier
1. Insulin for type 1 diabetes. ✅
the strongest ✅ in the book, established 1922 without > randomization. Figure 11.1 explains why that was legitimate and why it is not a precedent. → Continuity notes — Chapter 11
🧬 ×2 (§20.1, §20.2), 🔍 ×2 (§20.2, §20.4), 💊 ×1 (§20.3), 🔬 Read the Study ×2 (Figure 20.1 in §20.5, Figure 20.2 in §20.7), 📊 ×4 (§20.5, §20.7, §20.8, §20.9), ⚠️ ×1 (§20.8), 🩺 ×1 (§20.6). Within the 8–12 band. - Figures: **20.1** (runner's high, contested) and **20.2** (naloxone placebo, landmark) in → Continuity notes — Chapter 20
13 hours
long enough > for once-daily dosing, short enough that the drug substantially clears between doses. > > **Semaglutide** (Chapter 8). The same architecture, deliberately intensified: an **18-carbon > diacid** instead of a simple 16-carbon fatty acid, and a longer, more flexible spacer built from a > → Chapter 33: Peptide Engineering — How Scientists Modify Peptides to Make Better Drugs
154 ratings
140 attached to molecules or indications, 14 attached to *claim forms*. Ten of them are **split ratings** shown with a slash, and four are claims the book explicitly declines to rate. They are stated as the source chapters state them, with the same wording, the same qualifiers, and the same split ve → Appendix A — The Master Peptide Evidence Table
baseline assessment — **19.7**; irreproducible after the fact 19.7 - batch release — **19.1**; and recall path 19.1, 19.8 - BPC-157 — 19.2 (laundering example); dossier Field 10 worked entry (dossier); Ch 17 cross-ref 19.10 → Index entries — Chapter 19
19.4
two axes (evidence × preparation) — **19.10**; diagram 19.10 - two-in-the-morning test — **19.7** → Index entries — Chapter 19
19.8
release (batch) — see batch release - reporting pathway, absence of — **19.8** - "research use only" — **19.2** - residual solvents and process chemicals — **19.3** → Index entries — Chapter 19
19.9
anti-drug antibodies — **19.3**; cross-reactivity with endogenous peptide 19.3; misread as tolerance 19.3, 19.7 - aseptic processing — 19.3 - attribution error — **19.7**; both directions dangerous 19.7; requires a record 19.8 → Index entries — Chapter 19
1960s
reliable insulin assays make the oral-versus-intravenous comparison possible. The incretin effect is demonstrated. The hypothesis is vindicated after roughly half a century. → Case Study 1 — Forty Years of Nobody Caring
1970s
GIP is identified and characterized. Initially named for an inhibitory effect on gastric secretion, later renamed for its insulinotropic action — a name change that records a shift in understanding. → Case Study 1 — Forty Years of Nobody Caring
the first recombinant DNA drug approved anywhere. Approval records are public via Drugs@FDA. → Chapter 11 — Further Reading
1989
first U.S. approval, for strabismus and blepharospasm (as Oculinum). - **2002** — approval for temporary improvement of glabellar lines: the cosmetic indication. - **2010** — approval for chronic migraine prophylaxis. → Continuity record — Chapter 30 (Cosmetic Peptides)
1990s
exendin-4 is characterized from Gila monster venom and recognized as a DPP-4-resistant GLP-1 receptor agonist (Chapter 4, Case Study 1). → Case Study 1 — Forty Years of Nobody Caring
2-aminoisobutyric acid (Aib)
A non-proteinogenic amino acid: alanine bearing a second methyl group on the alpha carbon. The extra methyl sterically blocks proteases and favors helical backbone geometry. Because no codon or tRNA encodes it, its presence forces chemical rather than ribosomal synthesis. — Ch 33 §33.2 → Glossary contributions — Chapter 33 (Peptide Engineering)
2. Leptin for common obesity. ❌
and note explicitly **the evidence is not absent but > negative**: trials were run and produced modest, inconsistent effects, because circulating leptin is > already elevated and the problem is resistance. → Continuity notes — Chapter 13
roughly two decades later. The molecule that made the class a subject of general conversation, approved at a weight-management dose in **2021**, arrived **more than a decade after that**. Between the identification and the household name lies something on the order of thirty-five years, populated by → Appendix J — A Timeline of Peptide Science
*the criterion this rubric exists for* | **Has visibly revised a position in response to evidence at least twice**, said so out loud, and named what moved them. Treats revision as a result rather than a concession. Distinguishes "I was wrong" from "the evidence changed." | Has revised at least once → Rubric — Participation and Discussion
it asks students to attack the tool they were just given, and the correct answer (the filter would have rejected oral semaglutide; it is a burden-shifting device rather than a verdict) requires understanding both what the tool does and what it does not. A student who defends the filter unconditional → Instructor material — Chapter 4
40
capstone workshop | C (full) | **Full assembly; drift statement drafted** | Peer review, in class | | 29 | Capstone presentations | L, N | Revision from peer review | Presentation (assessed) | | 30 | Review and close | M | **Dossier due, final version** | **Final exam** (cumulative, weighted Parts I → Syllabus — Two-Semester Sequence
A rule of thumb from the dermatology literature holding that molecules above roughly 500 daltons penetrate intact skin poorly. A heuristic and a strong prior, not a law; lipophilicity, charge, vehicle, and barrier integrity all modify it. Most cosmetic peptides exceed the threshold. *(Ch 30 §30.2)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
503A
traditional pharmacy compounding in the United States, performed on patient-specific prescriptions and exempt from certain requirements including premarket approval (Ch. 38). → Chapter 38 — Glossary fragment
503A (US)
Traditional pharmacy compounding for an identified individual patient on a patient-specific prescription. Exempt from certain requirements applying to manufactured drugs, including premarket approval. No premarket review of safety or efficacy (§G.7). → Appendix G — Regulatory and Legal Quick Reference
503A compounding pharmacy
Prepares medications for individually identified patients under valid prescriptions; regulated primarily by state boards of pharmacy; exempt from CGMP and premarket approval. — Ch 19 §19.5 (introduced Ch 6, Ch 12) → Glossary contributions — Chapter 19
503A pharmacy
a compounding pharmacy preparing medications for individually identified patients pursuant to a prescription. (Ch.6) → Glossary fragments — Chapter 6
503B outsourcing facility
a compounder permitted to produce larger batches without patient-specific prescriptions, subject to more stringent manufacturing requirements than a 503A. (Ch.6) → Glossary fragments — Chapter 6
503B outsourcing facility (US)
A category created by federal legislation in 2013 for larger-scale compounders. Registers federally, may compound without patient-specific prescriptions, may distribute to healthcare facilities, and is subject to current good manufacturing practice requirements and federal inspection. **Still no pre → Appendix G — Regulatory and Legal Quick Reference
Long-term malignancy risk is **unresolved**. Mechanism is adverse; observational IGF-1 > associations exist but confounding is substantial and causation is not established; acromegaly shows > real harm at much higher, decades-long exposure. Open question, not a documented effect. → Chapter 14 — Worked Solutions
[background]
general framing of neuropeptides as drug targets and of the difficulties; supports the section's framing and the chapter's overall thesis. - Hökfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M. "Neuropeptides — an overview." *Neuropharmacology* (2000). **[background]** — co-transmission, dens → Bibliography contributions — Chapter 22
[cited in Further Reading]
hypocretins. - Sakurai T, Amemiya A, Ishii M, et al. *Cell* (1998). **[cited in Further Reading]** — orexins. The two 1998 papers together support the dual-naming statement. - Lin L, Faraco J, Li R, et al. *Cell* (1999). **[cited in Further Reading]** — canine narcolepsy and the OX2R mutation. - Che → Bibliography contributions — Chapter 22
[cited in text as FIGURE 22.2]
the provocation study. The 🔬 Read the Study box describes this design generically; if it is ever attributed by name, the hedged title should be quoted, since the chapter makes a point of the hedge. - Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. "Pathophysiology of M → Bibliography contributions — Chapter 22
[cited in text, described not named]
original identification; the "P" for powder naming. - Chang MM, Leeman SE, Niall HD. "Amino-acid sequence of substance P." *Nature New Biology* (1971). **[cited in text, described not named]** — sequence determination in the early 1970s. - Hill R. "NK1 (substance P) receptor antagonists — why are th → Bibliography contributions — Chapter 22
[cited in text]
isolation; family relationship to PYY and PP. - Reviews of NPY receptor subtypes and energy balance (e.g. in *Physiological Reviews*, *Neuropeptides*, *Progress in Neurobiology*). **[background]** — Y1/Y5 in feeding; Y2 as presynaptic autoreceptor; arcuate NPY/AgRP co-expression and leptin inhibitio → Bibliography contributions — Chapter 22
[constructed teaching example]
the following describes no real study, product, or company. The numbers are invented for teaching and should not be cited as findings. → Case Study 2 — The Vehicle Problem
[EXT]
a drug blocking inhibitory signals that restrain T cells. Not a peptide; the near-universal partner of cancer vaccines in current trials and the source of the attribution problem. §26.5, §26.7 → Glossary contributions — Chapter 26 (Peptide Vaccines)
[NEW]
the component of a vaccine that supplies the innate danger signal required to convert antigen exposure into a durable response. For peptide vaccines, frequently the entire difference between a response and nothing. §26.4 → Glossary contributions — Chapter 26 (Peptide Vaccines)
a short blockquote noting what the five tracks (💊 GLP-1, 🏋️ Performance, 🔬 Science, 💄 Cosmetic, 🏥 Clinical) should weight in this chapter. 4. **Numbered sections `## N.1 … ## N.x`** (typically 7–10), following `00-outline.md`. Each substantial section carries at least one callout and, where the topi → Style & Continuity Bible — Understanding Peptides
`_scratch/ALL-RATINGS.md`
every `📊 Evidence Rating` callout in the book, verbatim, in chapter order. **The source of truth for Chapter 37 and Appendix A.** - **`_scratch/RATINGS-INDEX.md`** — one line per rating, split into molecule ratings and claim-form ratings, with a tally. → Continuity Ledger — Understanding Peptides
`_scratch/glossary/chNN.md`
each first-defined term as `**Term** — definition. (Ch.N)`, one per block, blank-line separated. - **`_scratch/index/chNN.md`** — lines `- Topic — N.1, N.3` (chapter.section refs). - **`_scratch/answers/chNN.md`** — worked solutions to the daggered (†) and odd-numbered exercises, under `## Exercise → Style & Continuity Bible — Understanding Peptides
**25–40** items, graduated and mixed, drawn from the config's five interactivity modes: **"Evaluate this claim"** (a paraphrased popular claim, analyzed against the evidence); **"Read this study"** (interpret a constructed or real abstract — design, endpoints, results, limitations); **"Compare the e → Style & Continuity Bible — Understanding Peptides
`🧬 The Molecule`
the structural and chemical detail: sequence features, size, folding, what makes this molecule this molecule. Where the biochemistry lives. - **`🔬 Read the Study`** — the signature six-field device (§3.1) applied to a specific study, trial, or claim-presented-as-evidence. - **`📊 Evidence Rating`** — → Style & Continuity Bible — Understanding Peptides
the **treatment-regimen** estimand. *"What happens if a doctor prescribes this?"* > Counts everyone as randomized, including those who stopped. > > **~−22.5%** — the **efficacy** estimand. *"What happens if you take it, for the full period?"* > Restricted to those who remained on treatment. > > **Sa → Chapter 9 — Key Takeaways
§15.1
The one thing to drill is that a single random GH measurement is nearly uninterpretable. Students consistently under-appreciate this and it recurs in every later evaluation task. Consider opening with the exercise 15.2 scenario before any lecture. → Chapter 15 — Instructor Notes
§15.2
The DAC mechanism is a good place to reward students who remember albumin binding from Chapter 4. The high-value item is the **two-molecules-one-name** problem; students find it genuinely surprising and it generalizes to the whole gray market. → Chapter 15 — Instructor Notes
§15.3
The "selective therefore safe" Hype Check is the chapter's clearest example of a valid premise supporting an invalid conclusion. Worth diagramming on a board: *selectivity is a claim about receptors; safety is a claim about people over time.* → Chapter 15 — Instructor Notes
§15.4
Emphasize **MK-677 is not a peptide** early and repeatedly; it appears on quizzes and students who have absorbed the chapter's framing sometimes over-generalize the peptide arguments to it. Figure 15.1 is the single most important study in the chapter. → Chapter 15 — Instructor Notes
§15.5
The double lesson is easy to half-teach. Students will take away either "tesamorelin proves the class works" or "tesamorelin is irrelevant to the class." Both are wrong and the chapter says so. Make them state both halves in one sentence before moving on. → Chapter 15 — Instructor Notes
§15.6
Do not shortcut the steelman. Have students produce the four-point pro-secretagogue argument *before* you present any counter-argument (exercise 15.14 is designed for this). If you present the counter-arguments first, students will produce a weak steelman and the section will teach nothing. → Chapter 15 — Instructor Notes
§15.7
The seven-step diagram should end up on a board, reproduced from memory, more than once. Every subsequent claim-evaluation exercise in the course can be run against it. → Chapter 15 — Instructor Notes
§18.1
polymerization, and cell motility — ch18 §18.1 - α-MSH (alpha-melanocyte-stimulating hormone) — ch18 **§18.5** - KPV as C-terminal fragment of — ch18 §18.5 - angiogenesis - as repair mechanism — ch18 §18.7 - as tumor requirement — ch18 **§18.7** - animal research - publication filtering in — ch18 ** → Index entries — Chapter 18
§18.2
purity, identity, and concentration as independent questions — ch18 §18.1 (→ Ch. 34) → Index entries — Chapter 18
§18.3
fragment, peptide - activity transfer as hypothesis — ch18 **§18.1** - KPV studied under its own name — ch18 §18.5 - TB-500 as marketed fragment — ch18 **§18.1** → Index entries — Chapter 18
§18.5
non-absorption as design specification — ch18 **§18.5** - LL-37 — ch18 **§18.4** (→ Ch. 25) - dual antimicrobial and immunomodulatory activity — ch18 §18.4 - membrane selectivity problem — ch18 §18.4 → Index entries — Chapter 18
§18.6
five required specifications — ch18 **§18.6** - rated ❌ as a claim form — ch18 §18.6, §18.8 - immune system, independence of arms — ch18 §18.6 → Index entries — Chapter 18
this is the explicit payoff | | Ch 11 | insulin as first recombinant drug, 1982 | §32.5, Case Study 32.1 | | Ch 11, Ch 12 | the GLP-1 shortage, referenced repeatedly without explanation | **§32.7** — the explanation | | Ch 12 | drug pricing and market structure | §32.8 defers to it explicitly and do → Continuity — Chapter 32
Clinical attrition, causes of — ch35 **§35.10** - Disulfide-stapled architecture — ch35 **§35.2** - Endogenous ligand, inherited selectivity profile — ch35 **§35.5** - Fragments of human proteins, as a discovery route — ch35 §35.5, dossier - Intrathecal administration — ch35 **§35.4** - Intrinsicall → Index entries — Chapter 35
§35.9
Cushman, David — ch35 **§35.4** - Eng, John — ch35 **§35.3** - Hassabis, Demis — ch35 **§35.8** - Jumper, John — ch35 **§35.8** - Ondetti, Miguel — ch35 **§35.4** - Smith, George — ch35 **§35.6** - Winter, Greg — ch35 §35.6 - Zasloff, Michael — ch35 **§35.4** → Index entries — Chapter 35
§39.4, question 4
"Write the answer down, in your dossier, with the date. Chapter 40 will ask you to look back at it, and the looking back is where the learning is." Ch 40 must actually ask for this. 2. **Dossier section, opening** — "Chapter 40 assembles everything." 3. **Dossier section, closing** — "Chapter 40 wil → Continuity Record — Chapter 39: Talking to Your Doctor About Peptides
§40.10
population check → **§40.3 (Check 2)**, CS1 (Defect 1), EX L - press release, does not upgrade → **§40.5**, §40.6, QZ 15 - publication selection → **§40.6**, FR (Tier 3, Turner et al.) → Index contributions — Chapter 40
§40.7 (Use 1)
defects, three planted → **CS1** - deleting entries → §40.5, EX AC - device parameters (wavelength, irradiance, distance) → **CS2 (Fields 1, 4, 10)** - diet, twelve fields applied to → **§40.8** - drift, rating → **§40.6**, §40.5, KT, QZ 16 → Index contributions — Chapter 40
Fast. These are consolidation, not new content. The one item worth dwelling on is why MK-677 outranks CJC-1295 + ipamorelin despite being the less reputable compound. → Chapter 15 — Instructor Notes
† marks an extension exercise
longer, harder, or requiring you to go outside the chapter. Ten of the thirty-two are marked. If you are working through the 💄 Cosmetic path, the daggered items are the ones worth the extra hour. → Chapter 30 — Exercises
−10% at 68 weeks
meaningfully less than in STEP 1, and the book must explain why rather than quoting the larger number for everyone. | | **SELECT** | Semaglutide 2.4 mg in adults with **established cardiovascular disease and overweight or obesity but without diabetes**, followed for **about three years**: a **20% re → Continuity Ledger — Understanding Peptides
① Weight loss is upstream of many diseases
distinguished by whether comparable weight loss achieved by other means produces comparable benefit. **② Direct tissue effects at receptors in heart, kidney, vasculature, and immune cells** — distinguished by whether benefit appears before meaningful weight loss or in people who lose little. **③ Ant → Chapter 10 — Quiz
the tier where the evidence is real and does not settle the question, and therefore the only tier where "what would resolve this?" has a meaningful answer. Then write down, in enough detail that someone could go and run it, **the study that would resolve it.** → Chapter 35: Peptide Discovery — From Venom to Artificial Intelligence
✅ NK1 antagonists for CINV
22.5 - **❌ NK1 antagonists as analgesics or antidepressants** — 22.5 - **✅ CGRP-targeting therapies for migraine prevention** — 22.7 - **✅ Orexin receptor antagonists for insomnia** — 22.6 - **❌ Boosting NPY for stress resilience** — 22.3 → Index contributions — Chapter 22
❌ describes the evidence, not the molecule
extends naturally to *and certainly not the person taking it*. Say that extension out loud in the first week. → How to Teach This Book
❌ from absence
nobody ran the trial. The claim is unsupported. It might be true. - **⚠️ from disappointment** — the trial was run, the pharmacology worked, the outcome did not follow. The claim is not merely unsupported; evidence points away from it, and any future version has to explain this result rather than ig → Chapter 16: IGF-1, Myostatin Inhibitors, and the Muscle-Building Peptides
and note that the ❌ describes the evidence available for the claim as constructed, not a prediction that the drug will disappoint. → Chapter 36 — Worked Answers
A
A baseline
irreproducible after the fact, and the difference between an answer and an argument six months later. 2. **Monitoring matched to the compound** — a compound-specific list exists and somebody has to know which one applies. 3. **Dose adjustment on response and data** — including the recognition that a → Chapter 19 Key Takeaways — The Gray Market
the evidence differs by population and the cost > difference makes the type 2 question consequential. → Continuity notes — Chapter 11
A general review of peptide therapeutics
search for a recent review of the approved peptide drug landscape in a journal such as *Nature Reviews Drug Discovery*, *Drug Discovery Today*, or *Journal of Medicinal Chemistry*. Choose one with a table of approved agents. Read the table before you read the prose, and count how many entries you ha → Chapter 29 Further Reading — The Peptide Drugs Already in Your Pharmacy
A genuinely negative signal
the only one of the five. Not proof of inertness; sponsors sometimes file thin dossiers, and later programs sometimes succeed | | **3** | **Approved elsewhere, not here** | A registered medicine in another jurisdiction | **Ambiguous, and you must ask which.** Either two agencies applied different st → Appendix G — Regulatory and Legal Quick Reference
nothing more. (1) It does not license a rating upgrade, an efficacy claim, or a change in field 6. **Rule 3.** Chapter 22 is the canonical case: a target engaged exactly as designed and no clinical benefit. (1) → Practical Evaluation Exam — Open Book
and a claim can be an argument or a form of words as easily as it can be a molecule. 2. **❌ describes the evidence, not the molecule** — nor the person who tried it. 3. **Never upgrade with mechanism.** A plausible pathway is a reason to run a trial, not a substitute for one. 4. **Never downgrade wi → Appendix A — The Master Peptide Evidence Table
a recall requires knowing who has the product.
Chapter 10's asymmetry (observational data is strong for harms, weak for benefits) **depends entirely on a collection system existing.** Remove it and you get no evidence at all, which looks identical to a clean safety record. - 📊 **"Nobody has reported problems with this source, so it's safe" — ❌.* → Chapter 19 Key Takeaways — The Gray Market
A ⚠️ can read like a ✅
retatrutide's weight number is larger than tirzepatide's approved one — and the tier is the warning that the number is sitting on a weaker footing than its size suggests. → Appendix A — The Master Peptide Evidence Table
A1C
8.2 - **A1C as surrogate** — 8.2 - **abarelix** — 27.3, case study 27.2, naming, withdrawal from US market - ****absence of evidence**** — distinguished from negative evidence → 39.6 - **Absence of glucose-dependence** — 11.3, 11.4 - **Absolute risk reduction** — 12.2, 12.8 - **absorption enhancers* → Appendix L — Index
A1C (glycated hemoglobin)
the fraction of hemoglobin with glucose attached, reflecting average blood glucose over roughly three months; the standard endpoint in diabetes trials, and a surrogate for the complications of diabetes. (Ch.8) → Glossary fragments — Chapter 8
A2 — the one number (4 points).
**What was measured:** users' *reports* of smoother-looking skin — a self-reported, subjective appearance measure, not an objective one. (1.5) - **Who measured it:** the users themselves, in a study run by the seller, with no blinding described. (1.5) - **What it was compared against:** **the page d → Practical Evaluation Exam — Open Book
A4 — origin and mechanism (2 points, 1 each).
**Origin:** "a fragment of a structural protein your body already makes." Field 2 — origin carries no evidentiary weight. Letting it raise the rating is the field-2 error. - **Mechanism:** "signals your skin to produce more of its own collagen." **Rule 3 — mechanism never upgrades a rating.** → Practical Evaluation Exam — Open Book
Abaloparatide
a synthetic analog of parathyroid hormone-related protein, PTHrP(1–34), acting at the PTH type 1 receptor; an anabolic bone agent related to but distinct from teriparatide. (Ch 29) → Glossary contributions — Chapter 29
abarelix
US approval 2003, subsequent withdrawal from the US market. ⚠️ Verify the withdrawal year and the stated reasons; chapter says "within a couple of years, with systemic allergic reactions among the concerns." - FDA: **melphalan flufenamide** — accelerated approval 2021 for a multiple myeloma indicati → Bibliography notes — Chapter 27
absence of evidence
distinguished from negative evidence → 39.6 - **alternatives, including doing nothing** — as comparator question → 39.4 (question 3); in enthusiastic-clinic setting → CS 39.2 - **anesthesia** — *see* peri-operative considerations; sedation - **appointment length** — as structural pressure → 39.1; as → Index entries — Chapter 39
Absolute event rates in both groups
50% fewer than what? Two flares versus four is a very different finding from twenty versus forty. - **How a "flare" was defined**, and whether it was defined the same way in both groups. In a historical observational cohort, almost certainly not. - **How many participants contributed** to each figur → Practical Evaluation Exam — Open Book
Absolute risk reduction
the difference in risk between groups, in percentage points; the figure that determines what an individual can expect. (Ch.5) → Glossary fragments — Chapter 5
Absorption enhancer
an excipient co-formulated with a drug to increase its absorption across an epithelial barrier, making oral delivery of a molecule that would otherwise be destroyed or excluded partially possible. → Chapter 36 — Glossary Contributions
Accelerated approval
A conditional regulatory approval granted on the basis of a surrogate endpoint, carrying an obligation to confirm clinical benefit in a subsequent trial. It can be, and sometimes is, withdrawn. *First defined: Ch 27 §27.7.* Cross-ref: Ch 5 (evidence hierarchy), Ch 36. → Glossary contributions — Chapter 27
Accelerated blood clearance
The phenomenon in which a repeat dose of a PEGylated agent is eliminated substantially faster than the first, because antibodies raised against PEG have marked it for removal. — Ch 33 §33.5 → Glossary contributions — Chapter 33 (Peptide Engineering)
reflects what is evaluable, not a judgment that the research is poor | | Cerebrolysin for functional or cognitive outcomes in stroke or dementia | ⚠️ | **conflict-limited** — accessible trials and meta-analyses that disagree | | Dihexa or P21 for cognition in humans | ❌ | no completed human trials; → Chapter 23 — Key Takeaways
Acetyl hexapeptide-8
A six-residue cosmetic peptide of roughly 890 daltons derived from a portion of SNAP-25; also designated acetyl hexapeptide-3 and marketed under the ingredient trade name Argireline. Proposed to compete with SNAP-25 in SNARE complex assembly. *(Ch 30 §30.5)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
acetylated
capped with an acetyl group. This removes the free amine's positive charge and, importantly, removes the recognition feature that aminopeptidases use to begin chewing a peptide from its N-terminal end. → Appendix I — Peptide Nomenclature and How to Read a Sequence
Achondroplasia
the most common form of disproportionate short stature, caused by a gain-of-function mutation in the *FGFR3* gene that over-suppresses chondrocyte proliferation at the growth plate. The target population for the approved CNP analog. [Ch 28] → Glossary contributions — Chapter 28
Acromegaly
Chronic growth hormone excess in adulthood, almost always caused by a benign pituitary adenoma. Produces soft-tissue and skeletal overgrowth, arthropathy, cardiomyopathy, insulin resistance and diabetes, sleep apnea, increased colonic polyps, and reduced life expectancy that improves with biochemica → Ch14
Acromegaly outcome and mortality literature
cohort studies and national registries following patients over years to decades, consistently showing excess mortality relative to general populations and, critically, substantial improvement with biochemical control. This gradient is the causal backbone of §14.8. → Chapter 14 — Further Reading
The region of thymosin β4 that interacts with actin; the structural basis of the short fragment marketed as TB-500. A motif is not a molecule: a fragment containing a functional region is not automatically a functional molecule. *Ch 31 §31.2; developed in Ch 18.* → Glossary contributions — Chapter 31
activated complexes
receptor plus bound peptide plus the intracellular G protein it signals through, captured together in the active conformation. These were essentially unobtainable before. They show not merely where a peptide sits, but which of its residues contact which parts of the receptor, how the receptor's heli → Chapter 35: Peptide Discovery — From Venom to Artificial Intelligence
A compound that converts an amino acid's carboxyl group into a much more reactive form so that peptide bond formation proceeds at a useful rate during a coupling step. Different activating chemistries differ in speed, hazard at scale, and how much racemization they provoke. [Ch 32 §32.2] → Glossary contributions — Chapter 32
Active comparator
a control arm receiving a treatment already known to work, rather than placebo. The hardest test and the most useful result, which is why Chapter 28's sacubitril/valsartan trial changed practice. → Chapter 36 — Glossary Contributions
The drug substance itself, before formulation. Its provenance determines whether anything downstream of it can be trusted. (Ch.12) → Ch12
Activin A
A TGF-β superfamily member signaling through ActRIIB, involved in reproductive signaling, inflammation, and fibrosis. One of the off-targets of broad myostatin-pathway blockade. — *Ch 16 §16.3* → Glossary contributions — Chapter 16
Activin receptor type IIB (ActRIIB)
The type II receptor through which myostatin signals, shared with activin A and GDF-11. Blockade at this receptor is potent and unselective, which is the source of both the larger effect sizes and the safety signals seen with decoy-receptor approaches. — *Ch 16 §16.3* → Glossary contributions — Chapter 16
activity at MC4R and at other
subtypes
it is not a clean, single-subtype tool. Its central effects are attributed principally to MC4R and MC3R signaling in the hypothalamus; its pigmentation effects to residual MC1R activity. Melanotan II sits further toward the MC1R end of the same continuum, which is precisely why it tans more and why → Chapter 24: PT-141 (Bremelanotide) and the Sexual Function Peptides
actual paper, or its abstract
not an article about it. The gap between a study and the coverage of a study is where most public misunderstanding of medicine is manufactured; a press release describing a mouse experiment and a news article describing the press release are two degrees of separation, and by the second one the mice → Chapter 39: Talking to Your Doctor About Peptides
the clinical entity is opioid use disorder — is a different thing. It is defined by a pattern of behavior: compulsive use, loss of control over use, craving, and continued use despite harm. It involves reward and reinforcement circuitry, particularly mu receptor effects on dopaminergic signaling in → Chapter 20: Endorphins, Enkephalins, and the Opioid Peptides — Your Body's Natural Painkillers
Addiction (opioid use disorder)
a clinical diagnosis defined by a behavioral pattern: compulsive use, loss of control over use, craving, and continued use despite harm. Involves reward and reinforcement circuitry along with genetic, environmental, and social contributors. Distinct from physical dependence, and a treatable medical → Glossary contributions — Chapter 20
address
a targeting element whose selective binding delivers a payload where the receptor is and, crucially, delivers less of it everywhere else. Its job is not to have an effect; its job is to arrive somewhere specific. → Chapter 36 — Worked Answers
after surgery, when imaging shows no evident disease but recurrence risk is high, sometimes selected by circulating tumor DNA. There are good reasons to expect that setting to be the most favorable: tumor burden is lowest, the immunosuppressive microenvironment left with the tumor, the immune system → Chapter 26: Peptide Vaccines — Cancer Immunotherapy and Infectious Disease Prevention
Growth hormone deficiency arising in or persisting into adult life, usually from pituitary disease, pituitary surgery, cranial radiation, or traumatic brain injury. (Ch.14) → Ch14
Advanced in Ch. 4, 7, 8, 9, 32, 33, 36.
**The BPC-157 evidence gap.** Genuinely impressive rodent data across tendon, gut, and vascular models — and, as of this writing, no completed peer-reviewed randomized human trial in the published literature. The book's central case study in reading a gap honestly: the animal data is real, the human → Style & Continuity Bible — Understanding Peptides
Advanced in Ch. 6, 12, 19, 34, 38.
**The Ozempic conversation.** A friend asks the reader: "should I take this?" The book returns to this scene repeatedly, and the reader's answer gets better each time — from "I don't know" in Chapter 1 to a structured, evidence-cited, appropriately humble answer that ends with *"and here is what I'd → Style & Continuity Bible — Understanding Peptides
Adverse event report
A submitted account of a suspected harm associated with a medicine. Consumer reports are accepted by FDA MedWatch, the UK Yellow Card scheme, and comparable systems. — Ch 19 §19.8 → Glossary contributions — Chapter 19
Adverse event reporting
The mechanisms by which harms observed after a product reaches the market are collected and reviewed. What matters here is the absence: for gray-market compounds there is no reporting pathway, so "no reported side effects" describes silence rather than safety (Chapter 19). → Appendix G — Regulatory and Legal Quick Reference
adverse events
absence of reporting pathway through a creator → 42.6 - invisible denominator in visible testimony → 42.6 → Index entries — Chapter 42
advertising, direct-to-consumer
for approved drugs, rules governing → 42.7, case study 2 - for compounded preparations → 42.8, case study 1 - permitted in only two countries → case study 2 §1 - fair balance requirement → 42.7, case study 2 §2 - major statement (broadcast) → case study 2 §2 - adequate provision → case study 2 §2 → Index entries — Chapter 42
A linear analog of α-MSH with high MC1R activity, approved to increase pain-free light exposure in adults with erythropoietic protoporphyria. Formulated as a slow-release subcutaneous implant. — Ch 24 §24.5 → Glossary contributions — Chapter 24
affiliate marketing
payment forms (per click, per signup, per fill, revenue share, retainer, code, equity) → 42.3 - and retention alignment → 42.3, 42.9 - disclosure requirements → 42.3 - as step-2 economics in the funnel → 42.1 → Index entries — Chapter 42
Affinity
how tightly a ligand binds its receptor. High affinity means binding occurs at lower concentrations and persists longer. (Ch.2) → Glossary fragments — Chapter 2
Aggregation
the clumping together of peptide molecules in solution, which reduces active drug and substantially increases immunogenic risk. (Ch.4) → Glossary fragments — Chapter 4
an endogenous MC4R blocker released by hypothalamic neurons that leptin inhibits; blocking the receptor increases hunger. (Ch.13) → Glossary fragments — Chapter 13
attachment of a drug to albumin, the most abundant blood protein, dramatically extending half-life by defeating renal filtration and shielding the drug from proteases. (Ch.4) → Glossary fragments — Chapter 4
Albumin binding (as a design strategy)
Reversible, non-covalent association of a lipidated peptide with plasma albumin (~66,000 Da). Confers resistance to renal filtration, shields the peptide from proteases, and creates a slowly releasing circulating reservoir. — Ch 33 §33.4 → Glossary contributions — Chapter 33 (Peptide Engineering)
repeated controlled exposure, by injection or under the tongue, escalating over years — is an established treatment for several allergic conditions and can produce lasting benefit after the course ends. It has two well-known drawbacks: it takes a long time, and because it uses the whole allergen it → Chapter 26: Peptide Vaccines — Cancer Immunotherapy and Infectious Disease Prevention
Allometric scaling
the non-linear conversion of dose between species based on body mass and metabolic rate; the reason a milligram-per-kilogram figure in a rat does not correspond to the same figure in a human. (Ch.17) → Glossary fragments — Chapter 17
a coiled secondary structure with approximately 3.6 residues per turn and side chains projecting outward; the most common shape in peptide hormones. (Ch.1) → Glossary fragments — Chapter 1
Alpha-melanocyte-stimulating hormone (α-MSH)
The endogenous melanocortin peptide, cleaved from proopiomelanocortin, that signals melanocytes to produce pigment and participates in central appetite regulation. — Ch 24 §24.1 → Glossary contributions — Chapter 24
AlphaFold
DeepMind's computational method for predicting protein structure from amino acid sequence. AlphaFold2 produced a decisive result at the CASP14 blind assessment in 2020; the work led to a share of the 2024 Nobel Prize in Chemistry for Demis Hassabis and John Jumper. *(Ch 35)* → Glossary contributions — Chapter 35
and then defend the ambiguous ones. The defense is where the learning happens: weight is a surrogate for cardiovascular and metabolic outcomes, *and* it is arguably a patient-relevant outcome in itself, and the fact that a class can argue about it for fifteen minutes is exactly the sophistication yo → Where Students Get Stuck
Amino acid
the building block of peptides and proteins: a central (alpha) carbon bearing an amino group, a carboxyl group, a hydrogen, and a variable R group. Twenty are used in human biology. (Ch.1) → Glossary fragments — Chapter 1
Amino acid analysis (AAA)
complete hydrolysis of a peptide followed by separation and quantification of the liberated free amino acids. Establishes *composition*, not sequence. Because it is quantitative and requires only amino acid standards rather than a peptide reference standard, it is also a primary method for determini → Glossary contributions — Chapter 34
Amphipathic
Having spatially segregated hydrophobic and hydrophilic faces. In an α-helical AMP this arises because residues spaced three or four apart in sequence land on the same side of the helix. *(25.2)* → Glossary contributions — Chapter 25
Amplification
the multiplication of signal at each step of a cascade, allowing trace ligand concentrations to produce large cellular responses. (Ch.2) → Glossary fragments — Chapter 2
Amylin
a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells; slows gastric emptying, suppresses postprandial glucagon, and promotes satiety. (Ch.13) → Glossary fragments — Chapter 13
Amylin analog
a compound mimicking amylin, a peptide co-secreted with insulin that slows gastric emptying and promotes satiety. (Ch.9) → Glossary fragments — Chapter 9
An advertisement
from a telehealth service, a clinic, a compounding pharmacy, or a supplement seller. Anything where somebody is paying for your attention. 2. **A video** — short-form or long-form, from a creator rather than an institution. 3. **A comment thread** — under any of the above, or on a forum. Take the wh → Chapter 41: Ozempic Enters the Language
Anabolic agent (bone)
a drug that stimulates new bone formation rather than merely slowing the removal of existing bone. Teriparatide and abaloparatide are the peptide examples; contrast antiresorptive. (Ch 29) → Glossary contributions — Chapter 29
Analgesia
reduction of pain. Where the measurement is a reflex or withdrawal threshold rather than a report, the term used is *antinociception*. — Ch 20 §20.3 → Glossary contributions — Chapter 20
Analog
a molecule deliberately modified from a natural one to change its properties while preserving its activity. Semaglutide is a GLP-1 analog. (Ch.1) → Glossary fragments — Chapter 1
And stopping is the dangerous moment, not starting
the axis > is least able to meet demand immediately after an external supply is withdrawn, which is why > supervised withdrawal exists and why it belongs to a clinician rather than to a schedule found > online. A compound obtained outside medical care arrives with nobody monitoring for any of this. → Chapter 3: The Endocrine System: The Peptide Hormone Orchestra That Runs Your Body
And the indication expanded
dramatically. With supply no longer the constraint, growth hormone moved beyond severe deficiency into other conditions, and eventually into the off-label and anti-aging use that Chapter 14 examines. → Case Study 2 — Cadaver Growth Hormone
which trials, what design, what endpoint? A foreign approval resting on adequate randomized trials with clinical endpoints is strong evidence **because of the trials, not because of the approval.** → Appendix G — Regulatory and Legal Quick Reference
And, crucially, compounds that went the other way
where a modest Phase 2 signal became a substantial Phase 3 result. This is rarer, and it matters because it shows the effect is a distributional bias rather than a law. → Case Study 2 — The Phase 2 Graveyard
Treatment that reduces serum testosterone to castrate levels, used as the backbone of therapy in hormone-sensitive prostate cancer. Most commonly achieved with a peptide GnRH agonist. *First defined: Ch 27 §27.2.* Cross-ref: Ch 3 §3.5. → Glossary contributions — Chapter 27
anergic
switched off for that antigen — or is deleted, or becomes a regulatory cell that actively suppresses responses to it. **You can vaccinate someone into unresponsiveness**, and in the cancer setting that is not hypothetical; it is one plausible explanation for trials in which vaccinated patients, if a → Chapter 26: Peptide Vaccines — Cancer Immunotherapy and Infectious Disease Prevention
swelling of the deeper layers of the skin and mucosa, potentially involving the lips, tongue, and airway. Uncommon but potentially life-threatening. Associated with bradykinin accumulation, which is why it constrains any drug that inhibits bradykinin-degrading enzymes. [Ch 28] → Glossary contributions — Chapter 28
Angiogenesis
the growth of new blood vessels; central to healing in poorly vascularized tissue such as tendon, and the core of BPC-157's proposed unifying mechanism. (Ch.17) → Glossary fragments — Chapter 17
Angiogenesis and tumor biology
§18.7. The blood-supply requirement for tumor growth and the evasion of programmed cell death are foundational and covered by any current hallmarks-of-cancer review. No specific source needed; the argument requires nothing exotic. → Bibliography notes — Chapter 18
annualized growth velocity
a surrogate. Final adult height and functional outcomes are a separate, less settled claim. → Chapter 28 — Key Takeaways
annualized growth velocity over
one year
how fast a child grows during treatment — and nothing beyond it. Chapter 28 is explicit that final adult height and any health or functional outcome are separate claims resting on long-term follow-up that is still accumulating, and they do not inherit this row's symbol.* → Appendix A — The Master Peptide Evidence Table
a 28-amino-acid peptide stored preformed in granules in atrial myocardium and released rapidly in response to atrial stretch. Signals through NPR-A. Very short circulating half-life. [Ch 28] → Glossary contributions — Chapter 28
Antagonist
a ligand that binds a receptor without activating it, blocking access for the natural ligand. (Ch.2) → Glossary fragments — Chapter 2
Anti-drug antibody
an antibody raised against a therapeutic peptide or protein, which may reduce efficacy, neutralize the drug, or cross-react with the patient's own endogenous molecule. (Ch.4) → Glossary fragments — Chapter 4
Anti-drug antibody (ADA)
An antibody raised against an administered therapeutic. May neutralize the drug, and in rare cases may cross-react with the corresponding endogenous molecule. — Ch 19 §19.3 → Glossary contributions — Chapter 19
Anti-PEG antibody
An antibody recognizing polyethylene glycol. Both drug-induced and pre-existing forms are documented; both are associated with accelerated clearance, loss of efficacy, and infusion reactions. — Ch 33 §33.5 → Glossary contributions — Chapter 33 (Peptide Engineering)
Antiandrogen
A drug that blocks the androgen receptor, used alongside a GnRH agonist during the flare window so that a transient testosterone rise cannot reach its target. *Ch 27 §27.2.* → Glossary contributions — Chapter 27
everything ending in **`-mab`** — are not peptides. They are large, folded, glycosylated proteins of many hundreds of residues, and they belong to a different manufacturing world, a different regulatory pathway, and a different set of design problems. Chapter 38 §38.2 draws the working line at rough → Appendix E — Approved Peptide Medicines by Indication
Antidiuretic hormone (ADH)
Alternative name for vasopressin, naming its renal water-retention effect. A nickname of exactly the kind Ch 21 §21.9 warns about, though a comparatively harmless one. *(Ch 21 §21.8)* → Glossary contributions — Chapter 21
A short peptide, typically 12–50 residues, produced as part of innate immunity and capable of killing or inhibiting microorganisms. Usually cationic and amphipathic. Also called a host defense peptide when non-antimicrobial roles are emphasized. *(25.2)* → Glossary contributions — Chapter 25
Antimicrobial stewardship
The practice of restricting antibiotic use to preserve effectiveness. Clinically correct and commercially destructive; the core of the antibiotic market problem. *(25.6)* → Glossary contributions — Chapter 25
Antiproliferative effect
An effect on tumor growth itself, as distinct from control of the symptoms a tumor causes. A separate claim requiring separate evidence. *Ch 27 §27.4.* → Glossary contributions — Chapter 27
Antiresorptive
a drug that slows the removal of existing bone by inhibiting osteoclast activity. Bisphosphonates are the dominant class; denosumab (an antibody) and calcitonin also belong here. (Ch 29) → Glossary contributions — Chapter 29
any medical claim
a peptide, a supplement, a procedure, a screening test, a psychiatric medication, a specialist's recommendation. They are not peptide questions. They separate a claim with evidence behind it from a claim with a story behind it, and memorizing them will serve you for life in settings with nothing to → Chapter 39: Talking to Your Doctor About Peptides
Anything about handling after testing
temperature excursion, aggregation, degradation in transit. 3. **Anything the method did not look for.** A CoA reporting HPLC purity says nothing about endotoxin. 4. **Its own authenticity.** A document is trivially copied or fabricated. → Chapter 34 — Key Takeaways
Apnea-hypopnea index
the number of apnea and hypopnea events per hour of sleep; the standard objective measure of sleep apnea severity. (Ch.10) → Glossary fragments — Chapter 10
Apoptosis
Programmed cell death; the orderly removal of cells the body no longer wants. IGF-1 inhibits it, which is central both to tissue maintenance and to the cancer question about the growth axis. (Ch.14) → Ch14
the dossier: how to assemble everything that is known about a single compound, in order, so that you can produce a rating for something this book never covered. → Appendix A — The Master Peptide Evidence Table
a clinician cutting a topic short is usually triaging, not uninterested - **No clinician can know every compound** — thousands circulate, most with no literature attached - **"I don't know" is professionally expensive** in a system that rewards confidence - None of this is anyone's fault; misreading → Chapter 39 — Key Takeaways
Approval
a regulator's judgment that, for a specified indication and population, the evidence submitted shows benefits outweigh risks, together with an approved label describing that use. Indication-specific, submission-dependent, jurisdiction-specific, and revisable (Ch. 38). → Chapter 38 — Glossary fragment
a rare condition in which a child cannot produce IGF-1 despite normal or elevated GH, usually because the GH receptor or its downstream signaling is defective. These children are profoundly short. Giving them GH does nothing, because the problem is downstream of GH. Giving them IGF-1 works: they gro → Chapter 16: IGF-1, Myostatin Inhibitors, and the Muscle-Building Peptides
approved in a number of countries
notably for hepatitis B, and as an immune adjuvant in some jurisdictions — **and is not FDA-approved in the United States.** → Chapter 18 — Key Takeaways
approved in some
jurisdictions and not others
which is the §E.1 jurisdiction caution stated as a row rather than a warning. Chapter 18 rates it ⚠️, and Chapter 38 §38.4 explains the general principle: "approved elsewhere" is neither a credential nor a refutation. Regulators differ in what evidence they require, what they will accept from which → Appendix E — Approved Peptide Medicines by Indication
Approved indication
The specific use a regulator has reviewed and authorized, written into the label together with its population and conditions of use. (Ch.12) → Ch12
The water channel inserted into the collecting-duct apical membrane in response to V2 signaling; the molecular basis of urine concentration. *(Ch 21 §21.8)* → Glossary contributions — Chapter 21
Arcuate nucleus
the hypothalamic region containing the principal appetite-regulating neuron populations. (Ch.7) → Glossary fragments — Chapter 7
Area percent purity
purity expressed as the target peak's area divided by the total area of all detected peaks in a chromatogram, times 100. The conventional way purity is reported for peptides. Blind to any species the detector does not respond to, and not equivalent to a mass fraction. (§34.3) → Glossary contributions — Chapter 34
Area postrema
a hindbrain region with an incomplete blood-brain barrier, historically identified as the vomiting trigger zone, where circulating peptides can act directly on neurons. (Ch.7) → Glossary fragments — Chapter 7
a drug class combining inhibition of neprilysin with blockade of the angiotensin II receptor. The pairing is mechanistically required, because neprilysin also degrades angiotensin II. [Ch 28] → Glossary contributions — Chapter 28
aromatic side chains
tryptophan, tyrosine, phenylalanine — absorb. The choice matters enormously. At 280 nm, a peptide containing no aromatic residues is nearly invisible; so is a residual solvent, an inorganic salt, or a non-peptide contaminant. At 214 nm you see peptide bonds, which is better for this purpose, but you → Chapter 34: Peptide Analysis and Quality Control — How Anyone Knows What's Actually in the Vial
As a biomarker
"does NT-proBNP concentration indicate cardiac stress and help diagnose heart failure?" Tested by diagnostic accuracy studies comparing the test against a reference standard. Answer: yes, strongly. → Answers — Chapter 3
As a target for potentiation
"does inhibiting the enzyme that degrades natriuretic peptides, raising endogenous levels, improve outcomes in chronic heart failure?" Tested by a different randomized outcome trial. Sacubitril/valsartan succeeded. → Answers — Chapter 3
As an infused therapy
"does giving synthetic BNP improve outcomes in acute decompensated heart failure?" Tested by a randomized outcome trial. Nesiritide was approved and a subsequent large trial did not demonstrate the hoped-for benefits. → Answers — Chapter 3
as of this writing,
in 2026.
**1.** Why can this chapter not rate a claim about whether triple agonists will prevent more cardiovascular events than dual agonists? → Chapter 36 — Quiz
The final manufacturing operation in which a sterile solution is dispensed into sterile containers in a controlled environment. Required when a product cannot be terminally sterilized in its sealed container, which is the case for peptides because heat or radiation would damage the molecule. The bin → Glossary contributions — Chapter 32
Aseptic processing
Manufacturing that maintains sterility throughout the process rather than sterilizing the sealed finished product. Required where terminal sterilization would destroy the product. (Ch.12) → Ch12
aspiration
material entering the airway — during sedation or general anesthesia, when the reflexes that normally protect the airway are suppressed. Aspiration is not a minor complication. → Chapter 39: Talking to Your Doctor About Peptides
Aspiration risk
the risk of stomach contents entering the airway, elevated when the reflexes that normally protect the airway are suppressed by sedation or general anesthesia. The reason retained gastric contents are an anesthetic concern rather than merely a digestive one. *Ch 39 §39.2.* → Glossary contributions — Chapter 39
Associated deaths
In burden-of-disease modeling, all deaths occurring in the presence of the factor, including those that would have occurred anyway. Substantially larger than the attributable figure. *(25.1)* → Glossary contributions — Chapter 25
those subject to an anti-doping code through a federation, a national organization, an event, or an employer that has adopted one. **Many readers of this book are not subject to them at all**, and for those readers the Prohibited List is informational rather than binding. For those who are: **the Li → Appendix G — Regulatory and Legal Quick Reference
Atosiban
An oxytocin receptor antagonist used in some countries as a tocolytic to suppress preterm labor. Illustrates that a shared naming stem identifies a family, not a direction of action (Ch 1 §1.8). *(Ch 21 §21.2)* → Glossary contributions — Chapter 21
attachment
isomers
species with identical molecular formulas, nearly identical masses, different structures, and potentially different receptor activity and pharmacokinetics. → Case Study 33.1: Three Changes to a Hormone
attachment isomer
One of several molecules with identical composition and identical mass that differ only in the position at which a chemical group (such as a fatty acid) has been attached. Extremely difficult to separate or to distinguish by mass spectrometry, which is why semaglutide's design eliminates the possibi → Glossary contributions — Chapter 32
attachment isomers
distinct species with identical formulas, similar masses, different structures, and potentially different activity and pharmacokinetics. Separating them at manufacturing scale is difficult and expensive; controlling their proportions batch to batch is a permanent regulatory burden. → Chapter 33: Peptide Engineering — How Scientists Modify Peptides to Make Better Drugs
Attributable deaths
In burden-of-disease modeling, the excess deaths caused by a factor: those that would not have occurred had the factor been absent. *(25.1)* → Glossary contributions — Chapter 25
Attribution of controllability
The judgment an observer makes about how much a person could have prevented or changed their condition. It is the strongest single predictor of how harshly a condition is stigmatized, and it is the variable through which *both* of Chapter 44's opposing stigma mechanisms operate. *(Ch 44 §44.4)* → Glossary contributions — Chapter 44
the movement of credibility from the context in which it was earned into an unrelated context, notably when a clinical credential appears in a monetized channel where its scope is invisible. → Chapter 42: The Creator Economy and the Peptide Pipeline
judging the likelihood of something by how easily examples come to mind; amplified by search ranking and by testimonial volume. (Ch.6) → Glossary fragments — Chapter 6
Average daily gain (ADG)
Body mass added per day. One of the two primary endpoints of livestock growth-promotion research. *Ch 31 §31.3.* → Glossary contributions — Chapter 31
B
Bacitracin
a cyclic peptide antibiotic, the active agent in most over-the-counter topical antibiotic ointments. (Ch 25, expanded Ch 29) → Glossary contributions — Chapter 29
Backward (debts paid):
**Ch. 11 — insulin case study prediction.** Answered in full at §12.8. Five-feature table reproduced; ①–③ disease properties / ④–⑤ system properties restated; GLP-1 shares ③④⑤, ② partially, **not ①**; consequence developed at length (no attributable deaths → no headlines → no legislation; aggregate → Chapter 12 — Continuity Record
Backward:
**Ch.1** — peptide/protein convention (GH at 191 residues is on the "protein" side of the table yet universally called a peptide hormone); `-tropin` stem from §1.8; the "peptide as a credibility category" thesis; "peptides break down into amino acids" reassurance (reused in exercise D7). - **Ch.3** → Chapter 14 — Continuity Notes
The assay demonstrating that a product meets a numeric endotoxin limit derived from its route and amount of administration. Separate from the sterility test and routinely not performed on research-grade material. — Ch 19 §19.3 → Glossary contributions — Chapter 19
Barrel-stave model
A membrane-disruption mechanism in which peptides insert perpendicular to the surface and assemble into a discrete transmembrane channel lined entirely by peptide. *(25.3)* → Glossary contributions — Chapter 25
the historical frequency of an outcome in a reference class; here, the low proportion of compounds entering human trials that reach approval, which serves as the prior any pipeline claim must move you off before you grant it anything. → Chapter 36 — Glossary Contributions
The documented decision by a qualified person that a manufactured batch conforms to its written specification and may be supplied. The act that converts material into a product and creates traceability and a recall path. — Ch 19 §19.1 → Glossary contributions — Chapter 19
Batch-to-batch variation
you tested *that* batch. - **Chain of custody** — the vial you received is not the vial tested. - **Handling and storage** after testing. - **Aseptic filling** — a process guarantee no end-product test can replace. **You cannot test sterility into a product**: the test is destructive, so it samples, → Chapter 34 — Key Takeaways
Bayliss and Starling (1902)
the secretin experiment, the origin of both endocrinology and gut hormone research. Freely available; see Chapter 3's reading list. → Chapter 7 — Further Reading
several doses are studied and the best-performing is quoted; **regression to the mean** — an unusually good result is more likely to be followed by a less good one; and **shorter duration**, which can flatter an effect that attenuates. → Chapter 9 — Quiz
A radionuclide emitting electrons that travel roughly one to two millimeters in tissue. Lutetium-177 is the chapter's therapeutic example. *Ch 27 §27.5.* → Glossary contributions — Chapter 27
Beta sheet
an extended, pleated secondary structure formed by backbone strands hydrogen-bonded alongside one another. (Ch.1) → Glossary fragments — Chapter 1
Biased agonism
activation of some downstream signaling pathways from a receptor but not others; a design strategy for separating a drug's benefits from its harms. (Ch.2) → Glossary fragments — Chapter 2
Bimagrumab
an antibody against the activin type II receptors — is among the compounds studied in this context. Read the name with Chapter 1 §1.8 in hand: the `-mab` stem means monoclonal antibody. Roughly thirty times the mass of a peptide. Produced in living cell culture rather than by chemical synthesis, wit → Chapter 36 — Case Study 2: The Muscle Question, and the Trial That Would Actually Settle It
Every technique above accelerates **finding a molecule that binds a target**. - **The dominant causes of clinical failure are lack of efficacy in humans and unacceptable toxicity** — and neither is fixed by generating candidates faster. Chapter 9 (Phase 2 optimism), Chapter 10 (attrition), Chapter 1 → Chapter 35 — Key Takeaways
Bioavailability
the fraction of an administered dose that reaches the general circulation intact. Intravenous is 100% by definition; every other route is less. → Answers — Chapter 4
Bioequivalence
the demonstration that a follow-on product delivers the same amount of active drug to the bloodstream on the same time course as the reference product; the evidentiary basis of a generic application (Ch. 38). → Chapter 38 — Glossary fragment
bioequivalent
that the same amount of drug reaches the bloodstream on the same time course — and, that shown, the agency accepts the original efficacy data. Cheap to do, relative to a full development program, which is why generic small molecules cost a fraction of the originals. → Case Study 38.1 — Fifty-One and Thirty-One: A Number That Decides a Market
Biological product
in United States law, a category that includes alpha-amino-acid polymers with a specific, defined sequence of more than 40 amino acids; licensed through a Biologics License Application (Ch. 38). → Chapter 38 — Glossary fragment
a trial endpoint assessed by tissue sampling; invasive, subject to sampling error and reader variability, and generally still a surrogate for the clinical outcomes that matter. (Ch.10) → Glossary fragments — Chapter 10
biopsy with a dermal marker
an actual measurement past the barrier, which almost nothing in this literature has. Problems with the conclusion: no control arm of any kind (baseline-only comparison), and "proven to rebuild collagen" is both an overreach from a marker to a structural outcome and a drug claim (§30.7). → Answers and marking notes — Chapter 30 (Cosmetic Peptides)
Biosimilar
a copy of a biologic product demonstrated to be highly similar to its reference product; substantially harder to establish than small-molecule generic equivalence, which is one reason insulin competition was slow. (Ch.11) → Glossary fragments — Chapter 11
Biosimilar competition
Entry of follow-on versions of a complex biologic or peptide after exclusivity ends. The mechanism by which prices for this class eventually fall. Slower, more expensive to demonstrate, and less price-reducing than small-molecule generic competition. *(Ch 32; Ch 44 §44.6)* → Glossary contributions — Chapter 44
Informally, the most prominent warning a United States drug label can carry; formally a **boxed warning**, added when a regulator judges a risk serious enough to require highlighting. → Appendix G — Regulatory and Legal Quick Reference
blinded assessment of
appearance
human raters, not instruments — using the injected product as an active comparator. In that order. **The delivery question comes first, because without it the trial is testing whether a molecule that never arrived did something after it got there.** → Appendix H — Twenty Worked Evidence Evaluations
Blinding
concealing treatment assignment; single-blind conceals it from participants, double-blind from participants and investigators, and open-label conceals it from nobody. (Ch.5) → Glossary fragments — Chapter 5
the interface between blood and brain tissue formed by tight junctions between capillary endothelial cells, reinforced by efflux transporters, degrading enzymes, and supporting pericytes and astrocyte endfeet. It excludes most peptides by default. *(Ch 22; recurs in Ch 23, Ch 30)* → Glossary contributions — Chapter 22
BNP (B-type natriuretic peptide)
a 32-amino-acid peptide produced largely by ventricular myocardium in response to wall stress. Synthesized on demand rather than stored, giving it slower and steadier kinetics than ANP. The "B" originally stood for "brain," where it was first isolated; the name was subsequently reinterpreted. [Ch 28 → Glossary contributions — Chapter 28
Boc (tert-butyloxycarbonyl)
The acid-removable N-terminal protecting group used in Merrifield's original solid-phase strategy. Displaced for most commercial manufacture by Fmoc, which avoids the strongest acids, but still used for particular sequences. [Ch 32 §32.2] → Glossary contributions — Chapter 32
Body composition changed
Rudman replicated. - **Strength and functional capacity did not convincingly improve** — the surrogate moved and the outcome did not follow. - **Adverse effects were substantially more frequent** in treated participants: soft tissue edema, arthralgia, carpal tunnel syndrome, gynecomastia in men, imp → Case Study 14.1 — Twelve Men: Reading Rudman 1990 as a Paper
Body surface area normalization
The basis of standard cross-species dose conversion. Yields human-equivalent figures far below those produced by naive milligram-per-kilogram conversion, in a fixed direction. *Ch 31 §31.5.* → Glossary contributions — Chapter 31
A ~150,000-dalton protein produced by *Clostridium botulinum*, among the most potent biological toxins known. Its light chain is a zinc-dependent protease that cleaves SNARE proteins (type A cleaves SNAP-25), preventing acetylcholine release at the neuromuscular junction. Injected in tiny controlled → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Boxed warning
the most prominent form of safety labeling required by the U.S. FDA, applied to warnings judged to require special attention. (Ch.8) → Glossary fragments — Chapter 8
BPC-157 among them
do not qualify, which means "sold as a supplement" can be not merely uninformative but incorrect as a classification claim. → Chapter 38 Quiz: Peptide Regulation
a vasodilator peptide degraded by both neprilysin and angiotensin-converting enzyme. Its accumulation causes the cough and angioedema associated with ACE inhibitors, and it is the reason combined neprilysin–ACE inhibition failed. [Ch 28] → Glossary contributions — Chapter 28
Bradykinin-potentiating peptide (BPP)
a class of peptides in *Bothrops jararaca* venom that enhance the vasodilatory action of bradykinin by inhibiting angiotensin-converting enzyme; the ancestral lead for teprotide and captopril. *(Ch 35)* → Glossary contributions — Chapter 35
Brand name
The commercial name of a specific *product*: a molecule, in a formulation, by a route, approved for an indication. One molecule may carry several brand names, and the products are not interchangeable. (Ch.41) → Glossary contributions — Chapter 41
Bremelanotide (PT-141)
A cyclic seven-amino-acid melanocortin receptor agonist with activity at MC4R and other subtypes, approved for hypoactive sexual desire disorder in premenopausal women. Brand name Vyleesi. Roughly 1,025 Da. — Ch 24 §24.1 → Glossary contributions — Chapter 24
The total near-term expenditure a therapy imposes on a payer, as distinct from its cost-effectiveness. A therapy can be highly cost-effective per patient and simultaneously unaffordable in aggregate. Conflating the two produces most of the confused public argument about coverage. *(Ch 44 §44.3)* → Glossary contributions — Chapter 44
burden-shifting
the filter's job is to make the seller explain, cheaply and immediately. A student who abandons the filter because it is fallible has learned the wrong lesson; so has one who treats it as conclusive. → Instructor material — Chapter 4
by
any mechanism
dieting, bariatric surgery, illness, or a drug. It is a consequence of the weight change, not of the pharmacology that produced it. Rate and magnitude matter; mechanism does not. → Chapter 41: Ozempic Enters the Language
by its shape
randomized trials exist, meta-analyses exist, Cochrane reviews exist, results are mixed, heterogeneity is substantial, methodological criticism is persistent — rather than by naming individual studies. This is deliberate and should survive editing. It is also, conveniently, exactly the epistemic pos → Bibliography notes — Chapter 23
C
C > B > A.
**Source C** ran the right study — randomized, blinded, placebo-controlled, adequate duration, a patient-relevant primary endpoint — and got an answer. It establishes the most **even though the answer was negative**, and that is the whole lesson. - **Source B** generated a human signal but cannot at → Practical Evaluation Exam — Open Book
C-terminal amidation
Conversion of a peptide's C-terminal carboxyl group to an amide. Present in both oxytocin and vasopressin; blocks one route of enzymatic degradation and is required for activity. Cross-reference Ch 4 (half-life strategies) and Ch 33 (engineering). *(Ch 21 §21.1)* → Glossary contributions — Chapter 21
**p = 0.21** — the **primary endpoint**, physical function at 24 weeks. **Carries the most weight**, and it is negative. - **p = 0.03** — a **secondary endpoint**, a serum marker (a surrogate). Second in weight, and much less than its position in the Conclusions implies. - **p = 0.04** — a **post ho → Practical Evaluation Exam — Open Book
Cadaver-derived growth hormone
14.1, 3.CS2 - **cadaver-derived growth hormone** — 19.10, as standing precedent 19.8, **19.8**, case study 19.2 - **Cagrilintide** — 9.7, 13.3 - **cagrilintide** — 36.5, §33.9 - **CagriSema** — 9.7, 13.3, 36.5, **§33.9** - ****calcitonin**** — 22.7, shared gene with CGRP - ****calcitonin (salmon)*** → Appendix L — Index
a protein normally expressed only in germ cells and re-expressed by some tumors — tested in large randomized trials in lung cancer and melanoma. - A **mucin-derived antigen** delivered in a liposomal peptide formulation, tested in a large randomized trial in non-small-cell lung cancer. - A **telomer → Case Study 26.2 — Thirty Years of Failure
peers still observe, and reputation is not administrable. Students who conclude "therefore it cannot be made voluntary" should be pushed on whether that proves too much, since the same is true of many accepted workplace choices. → Answer guidance — Chapter 43
capping
Deliberately and permanently blocking chains whose coupling failed, converting deletion sequences into truncated sequences that are far easier to separate. Capping does not improve yield; it buys separability. [Ch 32 §32.3] → Glossary contributions — Chapter 32
Captopril
an orally available small-molecule ACE inhibitor, approved in the early 1980s, designed to reproduce the key interactions of venom-derived peptides. Not a peptide; medicine's earliest and most commercially important peptidomimetic. *(Ch 35)* → Glossary contributions — Chapter 35
Captopril is not a peptide
it is medicine's earliest and most commercially important peptidomimetic. Same arc as orforglipron in Chapter 33: **peptide lead → small-molecule drug.** - **Ziconotide** derives from **ω-conotoxin MVIIA** (*Conus magus*), blocks N-type calcium channels, and is approved for severe chronic pain — **o → Chapter 35 — Key Takeaways
Captopril lineage
Literature on bradykinin-potentiating peptides in *Bothrops jararaca* venom (1960s onward). - Clinical reports on teprotide as an injectable ACE inhibitor. - Retrospective accounts by Ondetti and Cushman describing the design of captopril from the peptide leads. Supports: §35.4 in full, and it is th → Bibliography notes — Chapter 35
Carbetocin
A longer-acting oxytocin analog; a heat-stable formulation was developed because oxytocin's cold-chain requirement is a major obstacle where postpartum hemorrhage kills most people. *(Ch 21 §21.2)* → Glossary contributions — Chapter 21
Carcass composition
The distribution of lean tissue, fat, and bone in a slaughtered animal, measured through variables including backfat thickness, loin eye area, and marbling score. *Ch 31 §31.3.* → Glossary contributions — Chapter 31
Carcinoid syndrome
Flushing, secretory diarrhea, sometimes wheezing, and over time right-sided valvular heart disease, caused by vasoactive substances released by some neuroendocrine tumors. *Ch 27 §27.4.* → Glossary contributions — Chapter 27
cardiovascular benefit in primary prevention
people **without** established cardiovascular disease. SELECT studied people who already had it, so the trial says nothing about a lower-risk population. → Chapter 8 — Quiz
Carpet model
A mechanism in which peptides accumulate flat on the surface until the bilayer is destabilized wholesale in detergent-like fashion, with no discrete pore. *(25.3)* → Glossary contributions — Chapter 25
surrogate improved, outcome never measured. Claim cannot exceed ⚠️; asserted confidently, usually ❌. - **Case B** — surrogate improved, outcome measured, outcome improved. The arrow held. - **Case C** — surrogate improved, outcome measured, outcome did **not** improve. The arrow broke. Worse than Ca → Chapter 16 — Key Takeaways
Case report
a written account of a single patient; valuable for flagging unexpected or harmful events, near-worthless for establishing efficacy, having no control, no blinding, no randomization, and no denominator. (Ch.17) → Glossary fragments — Chapter 17
Case Study 2
a structural analysis of an information environment. No vendor, forum, publication, clinic, or individual is named anywhere. All claims discussed are paraphrased composites of widely circulating types. - **Exercise section F (17.29–17.34)** — six paraphrased composite claims, constructed to be the * → Bibliography fragments — Chapter 17
Cash price
What an uninsured person is quoted. Historically tracks list price closely, because list is the only price they have standing to be charged. (Ch.12) → Ch12
CASP
the Critical Assessment of Structure Prediction — is a biennial blind assessment. Organizers take proteins whose structures have been determined experimentally but not published. Teams submit predictions without access to the answers. Predictions are scored against the withheld experimental structur → Case Study 35.2 — What AlphaFold Did and Did Not Change
CASP (Critical Assessment of Structure Prediction)
a biennial blind assessment in which teams submit structure predictions for proteins whose experimental structures have been solved but not published, scored by independent assessors against the withheld answers. *(Ch 35)* → Glossary contributions — Chapter 35
Castrate level
The low serum testosterone threshold that defines successful androgen deprivation; historically, the level achieved by surgical removal of the testes. *Ch 27 §27.1–27.2.* → Glossary contributions — Chapter 27
Cataplexy
sudden transient loss of muscle tone triggered by strong emotion; the feature that distinguishes narcolepsy type 1. *(Ch 22)* → Glossary contributions — Chapter 22
Category dismissal
rejecting a claim by rejecting the class it belongs to, without engaging with the specific claim. Contrast with engaging the claim ("there's no good human evidence for that, and here's what there is"). A category dismissal often reaches the correct verdict and still damages the conversation, because → Glossary contributions — Chapter 39
Cathelicidin
A family of host-defense peptides produced as part of innate immunity. LL-37 is the principal human member. Covered in full in Ch. 25. [ch18 §18.4] → Glossary contributions — Chapter 18
Cationic
Carrying a net positive charge at physiological pH, typically from lysine and arginine residues. The property that draws AMPs electrostatically toward negatively charged bacterial surfaces. *(25.2)* → Glossary contributions — Chapter 25
Causal manipulation studies
receptor antagonism and enhancement within targeted regions, and partner-preference outcomes. - **Reviews of the neurobiology of pair bonding** for the synthesis-level statement that receptor placement rather than ligand identity drives the species difference. - **Compiler note:** the chapter is emp → Bibliography notes — Chapter 21
The division of the U.S. Food and Drug Administration that approves and regulates animal drugs, including safety and effectiveness for a named species and indication, human food safety for food-producing species, and post-approval surveillance. *Ch 31 §31.1.* → Glossary contributions — Chapter 31
Central appetite effect
most plausible on current evidence. Central GIP receptors are documented, and tirzepatide's advantage over GLP-1 agonism alone is largest on weight, which is consistent with an appetite mechanism rather than a peripheral metabolic one. → Answers — Chapter 9
central diabetes insipidus
increasingly called arginine vasopressin > deficiency — in which the posterior pituitary does not produce enough vasopressin and the patient > passes large volumes of dilute urine and is perpetually thirsty. It is also approved for **nocturnal > enuresis** and for **certain bleeding disorders**, whe → Chapter 21: Oxytocin and Vasopressin — The "Love Hormones": What They Actually Do
Central sensitization
amplification of nociceptive signaling in the central nervous system that outlasts the triggering stimulus and can convert acute injury into persistent pain. *(Ch 22)* → Glossary contributions — Chapter 22
Whether a drug acts within the brain and spinal cord or in the peripheral tissues. In sexual medicine this is the distinction between a drug aimed at desire and a drug aimed at blood flow. — Ch 24 §24.3 → Glossary contributions — Chapter 24
A document reporting test results for a batch of material. Its evidentiary value depends entirely on which tests were run, by what named methods, by whom, and whether the batch can be connected to the material in hand. [Ch 32 §32.4, §32.9; Ch 34] → Glossary contributions — Chapter 32
Certificate of analysis (CoA)
A report of analytical tests performed on a sample. A claim about a sample, not a property of the container in hand. — Ch 19 §19.3 (full treatment Ch 34) → Glossary contributions — Chapter 19
cGMP (cyclic guanosine monophosphate)
the second messenger produced by guanylyl cyclases, including the natriuretic peptide receptors and the nitric-oxide-responsive soluble enzyme. Activates protein kinase G. The common currency linking natriuretic peptide signaling to nitric oxide signaling. [Ch 28] → Glossary contributions — Chapter 28
CGRP (calcitonin gene-related peptide)
a 37-residue peptide produced by alternative splicing of the calcitonin gene, among the most potent vasodilators known in human tissue, released from trigeminal sensory neurons, and the target of the first migraine-specific preventive drug class. *(Ch 22)* → Glossary contributions — Chapter 22
Ch 1
peptide/protein size convention (§16.4, follistatin is a protein); §1.8 naming conventions (IGF-1 LR3 known by a code, not a generic name). - **Ch 2 §2.9** — mechanism necessary, never sufficient; "roughly nine in ten compounds entering human trials never reach approval." Quoted in the Overview. - * → Chapter 16 — Continuity record
Ch 1 §1.2
cysteine/disulfide as "biology's staple"; side-chain families used to justify the position 8 leucine→arginine argument. - **Ch 1 §1.3** — proteolysis; "a nonapeptide swallowed on an empty stomach is food." - **Ch 1 §1.4** — residues doing structural work vs. receptor-contact work. - **Ch 1 §1.8** — → Continuity notes — Chapter 21
Ch 12 must honor this
it is the book's model for handling a genuinely contested access question. 4. **§6.9 is the most likely section to alienate a reader in the target audience.** It is written to attribute the failure to the *environment* rather than to the reader, and to include the author in the diagnosis. Later chap → Continuity notes — Chapter 6
Ch 13 §13.6 (ghrelin)
internal cross-reference, no external citation needed, but the compiler should verify the ghrelin section still contains the forward pointer to Ch 21. **This pairing is load-bearing in both directions.** - **Sources on other hormone nicknames** — cortisol, dopamine (motivation/prediction error rathe → Bibliography notes — Chapter 21
Ch 18
LL-37 immunomodulation and the vitamin D literature. Ch 25 says the clinical results have been "considerably less impressive than the mechanism suggested" and defers detail to Ch 18. **Coordinate.** - **Ch 19** — unregulated market. Referenced in the 🩺 callout in 25.5. - **Ch 26** — the Conclusion p → Continuity — Chapter 25
Ch 2
GPCRs; inhibitory G protein coupling; receptor distribution predicting effect profile; §2.7–2.8 desensitization and downregulation; **Case Study 2 (biased agonism at mu / oliceridine)** — *referenced twice, deliberately never retold.* If Ch 2's case study number changes, fix §20.3 and §20.9. - **Ch → Continuity notes — Chapter 20
Ch 21 (oxytocin/vasopressin)
named in the conclusion and offered as a dossier exercise target. Ch 21 is the immediate next chapter; the handoff sentence promises "subtler science, larger public claims, same discipline." - **Ch 22 (blood-brain barrier)** — referenced four times (§20.5, §20.8, §20.9, key-takeaways) and explicitly → Continuity notes — Chapter 20
Ch 22
the blood-brain barrier in full. Ch 21's conclusion ends on "the intranasal controversy is not an oxytocin problem — it is *the* problem," and case study 2 promises Ch 22 will establish the quantitative burden of proof for claiming central delivery. ⚠️ **Ch 22 must actually do this.** - **Ch 29** — → Continuity notes — Chapter 21
Ch 28
"A CNP analog increases annualized growth velocity in children with achondroplasia over one year of treatment." ✅ (ALL-RATINGS line ~1555) - **Ch 29** — "Claim B: Desmopressin reduces the number of wet nights in children with primary nocturnal enuresis." ✅ (line ~1593) - **Ch 29** — "Claim B: Icatib → Continuity — Chapter 37 (The Peptide Evidence Table)
Ch 30 / cosmetic track
the dossier's collagen worked example assumes oral collagen peptides for skin are rated ⚠️ somewhere in the book. Confirm that rating exists and matches; if Ch 30 rates it ❌, swap the worked example for a different ⚠️ entry. → Continuity — Chapter 35
Ch 32
how peptides are made; impurity chemistry. Referenced 3× in §19.3. - **Ch 34** — certificates of analysis; what analysis can and cannot establish. Referenced 2×. - **Ch 38** — regulatory framework; compounding law; jurisdictional structure. Referenced 3×. - **Ch 39** — talking to your clinician. Ref → Continuity — Chapter 19 (The Gray Market)
Ch 32 and Ch 34 should both use it.
**The delivery filter (§4.9)** is a new device introduced here. Five questions. **Ch 6, 17, 19, 30, and 34 should apply it by name rather than reinventing it.** Ch 30 (topical) in particular. - **The four vials** — not touched. Ch 6. - **The Ozempic conversation** — not advanced. → Continuity notes — Chapter 4
Ch 34
pick this up | | Exercises G.d † | same pre-commitment exercise, collected by instructor | **Ch 34** | → Continuity — Chapter 32
Ch 35
named in the Conclusion as manufacturing at scale, "where these controls stop being abstractions." **Verify Ch 35's actual topic before final assembly**; if Ch 35 is not manufacturing, the Conclusion's last paragraph needs one sentence changed. - **Ch 39** — patient-side conversation, cited in §34.8 → Continuity — Chapter 34
the six rating rules. §31.2 invokes rule 3 by name ("never upgrade with mechanism") when refusing to treat a ban as evidence. §31.1's ✅ commentary invokes rule 1. - **Ch 8** — rodent thyroid C-cell finding and GLP-1 receptor expression. §31.5 uses it as the standing receptor-distribution example and → Continuity — Chapter 31
Ch. 1
peptide/protein convention as a convention; the forty-amino-acid line is the same kind of arbitrary boundary but with legal force. - **Ch. 4** — route and formulation as part of what gets judged (case study 2, bremelanotide). - **Ch. 5** — the method that replaces the label. Named explicitly in §38. → Chapter 38 — Continuity notes
Ch. 1 §1.5
peptide/protein boundary is a convention. Used for Tβ4 at 43 residues. - **Ch. 1 §1.8** — a laboratory code implies regulatory history, not pharmacology. **Load-bearing**; quoted almost verbatim in §18.1 and Case Study 18.2 check three. - **Ch. 4** — oral peptide delivery constraints. Larazotide is → Continuity — Chapter 18
Ch. 17 overlap
verify after Ch. 17 lands that §18.2's treatment of the five translation problems does not duplicate Ch. 17's at length. Current draft assumes Ch. 17 introduced them and §18.2 *applies* them. → Continuity — Chapter 18
Ch. 19
chapter closes pointing at it: "why has nobody run the trial? … less about science than about who pays for evidence." Ch. 19 must deliver that framing. - **Ch. 25** — owns antimicrobial peptides *and* owes LL-37 a rating. §18.4 explicitly promises this and gives the Rule 5 reason for deferring. Also → Continuity — Chapter 18
Chain of custody
documented control of a material from its origin to its point of use. What connects an analytical result to a physical object; where it is absent, the connection does not exist and cannot be established retrospectively. (§34.9) → Glossary contributions — Chapter 34
Chain of custody (reinforced)
a documented, unbroken record of a substance's handling from manufacture to administration. Absent for gray-market compounds, which is why no clinician can verify a vial's contents in an examination room; closing the gap requires a laboratory, a method, and a reference standard. *Defined Ch 34; appl → Glossary contributions — Chapter 39
Changes when patents expire:
**Price.** Directly. Generic entry is the mechanism by which a molecule's price falls to a fraction of its originator level. - **Who can afford treatment.** Downstream of price, and the reason any of this matters. Coverage calculations invert, and health systems that could not consider population-le → Chapter 36 — Worked Answers
Chapter 1
dossier project opened; Field 1; the insulin/BPC-157 identity contrast reused in §40.2's 🧬 callout; the Step 3 "what you already believe, dated" instruction that §40.4 collects on. - **Chapter 5** — the rating system, the six rating rules, and Field 5's structure. - **Chapter 6** — Field 12 written → Bibliography contributions — Chapter 40
same molecule class, approved indications — used in §43.1 to demonstrate rating rule 1. Verify at final build that Chapter 14 does in fact treat approved growth-hormone-axis indications; if its scope changed during drafting, §43.1 and Spaced Review item 4 both need their reference adjusted. → Continuity — Chapter 43
Chapter 25
referenced once, at the very end of the Conclusion, as "Chapter 25 opens Part V." **Deliberately contentless.** If Part V's subject changes during editing, this line needs no revision. Do not add a topic description here without confirming Part V's contents. - **Chapter 32** — synthesis; non-standar → Continuity notes — Chapter 24
Chapter 29 covers it in full.
**Vasopressin itself is used in critical care** as a vasopressor in vasodilatory shock. - It has behavioral roles too, including in the vole literature — and a **V1a antagonist carried into large autism trials did not deliver on its primary endpoints.** Same symmetry as oxytocin: solid physiology, c → Chapter 21 Key Takeaways — Oxytocin and Vasopressin
"continues Part VI" (index.md Conclusion and Dossier section). Key-takeaways identifies it as **The Peptide Evidence Table**, assembling every rating in the book into one reference. **Chapter 37 must actually be that**, and must preserve one-molecule-many-ratings. - **Chapter 38** — named only as co → Chapter 36 — Continuity Record
Chapter 4
semaglutide structural modifications (Aib-8, Arg-34, lipidation). §32.3 and §32.6 rely on Chapter 4's sourcing rather than re-establishing it. - **Chapter 11** — insulin history, analogs, hexamer dissociation, formulation. §32.5's In the Clinic callout draws on it. - **Chapter 12** — drug pricing, m → Bibliography — Chapter 32
Chapter 5
the method. How the tiers are assigned, what the six rules mean, and why a claim without a population and an endpoint cannot be rated at all. This is the durable part; the table above is the perishable part. → Appendix A — The Master Peptide Evidence Table
which is the honest deliverable when a literature is inaccessible. Where a specific paper is not named below, that is deliberate: this book does not cite work it has not verified, and a search strategy you can run yourself is more useful than a citation you would have to take on trust. → Chapter 23 — Further Reading
Charge
swapping a lysine for an arginine keeps the positive charge but changes the chemistry, since arginine's guanidinium group is not a reactive handle the way a lysine's amine is, which matters enormously in §33.8. **Hydrophobicity** — a ring, a halogen, or an extra methylene changes how the molecule pa → Chapter 33: Peptide Engineering — How Scientists Modify Peptides to Make Better Drugs
A molecular cage, such as DOTA, that binds and holds a metal ion; the component that attaches a radionuclide to a targeting molecule. *Ch 27 §27.5.* → Glossary contributions — Chapter 27
the approved indication for NK1 receptor antagonists, and the one no NK1 program set out to develop. Delayed CINV, appearing more than a day after chemotherapy, is the component NK1 antagonists address particularly well. *(Ch 22)* → Glossary contributions — Chapter 22
Choose 5 to 10 peptides you personally care about
the ones you have actually wondered about, not the ones you think you should pick. Semaglutide because your sister started it. BPC-157 because your training partner swears by it. Copper peptides because you own a \$90 bottle. Growth hormone because a clinic advertised it to you. Whatever brought you → How to Use This Book
Chromatogram
the output of a chromatographic separation: detector response plotted against time, with each resolved component ideally appearing as a distinct peak. (§34.3) → Glossary contributions — Chapter 34
Chronic therapy
a treatment whose benefit persists only for as long as it is taken; semaglutide for obesity is chronic therapy in this sense, as an antihypertensive or a statin is. (Ch.8) → Glossary fragments — Chapter 8
Chronically elevated PTH removes bone
that is what hyperparathyroidism does. **Intermittent, once-daily exposure builds it.** Same molecule, same receptor, opposite outcome. - The only variable that changed is the **temporal pattern of exposure**. This is Chapter 3 §3.5's pulsatility principle producing an approved therapy rather than m → Chapter 29 Key Takeaways — The Peptide Drugs Already in Your Pharmacy
Circumventricular organ
one of a small number of brain regions where the blood-brain barrier is incomplete, permitting circulating molecules to reach neurons. (Ch.7) → Glossary fragments — Chapter 7
a sequence of sources each citing the next, frequently terminating in a primary paper whose actual content differs from the claim it is invoked to support. (Ch.6) → Glossary fragments — Chapter 6
Citation drift
the progressive loss of qualifying information as a finding is restated across successive citations, characteristically dropping the species first. (Ch.17; introduced Ch.6) → Glossary fragments — Chapter 17
A laboratory code applied to a modified GHRH(1-29) fragment, and — in its DAC form — to an albumin-tethered long-acting version of the same. Two pharmacologically different molecules are sold under this one name. (Ch.15) → Ch15
the chapter says the pattern is "documented" for other treatable conditions, and a reviewer should confirm the strength of that literature before the word "documented" survives. → Bibliography notes — Chapter 44
sentences rather than substances. These are kept separate from the master table on purpose, so that a reader scanning for a compound does not have to filter them out. → Appendix A — The Master Peptide Evidence Table
Claim quotations in the ⚠️ Hype Check
paraphrased composites of claim *types*. No vendor, clinic, influencer, or individual is named anywhere in this chapter, deliberately. - **Dossier Field 5 worked demonstrations** (TB-500, thymosin alpha-1) — teaching models demonstrating format and reasoning. Every factual line is checkable against → Bibliography notes — Chapter 18
Lysinylation of membrane phosphatidylglycerol in *S. aureus* reducing net negative charge (MprF-mediated in the primary literature; the chapter describes the mechanism without naming the gene). - D-alanylation of teichoic acids in Gram-positives (dlt operon). - Lipid A modification with aminoarabino → Bibliography notes — Chapter 25
Class B GPCR
the G-protein-coupled receptor family including the receptors for GLP-1, GIP, glucagon, parathyroid hormone, and calcitonin. Historically very difficult to crystallize; a major beneficiary of the cryo-EM revolution. *(Ch 2 introduced; Ch 35 structural detail)* → Glossary contributions — Chapter 35
Class B GPCRs
the GLP-1 receptor's family — were historically very hard to crystallize. **Cryo-EM** changed that, producing structures of activated receptor–ligand–G-protein complexes, which is what made §33.9's multi-agonist ratio problem a tractable engineering question. - **AlphaFold2** produced a decisive res → Chapter 35 — Key Takeaways
The final synthesis step releasing the completed chain from the linker, generally removing side-chain protecting groups at the same time because they were chosen to respond to the same conditions. [Ch 32 §32.2] → Glossary contributions — Chapter 32
Clinical attrition
the loss of candidate drugs during human trials. Dominated by lack of efficacy in humans and unacceptable toxicity rather than by any shortage of candidate molecules. *(Ch 10 introduced; Ch 35 applied to discovery technology)* → Glossary contributions — Chapter 35
Clinical judgment
a trained decision about a particular patient under uncertainty, with incomplete information. Legitimate, often excellent, and **not** a demonstration that a compound works. A prescription and a refusal are both clinical judgments; neither is evidence about a molecule. *Ch 39 §39.8; cf. Ch 38 §38.10 → Glossary contributions — Chapter 39
ClinicalTrials.gov
the registry check. Chapter instructs readers to read the recruitment-status field on every hit, to note that "Unknown status" means the sponsor stopped updating, and to look for a Study Results tab on anything marked Completed. Free. - **WHO International Clinical Trials Registry Platform (ICTRP)** → Bibliography fragments — Chapter 17
an insulin pump whose delivery is adjusted automatically by an algorithm driven by continuous glucose monitor readings; sometimes called an artificial pancreas, which overstates it, since such systems have no glucagon arm. (Ch.11) → Glossary fragments — Chapter 11
CNP (C-type natriuretic peptide)
a 22-amino-acid peptide produced mainly by endothelial cells and by chondrocytes, signaling through NPR-B. Minimal natriuretic activity despite the family name; important in vascular tone and growth-plate biology. [Ch 28] → Glossary contributions — Chapter 28
Co-elution
two or more species emerging from a separation column at the same time and being recorded as a single peak. The fundamental limitation of any separation method, and the reason a method's specificity must be demonstrated rather than assumed. (§34.3) → Glossary contributions — Chapter 34
Co-intervention
people who start a peptide frequently also change sleep, diet, training, and attention simultaneously. Any of these could produce the improvement. → Answers — Chapter 6
Co-transmission
release of more than one signaling molecule from the same neuron, typically a classical fast transmitter plus a neuropeptide, under different firing conditions. *(Ch 22)* → Glossary contributions — Chapter 22
Cochrane Database of Systematic Reviews
reviews of Cerebrolysin in acute ischaemic stroke and in vascular dementia. Referenced as an institution and a body of work in §23.4 and Tier 1 of further reading. **Do not add specific review titles, authors, or years without re-verification at the time of publication**; these reviews are periodica → Bibliography notes — Chapter 23
the refrigerated storage and transport required to keep a temperature-sensitive product stable from manufacture through to use. (Ch.4) → Glossary fragments — Chapter 4
Colistin (polymyxin E)
A cyclic lipopeptide permeabilizing the Gram-negative outer membrane; largely abandoned in the 1970s–80s for nephrotoxicity and neurotoxicity, revived in the 2000s as a last-line agent against multidrug-resistant organisms. *(25.8)* → Glossary contributions — Chapter 25
collective action problem
the family of situations that includes the prisoner's dilemma, the tragedy of the commons, and the arms race. The defining feature of all of them is that **the outcome is bad for everyone and no individual acted irrationally.** That combination is what makes them so resistant to solution by exhortat → Chapter 43: Enhancement Outside the Clinic — Work, Sport, Military, and the Coercion Question
Common failure modes to correct for.
**List one padded with near-certainties.** "Would not surprise me" is not "is guaranteed." If every item is a safe bet, the list costs nothing and grades trivially. - **List two containing things you actually expect.** If an item in "would surprise me" would not, in fact, surprise you, it belongs in → Chapter 36 — Worked Answers
Comparative physiology
The study of physiological variation across species. A productive source of therapeutic leads (exenatide, venom-derived compounds, salmon calcitonin) and a reminder that species differences are sometimes an opportunity rather than an obstacle. *Ch 31 §31.9.* → Glossary contributions — Chapter 31
what an intervention is being measured against. Every claim of benefit is implicitly a comparison, and "doing nothing" is a legitimate comparator and a real trial arm. *Defined Ch 5; question 3 of Ch 39 §39.4.* → Glossary contributions — Chapter 39
Comparator dose
semaglutide 1 mg was the approved diabetes dose at the time; higher semaglutide doses exist and were not the comparator. (2) **Indication** — this was a *diabetes* trial, and extending it to weight management in people without diabetes is a population swap. (3) **Funder** — manufacturer-sponsored by → Chapter 9 — Quiz
comparison discipline
two peptides, one indication, the same standard applied > to both. Chapter 10 adds the rule that most often goes missing: **one molecule can hold several > different ratings at once**, and collapsing them into a single verdict is how good drugs get > oversold. → Part II — Metabolic Peptides: The Revolution
compartment error
peripheral measurement ≠ central activity | Ch 21, Ch 22, Ch 15 (GH secretagogues), Ch 30 (topicals) | | The **antagonist experiment** as the workhorse causal test for central peptide effects | Ch 21 especially; referenced whenever a CNS peptide claim appears | | Tolerance / physical dependence / ad → Continuity notes — Chapter 20
The **1923 patent covered the 1923 product.** Modern analogs are separately developed and patented. - **List price is not net price.** Rebates lower net prices for insurers and leave the **uninsured** paying near list. - **Biosimilar competition was slow for real regulatory reasons** — demonstrating → Chapter 11 — Key Takeaways
composition, not sequence
the distinction Chapter 1's Sanger case study drew, and it still holds. **Edman degradation** (requires a free N-terminus) and MS/MS establish order. AAA's other major role is quantitative: it is a primary method for peptide content. → Chapter 34 — Key Takeaways
marketing layer built on the shortage opening → 42.8, case study 1 - vocabulary layer ("same active ingredient," "generic," "personalized") → 42.8 - migration after the opening closed → 42.8, case study 1 §6 - pharmacology and legal basis → *see* Chapter 12 → Index entries — Chapter 42
Compounded semaglutide
the anchor case, start to finish · 12.5 503A vs. 503B, and the salt-form problem · 12.6 Off-label prescribing: what it is, when it is legitimate · 12.7 Telehealth prescribing and the incentive structure · 12.8 Who gets access, and the equity argument · 12.9 Obesity as disease, lifestyle, or food env → Master Outline — Understanding Peptides
Compounding
the pharmacy practice of preparing a medication tailored to an individual patient's needs; compounded products are not FDA-approved and are not reviewed for safety or efficacy. (Ch.6) → Glossary fragments — Chapter 6
Compression
Reduction of a claim to a shorter form, losing qualifiers at each step. Chapter 6's central concept; a joke is its terminal case, and the only rung that also loses the claim itself. (Ch.41) → Glossary contributions — Chapter 41
concentrate at late Phase 2 and Phase 3
exactly where the question "does this help a person" first gets a real answer. Everything earlier is, in a precise sense, a prediction. Chapter 10 gives the base rates; the consequence for reading Part III is that a compound with encouraging animal data and no human efficacy trials is not "nearly th → Appendix G — Regulatory and Legal Quick Reference
Condensation reaction
a reaction joining two molecules with the release of a small molecule, usually water. Peptide bond formation is one. (Ch.1) → Glossary fragments — Chapter 1
condition 3
the proposal increases adoption and therefore accelerates the coercion structure it cannot address — or **unequal availability**. A student who cannot find an unanswered objection should be sent back to §43.6; the inability to find one is the diagnostic. → Answer guidance — Chapter 43
Condition 5 is the one most often satisfied
many peptides are cleared rapidly and their effects do not obviously persist — but it is satisfied *unverifiedly*, because demonstrating reversibility requires the long-term follow-up that condition 1 already told us does not exist. We believe these effects are reversible largely because we have no → Chapter 43: Enhancement Outside the Clinic — Work, Sport, Military, and the Coercion Question
the reflex can be triggered by an infant's cry and inhibited by stress, which means the same physical stimulus produces different hormonal output depending on the state of the organism. A continuous intravenous infusion of oxytocin reproduces none of that. It is a flat line where physiology drew a s → Chapter 21: Oxytocin and Vasopressin — The "Love Hormones": What They Actually Do
Confidence interval
a range of values consistent with the observed data; more informative than a p-value and less often reported. (Ch.5) → Glossary fragments — Chapter 5
Confirm §8.8 exists and covers this.
**Ch 8** is also cited for the Ozempic/Wegovy distinction and for obesity biology (appetite as a regulated signal). - **Ch 12** is cited for access, coverage, formularies, list-vs-net pricing, and shortage mechanics. - **Ch 6** is cited for the compression ladder — Ch 41 *adds a rung below the botto → Continuity — Chapter 41: Ozempic Enters the Language
the bias arising when clinicians select which patients receive a treatment, so that the treated group differs systematically from the untreated in ways related to the outcome. (Ch.10) → Glossary fragments — Chapter 10
Conotoxin
one of the short, disulfide-rich peptide toxins produced by marine cone snails (*Conus* species), usually targeting a specific ion channel or receptor subtype. *(Ch 35)* → Glossary contributions — Chapter 35
the reporting standard for randomized trials, which requires that analysis populations be specified. → Chapter 9 — Further Reading
Construct validity
The degree to which an animal model arises from the same underlying mechanism as the human condition it represents. *Ch 31 §31.5.* → Glossary contributions — Chapter 31
CONSTRUCTED BIOSCIENCES is not a company.
**The trials, figures, percentages, and p-values below were written for this exam and describe no actual study.** - **Nothing on this page may be quoted, cited, repeated, or shared as though it described a real product, company, study, or result.** → Practical Evaluation Exam — Open Book
Content (peptide content; assay; potency)
the mass of target peptide actually present in a preparation, determined against a reference standard, by amino acid analysis, or by nitrogen determination. Distinct from purity, and the quantity that determines exposure. (§34.4) → Glossary contributions — Chapter 34
CONTEXT DEPENDENCE
does the *direction* of the effect depend on context? Options: No / Yes (name moderators, rewrite claim, rate the rewrite) / Unknown (record as "unrateable as stated"). - **METHOD CAVEAT** — is there an unresolved question about whether the intervention reaches its target? If yes, nulls are ambiguou → Continuity notes — Chapter 21
associated in some settings with **increased in-group favoritism** and **increased defensiveness or hostility toward outsiders**, with reduced trust in some individuals, and with increased competitive emotions in competitive settings. - **Oxytocin is better described as modulating social salience th → Chapter 21 Key Takeaways — Oxytocin and Vasopressin
Continuity of care
One identifiable clinician holding the longitudinal picture of a patient and owning the consequences of a treatment over time. Chapter 42 adds the structural observation that its absence in high-volume remote models is architectural rather than negligent: the question "who is responsible for me in m → Glossary contributions — Chapter 42
Continuous glucose monitor
a device measuring interstitial glucose continuously and reporting both level and rate of change. (Ch.11) → Glossary fragments — Chapter 11
Control arm
the group in a trial receiving placebo, standard care, or no treatment, against which the treated group is compared. (Ch.5) → Glossary fragments — Chapter 5
Measurement of the electrical capacitance of the stratum corneum, reported as hydration. Highly responsive to moisturizer, which is why it is a weak efficacy endpoint for an active ingredient. *(Ch 30 §30.8)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Cosmeceutical
An informal term for a cosmetic containing biologically active ingredients. No legal standing in the United States; there is no third category between cosmetic and drug. *(Ch 30 §30.7)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
A product intended to cleanse, beautify, promote attractiveness, or alter the appearance. Requires no premarket approval, and **may not claim to affect the structure or function of the body**. *(Ch 30 §30.7)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Cost offset
Expenditure avoided elsewhere in a health system because a treatment prevented an expensive event. Usually partial rather than complete, typically arriving years after the cost that produced it, and frequently accruing to a different organization. *(Ch 44 §44.3)* → Glossary contributions — Chapter 44
also called tetracosactide — is the standard example: a synthetic fragment of adrenocorticotropic hormone, the first 24 amino acids of ACTH, which is the pituitary hormone telling the adrenal cortex to make cortisol. Native ACTH is 39 residues; as with teriparatide, the N-terminal portion carries th → Chapter 29: The Peptide Drugs Already in Your Pharmacy
Cosyntropin (tetracosactide)
a synthetic 24-residue fragment of adrenocorticotropic hormone, ACTH(1–24), used as a diagnostic agent to assess adrenal cortical responsiveness. (Ch 29) → Glossary contributions — Chapter 29
Counter-regulation
control of a variable by two opposing signals, each correcting excursions in one direction; insulin and glucagon are the archetype. (Ch.3) → Glossary fragments — Chapter 3
Counter-regulatory hormone
A hormone that opposes insulin's action. Growth hormone opposes insulin peripherally and promotes hepatic glucose output, and therefore raises blood glucose. Sometimes described as diabetogenic. (Ch.14) → Ch14
Counterfactual
What would have happened otherwise. Randomization is the standard machinery for constructing one. For population-level questions, no such machinery exists, which is the structural reason Chapter 44's questions cannot be settled by trials. *(Ch 5; Ch 44 §44.1)* → Glossary contributions — Chapter 44
counterion
The ion paired with a charged group on a peptide. **Trifluoroacetate (TFA)** is the most common on synthetic peptides because trifluoroacetic acid is used both in cleavage and as an HPLC mobile-phase additive. Contributes real mass and does not appear in an area-percent purity figure. [Ch 32 §32.4] → Glossary contributions — Chapter 32
The bond-forming step of a synthesis cycle, joining the next protected amino acid to the free N-terminus of the growing chain. [Ch 32 §32.2] → Glossary contributions — Chapter 32
Covers Chapters 1–19
the method (Part I), metabolic peptides (Part II), and growth and repair (Part III). → Midterm Exam — Parts I–III
a structural method that reconstructs three-dimensional structures by computationally combining many two-dimensional images of individual molecules frozen in vitreous ice. Requires no crystal, which is why it opened up membrane receptors. *(Ch 35)* → Glossary contributions — Chapter 35
CS1
Q1–Q5 have determinate answers drawn from §37.3 and Chapter 28; Q6 is open. In Q5 the expected answer is that a single positive trial moves the row to ⚠️ at most, never to ✅, and only if population and endpoint match the claim. → Answer notes — Chapter 37
CS1 (DCCT) is deliberately paired with Ch 5's CAST
one confirmed a widely held belief, one refuted it, and nothing predicted which in advance. **Ch 37 could use this pair.** 3. **The metabolic memory / EDIC material carries two explicit cautions** (observational; a named phenomenon is not an explained one). **Do not harden it elsewhere.** 4. **§11.9 → Continuity notes — Chapter 11
CS1 (Defect 2)
appendices, relation to dossier → §40.1, FR (Tier 1) - approval vs. clearance (devices) → **CS2 (Field 7)**, QZ 20 - assembly, dossier → **§40.2**, Dossier checkpoint (Steps 1–2) - audit, internal → **§40.3**, CS1, KT, EX Group 2 - audit, order of checks → §40.3, **CS1**, Dossier checkpoint (Step 3) → Index contributions — Chapter 40
CS2
Q1 is the sharpest item: entries 3, 7, and 10 involve splits, and a student who argues that entry 3 should be MATCH (against the ⚠️ arm) has a real case, which is exactly why the audit's matching rule specifies "the arm that matches the version you rated." Q6 has no correct answer; assess whether th → Answer notes — Chapter 37
registry, trial → FR (Tier 2), **FR ("If you only do one thing")** - removal of entries → §40.5 - right for the wrong reasons → **CS1 (Defect 2)**, §40.3, EX R - risk, "no reported side effects" → **§40.2 (🩺 callout)**, CS2 (Field 9) - route used vs. route studied → §40.2, §40.8, **CS2 (Field 4)** → Index contributions — Chapter 40
CS2 (Field 8)
Field 9 (Risks) → **§40.2 (🩺 callout)**, §40.8, CS2 - Field 10 (Status), five questions → §40.2, §40.8, **CS2 (Field 10)** - Field 12 (What would change my mind) → §40.2, **§40.3 (Check 4)**, §40.5, §40.6, CS1 (Defect 3) - Field 12, specificity test → **§40.3 (🔬 callout)**, EX P, FR ("If you only do → Index contributions — Chapter 40
Measurement of skin deformation and recovery under applied suction, reported as elasticity or firmness. An instrument endpoint whose relationship to visible change is unestablished. *(Ch 30 §30.8)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
seven amino acids, joined end to end and then > stapled into a ring by a bridge between two side chains. It weighs roughly **1,025 Da**, which puts > it near the small end of the peptide range on Chapter 1's size spectrum, comparable to oxytocin. > > Three structural features, each doing a specific → Chapter 24: PT-141 (Bremelanotide) and the Sexual Function Peptides
Cyclic peptide
A peptide whose chain has been closed into a ring, which raises potency by reducing conformational entropy on binding and slows degradation by denying proteases an extended backbone. — Ch 24 §24.1 → Glossary contributions — Chapter 24
cyclic undecapeptide
eleven residues, closed ring, containing a D-amino acid and heavily **N-methylated**. Those features defeat exopeptidases, defeat protease recognition, and remove backbone hydrogen-bond donors, which is what makes it **orally bioavailable and active at an intracellular target**. It made modern organ → Chapter 29 Key Takeaways — The Peptide Drugs Already in Your Pharmacy
Cyclization
Joining a peptide's termini or side chains to form a ring. Removes the free ends exopeptidases attack, and constrains conformation, often improving both stability and affinity. Routes: head-to-tail, side-chain-to-side-chain, disulfide. — Ch 33 §33.3 → Glossary contributions — Chapter 33 (Peptide Engineering)
Cyclosporine
a cyclic undecapeptide immunosuppressant isolated from a soil fungus, orally bioavailable and active at an intracellular target; made modern organ transplantation practical. (Ch 29) → Glossary contributions — Chapter 29
Cyclosporine's composition
cyclic undecapeptide, contains a D-amino acid, heavily N-methylated, includes non-standard residues (§29.8, exercises AA/AB, quiz item 20). Verify residue count and the specific modifications; the chapter says "a D-amino acid" (singular) in the rewritten text — confirm that is correct rather than pl → Bibliography working notes — Chapter 29
The mirror-image stereoisomer of a standard amino acid, not used in normal human protein synthesis. Incorporated deliberately into synthetic peptides because human proteases are stereospecific and handle D-residues poorly. — Ch 24 §24.1 *(Cross-ref: Ch 1 established the twenty L-amino acids; Ch 4 co → Glossary contributions — Chapter 24
DAC
designed to form a covalent bond with **albumin**, the > most abundant protein in blood plasma. Albumin circulates for weeks. A peptide tethered to it is > effectively hidden from kidney filtration and from many proteases, and its duration of action goes > from minutes to days. > > That is **CJC-129 → Chapter 15: Growth Hormone Secretagogues — CJC-1295, Ipamorelin, Tesamorelin, MK-677
DAC (Drug Affinity Complex)
A chemical group designed to bind covalently to circulating albumin, extending a peptide's duration of action from minutes to days. CJC-1295 with DAC carries it; the without-DAC version does not, and the two are pharmacologically different molecules commonly sold under a single name. (Ch.15) → Ch15
the US National Library of Medicine's repository of current FDA drug labeling. Search any somatropin product. The label is the single most useful primary document a non-specialist can read about an approved drug: the **Indications** section shows exactly which claims regulators accepted; **Warnings → Chapter 14 — Further Reading
DailyMed and Drugs@FDA
approved labels, which contain the trial data regulators actually evaluated. See Chapter 4's reading list. → Chapter 5 — Further Reading
Dalton (Da)
the unit of molecular mass, roughly the mass of a hydrogen atom. Aspirin is ~180 Da; insulin ~5,800 Da; a therapeutic antibody ~148,000 Da. (Ch.1) → Glossary fragments — Chapter 1
Daptomycin
A calcium-dependent cyclic lipopeptide active against Gram-positive organisms; approved 2003, in routine use, and inactivated by pulmonary surfactant so not used for pneumonia. *(25.8)* → Glossary contributions — Chapter 25
daptomycin is
not used for pneumonia
the drug works everywhere else in the body and is defeated by the biochemistry of the lung. This is one of the most elegant illustrations available of a lesson from Chapter 4: a drug's effect depends on what happens to it at the site of action, and a molecule can be potent, well-tolerated, and compl → Chapter 25: Antimicrobial Peptides — The Natural Weapons That Could Solve Antibiotic Resistance
Daptomycin's label excludes pneumonia
not from caution, but because pulmonary surfactant inactivates the molecule, so it does not work there. That is indication narrowness with a mechanistic explanation attached, and it is the most literal possible demonstration that an approved antibiotic is approved for *specified* infections rather t → Appendix E — Approved Peptide Medicines by Indication
Data monitoring committee
an independent group of statisticians and clinicians who review unblinded interim trial results and may recommend stopping for harm or for efficacy. (Ch.10) → Glossary fragments — Chapter 10
date check
The audit check requiring every rating row to carry a date. An undated rating is a claim about the eternal and cannot be evaluated against subsequent evidence. Necessary and far from sufficient: a fully dated dossier can still fail the other three checks. *(Ch 40 §40.3, Check 3.)* → Glossary contributions — Chapter 40
date-stamped
the date the list was written, which is what makes later grading possible. Items phrased as events, not as trends: "[specific thing] occurs by [date]" rather than "the field continues to advance." → Chapter 36 — Worked Answers
date-stamping
The practice of attaching an explicit assessment date to a rating so it can become visibly rather than invisibly out of date. Every rating in this book is stamped; the master table is stamped 2026. *(Introduced in Ch 5; restated as a rule in Ch 37 §37.2.)* → Glossary contributions — Chapter 37
db/db mouse
the leptin-receptor-deficient mouse strain; produces leptin in excess and cannot respond to it, demonstrating resistance decades before the molecule was found. (Ch.13) → Glossary fragments — Chapter 13
De novo design
computational design of proteins or peptides with no natural counterpart, using methods including ProteinMPNN (sequence design for a given backbone) and RFdiffusion (backbone generation, including backbones shaped to bind a specified target). *(Ch 35)* → Glossary contributions — Chapter 35
on epistemic grounds, not courtesy. 4. **Notice when a joke is doing a claim's work.** Test: would I accept it stated flatly? 5. **Ask how we would know** — of cultural assertions exactly as of pharmacological ones. → Chapter 41 — Key Takeaways
Defect 1
Entry 1's most confident row names no population or endpoint. | | Same-evidence test | **Defect 2** — Entries 2 and 3 have comparable evidence and different ratings, driven by distaste and by mechanism-plus-anecdote. | | Field 12 check | **Defect 3** — Entry 2, the highest-confidence entry in the fi → Case Study 1 — Auditing a Finished Dossier
Defensin
A family of small, disulfide-stabilized, β-sheet antimicrobial peptides. Humans make α-defensins (neutrophil granules, Paneth cells) and β-defensins (epithelial surfaces). *(25.4)* → Glossary contributions — Chapter 25
deferred
confirmatory evidence is deferred, not waived. Full credit for connecting this to Chapter 16: the surrogate-endpoint problem is a designed feature of accelerated approval, not an incidental criticism of it. → Chapter 38 Quiz: Peptide Regulation
Degradation
the molecule is cut up by enzymes. 2. **Clearance** — the molecule is removed from circulation, principally by the kidney. 3. **Receptor desensitization** — the receptor stops responding, on a timescale of minutes to hours, through phosphorylation, arrestin recruitment, and uncoupling from its G pro → Chapter 33: Peptide Engineering — How Scientists Modify Peptides to Make Better Drugs
Degrade the peptide
proteases and peptidases cleave the ligand. DPP-4 does this to GLP-1 within a minute or two. 2. **Clear it** — the kidney filters small peptides out of blood. 3. **Desensitize the receptor** — phosphorylation and beta-arrestin recruitment uncouple the receptor from its G protein within minutes. The → Answers — Chapter 2
Deletion sequence
A peptide missing one residue because a coupling step failed while the chain continued growing. Nearly identical to the target in mass and chromatographic behavior. — Ch 19 §19.3 → Glossary contributions — Chapter 19
an inhibitory GPCR opioid receptor mediating modest analgesia and mood effects; preferred by the enkephalins. Clinically undeveloped, partly because of convulsant liability in some agonist programs. — Ch 20 §20.3 → Glossary contributions — Chapter 20
Dense-core vesicle
the storage vesicle for neuropeptides, located farther from the synaptic active zone than the small clear vesicles holding classical transmitters, and requiring sustained, higher-frequency firing for release. *(Ch 22)* → Glossary contributions — Chapter 22
Depot
a formulation designed to release drug slowly over weeks to months after a single administration. (Ch.4) → Glossary fragments — Chapter 4
deprotection
Removal of a protecting group. In each synthesis cycle, the N-terminal cap is removed to expose exactly one reactive amino group in the whole system. [Ch 32 §32.2] → Glossary contributions — Chapter 32
Depsipeptide
A peptide-like molecule in which one or more amide bonds is replaced by an ester bond. Teixobactin is a depsipeptide. *(25.7)* → Glossary contributions — Chapter 25
Dermal wound
healing
models in which a wound is created and closure rate, re-epithelialization, and granulation tissue are measured. **Cardiac repair after injury** — infarction models following cardiac function, scar size, and vessel formation after treatment. **Corneal healing** — models of corneal injury, where trans → Chapter 18: TB-500, Thymosin Alpha-1, and Other Recovery and Immune Peptides
Descending inhibition
modulation of incoming nociceptive signals by circuitry projecting from brain to spinal cord: periaqueductal gray → rostral ventromedial medulla → spinal dorsal horn. Endogenous opioid peptides are a principal currency of this modulation. — Ch 20 §20.4 → Glossary contributions — Chapter 20
V2-selective, longer-acting synthetic vasopressin analog. Approved for central diabetes insipidus, nocturnal enuresis, and certain bleeding disorders. **Chapter 29 owns the full treatment.** *(Ch 21 §21.8; Ch 29)* → Glossary contributions — Chapter 21
Desmopressin (DDAVP)
a vasopressin analog engineered for V2 selectivity and extended duration, approved for central diabetes insipidus, primary nocturnal enuresis, and certain bleeding disorders. (Ch 29) → Glossary contributions — Chapter 29
DEXA
dual-energy X-ray absorptiometry, a body composition measurement. A surrogate for function, and an unusually treacherous one, because an agent that adds lean mass acts directly on the yardstick. → Chapter 36 — Glossary Contributions
Diabetic ketoacidosis
the acute metabolic emergency of severe insulin deficiency, in which fat metabolism produces accumulating ketones; fatal within days if untreated. (Ch.11) → Glossary fragments — Chapter 11
diacid
a fatty chain bearing a carboxylate at both ends — to the lysine 26 amine, through a spacer built from a glutamate unit and two short, flexible glycol-like linkers. → Case Study 33.1: Three Changes to a Hormone
How well a test identifies the presence or absence of a condition, reported as sensitivity, specificity, and predictive values. Never a single number, and never meaningful without a stated population. (Ch.41) → Glossary contributions — Chapter 41
Diagnostic accuracy study
a study design that enrolls patients with a presenting symptom, applies a test, and compares the result against a blinded reference diagnosis. Yields sensitivity, specificity, and predictive values. Cannot establish that acting on the test result benefits anyone. [Ch 28] → Glossary contributions — Chapter 28
Dietary ingredient
the statutory categories a substance must fall into to be lawfully sold as a dietary supplement; regulators have taken the position that certain synthetic peptides do not qualify (Ch. 38). → Chapter 38 — Glossary fragment
Dietary ingredient (US)
The statutory categories a substance must fall into to be lawfully sold as a dietary supplement. Regulators have taken the position that certain synthetic peptides do not qualify (§G.8). → Appendix G — Regulatory and Legal Quick Reference
Dietary supplement
a United States product category created by DSHEA in 1994 with no premarket approval requirement; membership requires that the substance qualify as a dietary ingredient (Ch. 38). → Chapter 38 — Glossary fragment
a synthetic peptide kappa receptor agonist built from D-amino acids and deliberately designed not to cross the blood-brain barrier, so that it engages peripheral kappa receptors without central dysphoria. Approved for pruritus associated with chronic kidney disease in hemodialysis patients — not for → Glossary contributions — Chapter 20
Differences in metabolic state
including insulin resistance, which affects how the body responds to reduced intake. → Answers — Chapter 8
Different biology
species differ in metabolism, healing rate, tissue architecture, proteolytic environment, immune response, and lifespan. 2. **Different disease** — a model captures a piece of a condition, deliberately simplified so the experiment is possible. The question is always whether the discarded complexity → Answers — Chapter 17
different publication pressure
the least discussed. Animal studies are much less likely to be pre-registered, so the published animal literature is a filtered sample of the experiments actually run, in a way the human trial literature increasingly is not. → Chapter 5 — Quiz
different triggers
Fmoc comes off with base every cycle; side chains and linker come off with acid, once, at the end. - Chains are built C-terminus toward N-terminus, the reverse of a ribosome. The final molecule is identical. - **Racemization** during activation gives a mirror-image residue at nearly identical mass. → Chapter 32 — Key Takeaways
Differential diagnosis
the ordered list of possible causes a clinician builds for a presentation and works through, constructed from what they know about the patient. An incomplete history does not merely shorten the list; it redistributes probability across the wrong candidates and produces a workup that solves a differe → Glossary contributions — Chapter 39
differently
with a substitution, with a D-residue, with a modified terminus. Every analog in Chapter 21 and Chapter 27 descends conceptually from the moment a peptide hormone became something a chemist could make. → Appendix J — A Timeline of Peptide Science
difficult sequence
A stretch of sequence that causes growing chains to aggregate on the resin, burying the reactive amino group and driving down per-step coupling efficiency. Not reliably predictable from first principles. [Ch 32 §32.2] → Glossary contributions — Chapter 32
a model in which a consumer initiates contact with a service in response to advertising and receives a prescription without an antecedent referral or established clinical relationship. → Chapter 42: The Creator Economy and the Peptide Pipeline
Direct-to-consumer telehealth
A model in which the clinical consultation, the prescription, and the sale of the product are bundled inside one commercial entity. (Ch.12) → Ch12
Directed evolution
iterated cycles of variation and selection applied to molecules in the laboratory. Recognized alongside phage display in the 2018 Nobel Prize in Chemistry (Frances Arnold). *(Ch 35)* → Glossary contributions — Chapter 35
direction of error
§31.5 limits for peptides — §31.5; case study 2 animal model face validity — §31.5 construct validity — §31.5 **predictive validity** — §31.5 route mismatch — §31.5 subject characteristics — §31.5 animal-to-human inference **five mechanisms of failure** — §31.5 direction of inference — §31.9 as dist → Index entries — Chapter 31
A systematic tendency to rate consistently higher or consistently lower than the evidence supports. **Generous drift** rates up on compounds the rater has a stake in; **severe drift** rates down on compounds whose presentation the rater dislikes. Neither is more respectable; severe drift is harder t → Glossary contributions — Chapter 37
Directory slug mismatch
see the boxed issue at the top. Orchestrator action required. 2. **Exercise ee quotes a phrase not in index.md.** The exercise attributes to the chapter the phrase *"the most seductive possible surrogate."* §36.6's actual wording is *"One wrinkle makes this surrogate especially treacherous."* The an → Chapter 36 — Continuity Record
Disclosure
telling a treating clinician what you are actually taking, including unprescribed and unregulated substances. Framed in this book as a **clinical** necessity rather than a moral obligation, on the grounds that the moral framing is what produces minimization. *Ch 39 §39.2.* → Glossary contributions — Chapter 39
Disclosure norm
A social expectation that certain information be volunteered. This book presents both sides of the medical-disclosure question for public figures and declines to impose a duty. (Ch.41) → Glossary contributions — Chapter 41
Dismissal
"that's not a real drug, throw it away" — ends the conversation and, more > importantly, ends disclosure. A patient told the thing they are using is not worth discussing > generally keeps using it and stops mentioning it, which removes the clinician's ability to interpret > symptoms, laboratory resu → Chapter 34: Peptide Analysis and Quality Control — How Anyone Knows What's Actually in the Vial
Dispensing practice
a clinical practice that supplies the products it recommends from its own inventory. A knowable structural fact rather than an accusation. *Ch 39 §39.8.* → Glossary contributions — Chapter 39
Display technology
any method that maintains a physical link between a candidate molecule and the genetic information encoding it, so that molecules selected by binding can subsequently be identified by sequencing. Includes phage, ribosome, and mRNA display. *(Ch 35)* → Glossary contributions — Chapter 35
Distractors worth discussing in class:
**Q2 (d)** and **Q9 (a)** both fail on the naturalness fallacy. If students pick these, the problem is Chapter 1, not Chapter 35. - **Q5 (b)/(c)** attribute semaglutide's albumin-binding solution to exendin-4. This is the single most common conflation in the chapter and is worth catching explicitly. → Answer notes — Chapter 35
Distress criterion
The requirement, in certain diagnoses, that the condition cause marked distress or interpersonal difficulty. In HSDD it is what distinguishes a disorder from ordinary variation: low desire that does not trouble the person is not a disorder. — Ch 24 §24.4 → Glossary contributions — Chapter 24
Disulfide bond
a covalent link between the sulfur atoms of two cysteine residues; biology's staple, holding peptide shapes and separate chains together. (Ch.1) → Glossary fragments — Chapter 1
the chapter's own argument is that magnitudes from truncated trials should be held loosely, and quoting one would undercut it. → Continuity notes — Chapter 10
Do not add primary citations for them here
if Chapter 28's figures are ever revised, Chapter 37 must inherit the revision rather than diverge from it. See `continuity/ch37.md` §10 for the list of files that move together. → Bibliography — Chapter 37
Do not cite these as findings.
**The five-rung genericization ladder** (§41.1). A pedagogical device, not a linguistic taxonomy from the literature. - **The nine-observation table** (§41.5). Composite. The individual readings are commonplace; the table is assembled to make the unfalsifiability visible in one view. - **The base-ra → Chapter 41 — Further Reading
Do not cut it
without it the case study reads as a blanket dismissal of epidemiology, which would be wrong and would undermine Ch 19. 3. **§10.6 states that a mechanical explanation is "a complete explanation rather than a criticism."** This is a substantive position and answer 10.30 develops it into a rule (mech → Continuity notes — Chapter 10
Do not grade a low match count as a poor result.
**Quiz:** items 1–17 have single correct answers; 18–22 are short answer with a rubric in the key. Item 3 is the discriminator — a student who misses it has not absorbed §37.3. - **Case Study 37.2** is the best single summative assessment in the chapter. Question 6 (right answer for a wrong reason) → Instructor Notes — Chapter 37: The Peptide Evidence Table
Do not remove it
a tidy explanation presented without that caveat would be exactly the overreach the book warns about. 3. **CS2 argues that Chapter 5's small-sample red flag applies with much less force to setmelanotide**, on the grounds that the effect is large relative to variability, the mechanism is confirmed ra → Continuity notes — Chapter 13
**The size of the treatment effect.** A molecule does not become more effective when it becomes inexpensive. The effect size was measured in trials that patent status does not touch. - **The strength of the evidence.** The trials already ran. Their design, size, endpoints, and results are fixed fact → Chapter 36 — Worked Answers
does not depend on any moral premise
it holds whatever you concluded about permissibility. - Sharpened here by invisibility, **unattributability** ("you cannot be compensated for a harm nobody can attribute"), relationships that end before exposures do, and the total absence of the compensation structures we built for every other occup → Chapter 43 — Key Takeaways
Dorsal horn
the region of the spinal cord where incoming nociceptive fibers make their first synapse; the principal site at which descending inhibition is applied. — Ch 20 §20.4 → Glossary contributions — Chapter 20
Dose-response curve
a plot of effect against drug concentration, from which potency (horizontal position) and efficacy (height) can be read. (Ch.2) → Glossary fragments — Chapter 2
Dossier
state (A) studied and disappointing — ch18 Dossier - state (B) not studied — ch18 Dossier - state (C) studied in a different molecule — ch18 **Dossier** - separating two confidences — ch18 Dossier - trigger sentence — ch18 Dossier → Index entries — Chapter 18
Double muscling
The extreme muscularity of certain cattle breeds, notably Belgian Blue and Piedmontese, produced by naturally occurring loss-of-function mutations in the myostatin gene. Largely a developmental hyperplasia phenotype. — *Ch 16 §16.3* → Glossary contributions — Chapter 16
Downregulation
Reduced receptor number or responsiveness following persistent stimulation. One of two reasons to expect a secretagogue's effect to attenuate over continued use. (Ch.15) → Ch15
an enzyme that cleaves two residues from the N-terminus of susceptible peptides; responsible for the ~1–2 minute half-life of native GLP-1. (Ch.4) → Glossary fragments — Chapter 4
drift audit
The five-step dossier procedure in Chapter 37 comparing a reader's own ratings against the master table, counting MATCH / HIGHER / LOWER, and sorting disagreements into those the reader can defend with named evidence and those they cannot. The output is one dated sentence about the reader rather tha → Glossary contributions — Chapter 37
the FDA-maintained list of drugs in shortage; its entries activate a provision permitting compounding of copies of otherwise-unavailable approved drugs. (Ch.6) → Glossary fragments — Chapter 6
Drugs@FDA
approval records for tirzepatide (type 2 diabetes 2022; weight management 2023), including review documents. → Chapter 9 — Further Reading
DSHEA
the Dietary Supplement Health and Education Act of 1994, which established the United States dietary supplement category and its requirements (Ch. 38). → Chapter 38 — Glossary fragment
an approved class of insomnia medicine (suvorexant, lemborexant, daridorexant) blocking both orexin receptors. Mechanistically distinct from benzodiazepines and Z-drugs, which enhance GABA-A signaling. *(Ch 22)* → Glossary contributions — Chapter 22
during continued
treatment
that is, tolerance or escape while still on the drug — or a serious harm emerging with multi-year use at a rate outweighing the benefit. → Chapter 8 — Quiz
Dynamic stimulation testing
Provoking hormone release and measuring the response, rather than measuring a static level. Used to diagnose growth hormone deficiency because a snapshot cannot distinguish a healthy trough from true deficiency. (Ch.14) → Ch14
Dynorphin
a family of endogenous opioid peptides derived from prodynorphin, acting principally at the kappa receptor. Dynorphin A is 17 residues. Associated with dysphoria and stress responses. — Ch 20 §20.2 → Glossary contributions — Chapter 20
Dysphoria
an unpleasant, distressed mood state. Characteristically produced by kappa receptor activation, and the reason kappa agonists have not become clinical analgesics despite an otherwise attractive profile. — Ch 20 §20.3 → Glossary contributions — Chapter 20
E
early and narrow
one tumor type, one setting, recurrence endpoints, confirmatory trials still accruing. - **The intervention is a process, not a molecule.** Every patient receives a different product; what a trial validates is a pipeline, and its transferability is genuinely open. - **Attribution against an active c → Chapter 26 — Key Takeaways
Early twentieth century
the "incretin" hypothesis is proposed: some intestinal factor stimulates the pancreas. It is untestable with available methods and largely set aside. → Case Study 1 — Forty Years of Nobody Caring
the concentration producing half of a drug's maximum effect; the standard measure of potency. (Ch.2) → Glossary fragments — Chapter 2
Ecological fallacy
Inferring something about individuals from patterns observed in aggregates, or inferring something about aggregates from findings in individuals. Runs in both directions; the second direction is more often forgotten. *(Ch 44 §44.1)* → Glossary contributions — Chapter 44
economically marginal targets
rare diseases, neglected infections — viable to pursue at all. That is a real and significant gain. It is simply **not the same claim** as "AI will cure disease faster." → Chapter 35 — Key Takeaways
Edman degradation
sequential chemical labeling, cleavage, and identification of the N-terminal residue, reading a sequence one residue at a time. Requires a free N-terminus; efficiency losses limit readable length. Largely displaced by MS/MS but retained as an orthogonal confirmation. (§34.6) → Glossary contributions — Chapter 34
Effect size
the magnitude of a difference, as distinct from whether it is statistically significant. (Ch.5) → Glossary fragments — Chapter 5
Effects on blood glucose
inhibiting both insulin and glucagon has opposing effects on glucose, so the net direction is not predictable from mechanism alone, but glucose dysregulation of some kind is likely. - **Gastrointestinal effects** — inhibiting gut hormones that regulate motility, secretion, and gallbladder contractio → Answers — Chapter 3
Efficacy
the maximum effect a drug can produce at any dose; the ceiling of its dose-response curve. (Ch.2) → Glossary fragments — Chapter 2
efficacy in humans is actually tested
late Phase 2 and Phase 3. That is exactly where you would expect them to concentrate, because that is the first place the question "does this help a person" gets a real answer. Everything before that stage is, in a precise sense, a prediction. → Chapter 38: Peptide Regulation — Approval, Off-Label, Compounding, and Doping
*see* appointment length - **emergencies** — undisclosed exposure in → 39.2 - **endpoint** → 39.4 (question 2); *see also* surrogate endpoint - **enthusiasm, clinician** — not a stronger signal than refusal → 39.8; five questions applied regardless of direction → 39.8; worked example → CS 39.2 - **e → Index entries — Chapter 39
Ejection fraction
the proportion of blood in the left ventricle expelled with each beat. The principal axis along which heart failure populations are divided in trials. [Ch 28] → Glossary contributions — Chapter 28
Electrospray ionization (ESI)
a soft ionization method in which a solution passed through a fine charged capillary emerges as a spray of droplets that evaporate to bare gas-phase ions. Charges molecules without fragmenting them, and typically produces multiply charged species. (§34.2) → Glossary contributions — Chapter 34
wrapped in a membrane vesicle. Inside an endosome is topologically still outside > the cytosol. Escaping the endosome is inefficient, hard to measure, and the rate-limiting step for > most delivery technologies. A peptide can be abundantly "inside cells" by microscopy and > functionally absent from → Chapter 33: Peptide Engineering — How Scientists Modify Peptides to Make Better Drugs
the molecule the body itself produces to activate a given receptor; the starting point for route 2 discovery. *(Ch 2 introduced; Ch 35 as a discovery route)* → Glossary contributions — Chapter 35
Endogenous opioid peptide
any peptide produced by the body that acts at opioid receptors, comprising the endorphin, enkephalin, and dynorphin families. — Ch 20 §20.1 → Glossary contributions — Chapter 20
Lipopolysaccharide fragments of the outer cell wall of Gram-negative bacteria. They survive sterilization, pass through sterilizing filtration, and produce fever and systemic inflammatory responses when injected. A separate concern from sterility. — Ch 19 §19.3 → Glossary contributions — Chapter 19
The situation in which a body of evidence is real and rigorous but measured something other than the outcome under discussion, and is therefore silent on it rather than supportive of it. *Coined for use in Ch 31 §31.3.* → Glossary contributions — Chapter 31
either of two pentapeptides, met-enkephalin (Tyr-Gly-Gly-Phe-Met) and leu-enkephalin (Tyr-Gly-Gly-Phe-Leu), derived from proenkephalin. Prefer the delta receptor; degraded within seconds by ectopeptidases. — Ch 20 §20.2 → Glossary contributions — Chapter 20
enkephalins
from the Greek for "in the head." Others followed: a thirty-one-residue peptide named **β-endorphin**, a contraction of "endogenous morphine," and later a family named **dynorphins** for their unusual potency. By the end of the decade the picture had inverted. Opiate drugs were no longer foreign che → Chapter 20: Endorphins, Enkephalins, and the Opioid Peptides — Your Body's Natural Painkillers
Enteroendocrine cell
a hormone-secreting cell scattered through the intestinal lining, sensing gut contents at its luminal surface and releasing hormones into the bloodstream at its base. (Ch.7) → Glossary fragments — Chapter 7
Louis Pasteur, Lille lecture 1854. Not Sinclair, Feynman, or Munger. ✓ - **American spelling.** ✓ - **Currency** — no currency figures appear in this chapter, so no `\$` escapes were required. - **No fabricated precision.** Deliberate approximations: "roughly half its residues," "early 1990s," "earl → Continuity — Chapter 35
Epigraph uniqueness
confirm Weiser is not used in another chapter. 3. **Cyclosporine's D-amino acid count** — the text says "a D-amino acid" (singular). Verify. 4. **The `📋` Dossier heading** renders as `## 📋 Your Evidence Dossier`; confirm the TOC generator handles the emoji in the anchor. 5. **§29.10's box-six taxono → Continuity record — Chapter 29
Epistemic laundering
assembling a claim from individually defensible components so that no single participant has stated it while collectively it has been communicated. (Ch.6) → Glossary fragments — Chapter 6
the surface-area method estimates a maximum safe *starting* dose for a first-in-human safety study, a deliberately conservative floor followed by further safety factors and a monitored escalation over months. Strip that structure away and only a number remains. Listen for students who notice that fi → Instructor notes — Chapter 31
erythropoietic protoporphyria
a rare disorder in which accumulated protoporphyrin IX absorbs visible light and produces severe burning pain within minutes. - It works exactly where the map predicts: MC1R agonism drives eumelanin production, putting a photoprotective layer between light and the molecule that reacts to it. It does → Chapter 24 — Key Takeaways
Erythropoietic protoporphyria (EPP)
A rare inherited disorder of heme synthesis, most often from reduced ferrochelatase activity, causing accumulation of protoporphyrin IX in erythrocytes and skin and producing severe burning pain within minutes of visible-light exposure. — Ch 24 §24.5 → Glossary contributions — Chapter 24
Essentially a copy
a compounded product that duplicates a commercially available approved drug; generally restricted outside defined circumstances such as a shortage (Ch. 38). → Chapter 38 — Glossary fragment
Established safety at the relevant exposure
in healthy people, at the exposures actually used, for the durations actually used. 2. **Genuine informed consent** — real information *and* a real alternative. 3. **Absence of coercive structure** — non-adopters not made worse off. 4. **Risk borne by the beneficiary** — through compensation, liabil → Chapter 43 — Key Takeaways
Estimand
the precise quantity a trial analysis estimates; it determines whether participants who discontinued are counted, and therefore which of two correct figures a trial reports. (Ch.5) → Glossary fragments — Chapter 5
Estimands
why one trial reports two weight-loss figures (the SURMOUNT-1 worked example) · 5.10 Red flags: no control, tiny n, short duration, sponsor-only data, predatory journals, conference abstracts that never publish · 5.11 The four-tier rating system, formally introduced · 5.12 Practice: rating four clai → Master Outline — Understanding Peptides
euphemism dialects
deliberate misspellings, code words, oblique references, and hand signals that keep content circulating. And precision is a casualty. A precise claim requires the precise noun. When the noun is penalized, what circulates is a vaguer claim about a vaguer object, which is less checkable, less rebuttab → Chapter 42: The Creator Economy and the Peptide Pipeline
event-triggered review
The practice of revisiting an entry when a specific event occurs — a readout, an approval or withdrawal, a shortage, a safety signal, an unanswerable question — rather than on a calendar. Scheduled review manufactures upgrades by sending the reader looking for news at intervals. *(Ch 40 §40.5.)* → Glossary contributions — Chapter 40
Every rating carries a date-stamp sentence
"as of this writing" plus what would change it: "a completed Phase II with a control arm would move this to ⚠️." A rating that cannot be falsified is not a rating. 6. **Ratings live in the `📊 Evidence Rating` callout** (§6) and are collected verbatim into Chapter 37 and Appendix A. **Use the exact w → Style & Continuity Bible — Understanding Peptides
evidence absent
The state of knowledge behind an ❌ where adequate human trials were never run. The claim is unsupported *and untested*. Such a rating can move in either direction as soon as somebody studies the question, because nothing anchors it. *(New in Ch 37 §37.3.)* → Glossary contributions — Chapter 37
evidence absent vs. evidence present and negative
**(reprise)** The two kinds of ❌. The first means no adequate trial has been run; the second means one was run properly and returned a negative result. The second is a substantially stronger state of knowledge, and the two are routinely confused in the direction that flatters the untested compound. → Glossary contributions — Chapter 40
evidence dossier
A personal, maintained reference on a small set of compounds, organized by twelve standing questions rather than by compound, and structured so that it can be updated when the evidence changes. Distinguished from a summary, which compresses someone else's conclusions and cannot be updated by the per → Glossary contributions — Chapter 40
Evidence is present, adequate, and negative
a different situation > from the ❌ compounds in Part III, where evidence is largely absent. > **What would change it:** this claim has been tested at scale in the population it was approved > for, and answered. Reopening it would require a trial in a materially different population or > illness phas → ALL EVIDENCE RATINGS — harvested, do not edit by hand
evidence present and negative
The state of knowledge behind an ❌ where adequate human trials were run and answered no. A substantially stronger state of knowledge than evidence-absent, and routinely mistaken for a weaker one. Marked **(N)** in the master table where the source chapter made the situation unambiguous. *(New in Ch → Glossary contributions — Chapter 37
An inactive formulation ingredient: bulking agent, buffer, stabilizer, preservative. Grade and suitability for injection are separate questions from the identity of the active. — Ch 19 §19.3 → Glossary contributions — Chapter 19
Exenatide
synthetic exendin-4, approved in 2005 as the first GLP-1 receptor agonist. *(Ch 7 introduced clinically; Ch 35 origin)* → Glossary contributions — Chapter 35
Exendin-4
a peptide identified in the venom of the Gila monster (*Heloderma suspectum*), work associated with John Eng in the early 1990s. Shares roughly half its residues with human GLP-1 — enough to activate the human GLP-1 receptor, and different at the critical position so that human DPP-4 does not cleave → Glossary contributions — Chapter 35
Exendin-4 / exenatide
Original characterization of exendin-4 from *Heloderma suspectum* venom; work associated with John Eng, early 1990s. Supports: §35.3 identification, GLP-1 receptor activity, sequence relationship. - Regulatory approval documentation for exenatide, 2005. Supports: §35.3 approval date and first-in-cla → Bibliography notes — Chapter 35
exists and is
disappointing
a worse position for a claim than a ❌ awarded for pure absence, despite the friendlier symbol. And the final ❌ is stronger than an ordinary one: the disease trials that ran are evidence *against* the performance claim, not merely absence of evidence for it. → Chapter 16 — Key Takeaways
Expect Field 3 to be easy for approved drugs
receptor identified, class known, downstream signaling characterized, endogenous role documented. Semaglutide, insulin, teriparatide, and octreotide all resolve quickly through the IUPHAR/BPS Guide or a drug label. → Answers — Chapter 2
someone who researched, paid for, injected, and told friends about a compound is not a neutral observer of their own outcome. Expectation effects on subjective endpoints are large and operate below awareness. → Answers — Chapter 6
Expected physiology, not a malfunction.
**Rudman canon sentence, used verbatim in index §14.5, key-takeaways, case study 1, quiz #20, answers:** *Twelve men over 60, six months of growth hormone versus untreated controls: increased lean mass and decreased fat mass. It did not measure strength, function, or long-term safety.* - Somatopause → Chapter 14 — Continuity Notes
expression system
The host organism and genetic machinery used in recombinant production; commonly *E. coli*, yeast, or a mammalian cell line. [Ch 32 §32.5] → Glossary contributions — Chapter 32
Externality
A cost or benefit falling on someone other than the parties to a transaction. Food reformulation benefiting people who never took the drug would be a positive externality; the crowding-out of structural prevention would be a negative one. *(Ch 44 §44.2, §44.5)* → Glossary contributions — Chapter 44
Extra-label use
Administration of a drug in a manner not described on its approved label; the veterinary analogue of off-label prescribing. Permitted under defined statutory conditions rather than freely. *Ch 31 §31.7.* → Glossary contributions — Chapter 31
41.3, CS 41.1 - **Facial volume loss, causes other than drugs** — 41.3 - **factor VIII, desmopressin release of** — ch21 §21.8 - **FAERS** — 19.8 - **failure modes and artifacts** — ch35 §35.6 (Read the Study) - **failure rate, why none is defensible** — **§34.8** - **falsifiability** — 36.1, 36.2, → Appendix L — Index
Facial volume loss
Reduction of fat in the discrete compartments of the face following substantial weight loss, producing hollowing and apparent aging. Occurs after weight loss by any mechanism; magnitude and rate matter, mechanism does not. (Ch.41) → Glossary contributions — Chapter 41
Facility and equipment qualification
demonstrating that equipment does what it is supposed to do, reproducibly - **Environmental monitoring**, particularly for sterile operations - **Change control** — a formal process ensuring that no change to a process, material, or supplier happens without assessment of its impact - **Deviation and → Chapter 34: Peptide Analysis and Quality Control — How Anyone Knows What's Actually in the Vial
Fair balance
the requirement that promotional material for an approved drug present risk information with prominence comparable to benefit claims. Attaches to manufacturers, not to creators. → Chapter 42: The Creator Economy and the Peptide Pipeline
Falsifiability
the property of a claim that specifies what observation would show it to be false; required by rating rule 5, and absent from essentially every claim this book teaches you to distrust. → Chapter 36 — Glossary Contributions
falsifiability (of a dossier entry)
The property of an entry that specifies, in advance, what observation would overturn it. An entry with an empty Field 12 is not a conclusion but a belief — true of a confident ❌ as much as of a hopeful ⚠️. *(Ch 6 origin; formalized Ch 40 §40.3.)* → Glossary contributions — Chapter 40
falsifiability (of a rating)
The property, required of every rating in this book, that the rater can state in advance what evidence would change the rating and to what. It is the property that makes a rating a scientific statement rather than an opinion, and it is what the fourth line of every rating callout supplies. *(Introdu → Glossary contributions — Chapter 37
Falsifiable condition
A statement that would have to hold for a scenario to occur, expressed so that its failure would be observable. The honest alternative to a prediction when the evidence base cannot support one. Distinguished from a forecast by being checkable before the outcome arrives. *(Ch 44 §44.7–44.8)* → Glossary contributions — Chapter 44
an expectation specific enough to be wrong, with a magnitude and a date attached. Produced by question 4 of the five. The antidote to the escalating-dose spiral, because an expectation that cannot fail provides no point at which stopping is the honest conclusion. *Ch 39 §39.4; cf. Ch 2 §2.8.* → Glossary contributions — Chapter 39
Falsifier
the specific, pre-specified observation that would change a rating. A rating without one is a position rather than a scientific claim. (Ch.17) → Glossary fragments — Chapter 17
fast
a snake that immobilizes a rodent in an hour has lost the rodent. It must act at **very low doses**, because the animal delivers a small volume and producing venom is metabolically expensive. And it must act on **vertebrate physiology** — on nervous transmission, on blood pressure and coagulation, o → Chapter 35: Peptide Discovery — From Venom to Artificial Intelligence
Fc fusion
Genetic fusion of a peptide to the constant fragment of an antibody, conferring large size and access to FcRn recycling. Converts the product from a peptide into a biologic. — Ch 33 §33.6 → Glossary contributions — Chapter 33 (Peptide Engineering)
FcRn (neonatal Fc receptor)
The salvage receptor that binds IgG Fc in acidified endosomes and returns it to the circulation instead of the lysosome. The reason antibodies persist for weeks. The same receptor, at a distinct site, also recycles albumin. — Ch 33 §33.6 → Glossary contributions — Chapter 33 (Peptide Engineering)
FDA (fda.gov)
Drugs@FDA gives approval histories for growth hormone products, including the sequence in which indications were added. The regulatory chronology is itself an argument: it shows which claims were supported well enough to be approved, and when. → Chapter 14 — Further Reading
FDA compounding pages and compounding risk alerts
`fda.gov`, human drug compounding section. The authoritative statement of what compounders may and may not do, the difference between 503A pharmacies and 503B outsourcing facilities, the bulk drug substances lists, and the agency's specific alerts on compounded GLP-1 products including the salt-form → Chapter 12 — Further Reading
FDA Drug Shortages database
the searchable list that determines whether the compounding exception is open for a given drug. Also carries resolution notices. This is the single fact that drove the entire case study in `case-study-01.md`. → Chapter 12 — Further Reading
FDA registered outsourcing facility list
the roster of 503B facilities. A supplier claiming 503B status either appears here or does not, and checking takes under a minute. → Chapter 12 — Further Reading
Feed conversion ratio (FCR)
Kilograms of feed consumed per kilogram of body mass gained. The other primary endpoint of livestock production research. *Ch 31 §31.3.* → Glossary contributions — Chapter 31
regulatory status, approved indications, availability, cost structure, who is selling it, what is not known, **date checked**, and where to re-check. Demonstrated in the chapter on compounded semaglutide and contrasted with the branded product. This is the field that goes stale fastest; an undated F → Chapter 12 — Key Takeaways
Field 12 check
The audit check requiring every entry to be falsifiable. Its operational test: could a reasonable person disagree about whether the named readout had arrived? *(Ch 40 §40.3, Check 4.)* → Glossary contributions — Chapter 40
Field 2 (Mechanism)
in the version built for **systems** rather than single molecules. Use it whenever a peptide belongs to a family with multiple ligands, multiple receptors, and internally opposing effects. The two rows that earn their keep are **Opposing effects** (where two arms of one system pull against each othe → Chapter 20 — Key Takeaways
Field 3 (Mechanism)
one plain sentence, then the receptor detail. | GLP-1 at its receptor | | 3 | **Field 2 (Origin)** — endogenous, analog, or wholly synthetic? | growth hormone vs. CJC-1295 | | 4 | **Field 4 (Pharmacology)** — route, half-life, and the modification that made it a drug. | semaglutide vs. native GLP-1 → Continuity Ledger — Understanding Peptides
fifteen-residue sequence
a **pentadecapeptide**, from the Greek for fifteen — described as derived from a gastric protein (Chapter 17). "Pentadecapeptide" is ordinary chemical vocabulary meaning exactly "a peptide of fifteen residues" and nothing more. The family is worth knowing: *di-* (2), *tri-* (3), *tetra-* (4), *penta → Appendix I — Peptide Nomenclature and How to Read a Sequence
Figure numbering
16.1 in index.md, 16.2 in case-study-01.md. Confirm the build's convention. 3. **Ch 8 §8.8 consistency check** at integration. §16.6's argument depends on Ch 8 reporting lean mass *falling* while physical function *improves*. 4. **§16.7's "no approved drug for sarcopenia"** is date-sensitive. Re-ver → Chapter 16 — Continuity record
Fill-finish
The manufacturing stage in which sterile drug product is filled into its final container. Capital-intensive, heavily regulated, slow to expand, and the binding constraint during the GLP-1 shortage. (Ch.12) → Ch12
the places where you were more generous or more severe than the evidence warranted, > and, more revealingly, whether you were consistently more generous about the compounds you wanted > to work. > > Everyone drifts. Noticing the direction of your own drift is the last skill the *method* has to > tea → Part VII — Synthesis and Reference
Find it in nature
isolate a molecule some organism already makes. 2. **Start from an endogenous ligand and modify it** — the Chapter 33 route. 3. **Screen an enormous library and select what binds** — display technologies. 4. **Design it computationally** — structure-based and de novo design. → Chapter 35 — Key Takeaways
First person appears sparingly and deliberately
chiefly in §43.2 ("I would rather leave you with a hole"), §43.4 ("I cannot source contemporary specifics"), and §43.6 ("I am not going to resolve this"). Each instance marks a place where the author is declining to do something, which is the one use of first person this book's voice permits. → Continuity — Chapter 43
First-pass metabolism
clearance by the liver of drug absorbed from the gut, before it reaches the general circulation. (Ch.4) → Glossary fragments — Chapter 4
Five claims, one category, four rating tiers
this chapter is the book's best single demonstration of rule 6 (one molecule/category, many ratings) and should be referenced as such if a later chapter needs an example. → Continuity — Chapter 25
Flag as an editorial choice
carry it with a note, or move it to a methodological row. Rating 2's split-by-population structure should be reproduced exactly. → Continuity notes — Chapter 11
The transient surge of hormone release preceding suppression when a pulsatile axis is stimulated continuously by a receptor agonist; clinically recognized and managed for in GnRH agonist therapy. (Ch.15) → Ch15
FLOW
the randomized outcomes trial of semaglutide in adults with type 2 diabetes and chronic kidney disease, stopped early for efficacy. (Ch.10) → Glossary fragments — Chapter 10
FLOW (kidney) was stopped early for efficacy
genuinely good news and a statistical complication. Trials that cross an interim boundary are enriched for chance-favorable results. **Direction trustworthy; magnitude held loosely.** → Chapter 10 — Key Takeaways
Fluid retention
GH axis > stimulation causes sodium and water retention, which can produce swelling, joint discomfort, and > carpal-tunnel-type symptoms, and which inflates lean mass measurements. **Appetite stimulation** — > MK-677 acts at the ghrelin receptor, and increased hunger is commonly described. Whether t → Chapter 15: Growth Hormone Secretagogues — CJC-1295, Ipamorelin, Tesamorelin, MK-677
The base-removable N-terminal protecting group used in the dominant modern synthesis strategy, paired with acid-removable side-chain groups so that the two respond to different triggers. [Ch 32 §32.2] → Glossary contributions — Chapter 32
Follistatin
An endogenous secreted glycoprotein of roughly 35–40 kDa that binds and inhibits myostatin, activin A, GDF-11, and some bone morphogenetic proteins. Named for its original discovery as an inhibitor of FSH secretion. Broad-spectrum rather than selective. — *Ch 16 §16.4* → Glossary contributions — Chapter 16
Follistatin-344
A gray-market compound named for the 344-residue follistatin precursor isoform. Not approved anywhere. Its size and glycosylation make product identity an unanswerable question from outside the seller. — *Ch 16 §16.4* → Glossary contributions — Chapter 16
Food noise
a patient-derived term for intrusive, persistent background preoccupation with food; frequently reported to quiet on GLP-1 receptor agonists, and currently lacking a validated measurement instrument. (Ch.7) → Glossary fragments — Chapter 7
a statement about the future that names what would prove it wrong and can therefore be graded, as distinct from a prediction, which merely asserts and can never be scored. → Chapter 36 — Glossary Contributions
the United States regulatory threshold separating drugs from biological products: more than 40 amino acids in a specific, defined alpha-amino-acid polymer is a biologic; 40 or fewer is a drug. It determines the follow-on competition pathway (Ch. 38). → Chapter 38 — Glossary fragment
Forward references made (must be honored):
**Ch 36** — "turns from how peptides are found to how they are made at scale." **CHECK THIS.** The part-06 directory currently contains both `chapter-36-the-future-of-peptide-medicine` and `chapter-36-whats-actually-coming`, and Ch 32 is titled "How Peptides Are Made." The closing sentence of §Concl → Continuity — Chapter 35
Forward:
**Ch. 13** — tirzepatide / retatrutide multi-agonists (Conclusion). - **Ch. 19** — unregulated market, "who is selling it" with no good answer (§12.3 callout, Dossier). - **Ch. 30** — cosmetic peptide market runs on the off-label and bundled-telehealth structures (Learning Paths, §12.6/§12.7). - **C → Chapter 12 — Continuity Record
A short peptide corresponding to a portion of a larger parent molecule. Whether a fragment reproduces the parent's activity is a testable hypothesis, not an inference available from structure. Fragment-based design is legitimate; the error is treating the parent's evidence as the fragment's. Compare → Glossary contributions — Chapter 18
fragment condensation
Building a long peptide by synthesizing and purifying shorter pieces separately and then joining them, avoiding the exponential yield collapse of many sequential couplings. [Ch 32 §32.6] → Glossary contributions — Chapter 32
Franz diffusion cell
An apparatus mounting excised skin between donor and receptor chambers to measure what crosses over time. Systematically overestimates penetration in living skin, because excised skin has no circulation and no living metabolism. *(Ch 30 §30.2)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
friction
as commercial defect → 42.1 - as clinical safety mechanism → 42.1 - conversion metrics blind to the distinction → 42.1 → Index entries — Chapter 42
From the brief's fact block, used as worded:
GHRH stimulates / somatostatin inhibits; GH acts largely via liver IGF-1; accelerator and brake. - GH secretion strongly pulsatile, mostly nocturnal, near-undetectable between bursts; single random GH measurement nearly uninterpretable; IGF-1 is the stable downstream measure. - GHRH analogs act at t → Chapter 15 — Continuity Record
Frontmatter `peptides_rated: []`
deliberate. The four ratings attach to structural claim-forms, not to molecules, and the Overview says so explicitly. Do not "fix" this by populating the field. - Currency escaped as `\$` where it appears. American spelling throughout. → Continuity — Chapter 42
the most interesting and least established. It would reconcile the animal knockout data with the clinical results, and Chapters 2 §2.7 and 3 §3.5 make it entirely coherent rather than absurd. It also predicts that a GIP *antagonist* should produce similar effects — which is being tested, since both → Answers — Chapter 9
Functional endpoint
A measurement of what a person can actually do: gait speed, chair-stand time, stair climb, six-minute walk distance, timed function tests, ambulatory assessment scales. Contrasted with surrogate endpoints such as lean mass. — *Ch 16 §16.6* → Glossary contributions — Chapter 16
Funnel
a designed sequence of steps converting a stranger's attention into a purchase and, usually, a recurring payment. A term used by the people who build them, not only by critics. → Chapter 42: The Creator Economy and the Peptide Pipeline
Further reading, Tier 1.
Erving Goffman, *Stigma: Notes on the Management of Spoiled Identity* (Prentice-Hall, 1963). - Susan Sontag, *Illness as Metaphor* (1978) and *AIDS and Its Metaphors* (1989). - Peter Conrad, *The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders* (Johns Ho → Bibliography notes — Chapter 44
Further reading, Tier 2.
Michael Bliss, *The Discovery of Insulin* (University of Chicago Press, 1982). - Marion Nestle, *Food Politics* (University of California Press, 2002). - Michael Moss, *Salt Sugar Fat* (Random House, 2013). - Attribution-theory stigma literature — described by search term rather than by citation, be → Bibliography notes — Chapter 44
G
G protein
an intracellular molecular switch activated by a GPCR, which then activates effector enzymes. (Ch.2) → Glossary fragments — Chapter 2
G-actin
The free, unpolymerized ("globular") form of actin, as distinct from the polymerized filamentous form. Thymosin β4's best-characterized biochemical activity is sequestering G-actin, buffering the pool available for polymerization; polymerization is how cells change shape, crawl, extend processes, an → Glossary contributions — Chapter 18
G-protein-coupled receptor (GPCR)
the largest family of membrane receptors, spanning the cell membrane seven times; the target of most peptide drugs and roughly a third of all approved drugs. (Ch.2) → Glossary fragments — Chapter 2
G-protein-coupled receptors
the receptor family that most peptide drugs target, and the subject of the 2012 Nobel Prize in Chemistry (Lefkowitz and Kobilka), whose lectures are, again, free. → Chapter 1 — Further Reading
a one-line note of the distance between what is approved and how a compound is discussed — which later chapters may ask readers to fill for other entries. → Continuity notes — Chapter 24
Gastric emptying
the rate at which stomach contents pass into the small intestine; slowed by GLP-1, flattening the post-meal glucose rise and producing the class's characteristic nausea. (Ch.7) → Glossary fragments — Chapter 7
Gastroparesis
severely delayed gastric emptying; for GLP-1 receptor agonists, the intended mechanism at its extreme rather than an unrelated adverse event. (Ch.8) → Glossary fragments — Chapter 8
GDF-11
A TGF-β superfamily member closely related to myostatin, signaling through the same type II receptor. Argued about in aging research. Relevant here as an off-target of pathway blockade. — *Ch 16 §16.3* → Glossary contributions — Chapter 16
General venom pharmacology
Toxinology reviews on venom composition, component diversity within single venoms, and disulfide-rich structural families recurring across unrelated lineages. Supports: §35.2 throughout, including the convergence claim and the protease-resistance argument. - **Claim strength note:** §35.2's "specifi → Bibliography notes — Chapter 35
Generic
a follow-on version of an approved drug, approved through an abbreviated application resting on demonstrated bioequivalence rather than repeated clinical trials (Ch. 38). → Chapter 38 — Glossary fragment
The single internationally assigned name for a molecule, identical across countries and across every product containing it. Assigned under INN/USAN convention using informative stems. (Ch.41) → Glossary contributions — Chapter 41
Genericide
The trademark-law endpoint of genericization, in which a mark becomes the common name for its category and loses legal protection. *Aspirin*, *escalator*, and *thermos* are completed cases. (Ch.41) → Glossary contributions — Chapter 41
Genericization
The process by which a brand name becomes the common noun for an entire product category. Harmless when one word maps to one molecule; harmful when one word covers multiple non-interchangeable products. (Ch.41) → Glossary contributions — Chapter 41
generous drift
See *directional bias*. Fingerprint: rating ⚠️ where the evidence supports ❌, with reasoning that leans on mechanism, animal data, or anecdote volume. *(New in Ch 37 §37.10.)* → Glossary contributions — Chapter 37
a small-molecule CGRP receptor antagonist (ubrogepant, rimegepant, atogepant, zavegepant). Not a peptide. *(Ch 22)* → Glossary contributions — Chapter 22
GH axis
the growth hormone axis: GHRH (stimulating) and somatostatin (inhibiting) to growth hormone to IGF-1. (Ch.3) → Glossary fragments — Chapter 3
GHK / GHK-Cu
Glycyl-histidyl-lysine, a naturally occurring tripeptide (~340 Da) first isolated from human plasma in the early 1970s, which binds copper with high affinity; the complex is listed on cosmetic labels as copper tripeptide-1. *(Ch 30 §30.4; rating first issued Ch 6 §6.8)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Ghrelin
a stomach-derived peptide that rises before meals and stimulates appetite; the only substantially orexigenic gut hormone known. (Ch.13) → Glossary fragments — Chapter 13
removed one hunger signal from a system with several others. Redundancy absorbed it. Ghrelin also has roles beyond appetite, so blockade was not clean. → Answers — Chapter 13
Ghrelin receptor (GHS-R)
The growth hormone secretagogue receptor; molecular target of GHRP-2, GHRP-6, ipamorelin, and MK-677. Characterized before its natural ligand was identified, which is the origin of its clunky name. (Ch.15) → Ch15
ghrelin receptor agonist
the same door as ipamorelin and the GHRPs, a completely different kind of molecule walking through it. It came out of a pharmaceutical discovery program aimed explicitly at that goal: find something that does what the GHRPs do, but that survives the stomach and can be swallowed. → Chapter 15: Growth Hormone Secretagogues — CJC-1295, Ipamorelin, Tesamorelin, MK-677
A hypothalamic peptide that stimulates growth hormone release from the pituitary. The accelerator of the GH axis. (Ch.14) → Ch14
GHRH (growth hormone-releasing hormone)
The hypothalamic hormone that stimulates pituitary growth hormone release; the accelerator of the GH axis. Native human GHRH is 44 amino acids, with biological activity residing in the first 29. (Ch.15) → Ch15
GHRH receptor
The pituitary receptor for GHRH, and the molecular target of sermorelin, CJC-1295, and tesamorelin. (Ch.15) → Ch15
GHRH(1-29)
The first 29 residues of native GHRH, sufficient to activate the GHRH receptor; the scaffold on which essentially every GHRH analog is built. (Ch.15) → Ch15
GHRP (growth hormone releasing peptide)
The family of peptides acting at the ghrelin receptor. GHRP-6 and GHRP-2 are the historical prototypes. (Ch.15) → Ch15
Gigantism
Growth hormone excess beginning before the growth plates close, producing extreme stature because the long bones can still lengthen. (Ch.14) → Ch14
GIP
glucose-dependent insulinotropic polypeptide, originally named gastric inhibitory polypeptide, which is a good illustration of how a molecule's name can outlive the understanding that produced it — is the other principal human incretin. It is a 42-amino-acid peptide, released from → Chapter 7: The Incretin System: GLP-1, GIP, and How Your Gut Tells Your Brain You're Full
a 42-amino-acid incretin from K cells; probably the larger contributor to the incretin effect in health, substantially blunted in type 2 diabetes, and with an unresolved role in obesity pharmacology. (Ch.7) → Glossary fragments — Chapter 7
glucagon-like peptide-1, the identity of the parent sequence. - **(7-36)** — this molecule consists of residues 7 through 36 of that parent, inclusive. Residues 1 through 6 exist in the precursor and are absent from the active hormone. - **amide** — the C-terminus is amidated rather than a free acid → Appendix I — Peptide Nomenclature and How to Read a Sequence
Glucagon
a 29-amino-acid peptide hormone from pancreatic alpha cells, cut from the proglucagon precursor, which raises blood glucose; used as rescue therapy for severe hypoglycemia. (Ch 7 for the precursor; Ch 29 for the drug) → Glossary contributions — Chapter 29
Glucose-dependence
the property, characteristic of incretin action, whereby insulin secretion is amplified only when blood glucose is elevated; the main reason GLP-1 receptor agonists rarely cause hypoglycemia alone. (Ch.3) → Glossary fragments — Chapter 3
GLUT4
the glucose transporter that relocates to the cell membrane in response to insulin, allowing glucose entry into muscle and fat cells. (Ch.11) → Glossary fragments — Chapter 11
Glycopeptide
A peptide bearing attached sugar groups. Vancomycin and teicoplanin are glycopeptides; their mechanism is cell wall inhibition rather than membrane disruption. *(25.8)* → Glossary contributions — Chapter 25
The enforceable framework of standards governing pharmaceutical manufacture: facilities, processes, documentation, testing, and release. "Manufactured under GMP to a named monograph" is a checkable claim; "pharmaceutical grade" is not. [Ch 32 §32.4] → Glossary contributions — Chapter 32
GMP — good manufacturing practice
Manufacturing quality requirements for regulated production. In the United States, 503B outsourcing facilities are subject to current GMP requirements and 503A compounding is not. A **manufacturing** standard, not a statement that a product works. → Appendix G — Regulatory and Legal Quick Reference
GnRH
gonadotropin-releasing hormone — is released by the hypothalamus in pulses, and those > pulses drive the pituitary to release the hormones that run the reproductive axis. Deliver GnRH in > pulses, and you stimulate the axis; this is used therapeutically to induce fertility in certain > conditions. > → Chapter 15: Growth Hormone Secretagogues — CJC-1295, Ipamorelin, Tesamorelin, MK-677
GnRH (gonadotropin-releasing hormone)
The hypothalamic hormone whose pulsatile release into the pituitary portal system drives LH and FSH secretion. Continuous rather than pulsatile stimulation desensitizes the pituitary and suppresses the axis. — Ch 24 §24.7 → Glossary contributions — Chapter 24
GnRH agonist
A stabilized analog of gonadotropin-releasing hormone that, delivered continuously, first stimulates and then desensitizes the pituitary receptor, producing sustained suppression. Generic names carry the `-relin` stem. *Ch 27 §27.2.* Cross-ref: Ch 1 §1.8. → Glossary contributions — Chapter 27
GnRH antagonist
A molecule that blocks the GnRH receptor directly, producing suppression without an initial surge. Peptide antagonists carry the `-relix` stem; nonpeptide oral antagonists do not. *Ch 27 §27.3.* → Glossary contributions — Chapter 27
trade in compounds sold without approval for human use, typically labeled "research use only"; carries identity, purity, potency, sterility, and endotoxin risks entirely independent of the molecule's pharmacology. (Ch.17; owned by Ch.19) → Glossary fragments — Chapter 17
Grip strength
a handheld dynamometer, squeezed. Cheap, fast, reproducible, and it predicts a > startling range of outcomes (disability, hospitalization, mortality) better than most expensive > measurements do. > **Chair-stand test** — rising from a chair five times without using the arms, timed. Functional > lowe → Chapter 16: IGF-1, Myostatin Inhibitors, and the Muscle-Building Peptides
Growth hormone (GH)
A 191-amino-acid, approximately 22 kDa single-chain peptide hormone secreted by somatotroph cells of the anterior pituitary. Acts directly on target tissues and indirectly through IGF-1. (Ch.14) → Ch14
Growth hormone deficiency (GHD)
Inadequate growth hormone production. In children it presents as growth failure; in adults as a characterized syndrome of increased central fat, reduced lean mass, reduced bone mineral density, adverse lipids, reduced exercise capacity, and impaired quality of life. (Ch.14) → Ch14
Growth hormone secretagogue
Any compound that stimulates the pituitary to release growth hormone rather than supplying growth hormone itself. Includes GHRH analogs, ghrelin receptor agonists, and non-peptide molecules such as MK-677. (Ch.15) → Ch15
Growth promotion
Intervening to increase growth rate or feed efficiency in food animals. An economic objective, not a clinical one. *Ch 31 §31.3.* → Glossary contributions — Chapter 31
Guanylate cyclase-C agonist
a drug that activates the guanylate cyclase-C receptor on the luminal surface of intestinal epithelium, increasing fluid secretion and transit. Linaclotide and plecanatide. (Ch 29) → Glossary contributions — Chapter 29
Guanylyl cyclase (particulate)
the enzyme activity built into the intracellular domain of NPR-A and NPR-B. Binding the peptide activates the enzyme directly, without a G protein. Contrast with → Glossary contributions — Chapter 28
the bidirectional signaling between gastrointestinal tract and central nervous system, carried by hormones, neural pathways, and other routes. (Ch.7) → Glossary fragments — Chapter 7
the rate of events in the treated group relative to the control group; 0.80 means events occurred at 80% of the control rate, a 20% relative reduction. (Ch.5) → Glossary fragments — Chapter 5
Head-to-head trial
a trial comparing two active treatments directly rather than either against placebo; comparatively rare, and valuable when the comparator is used at an appropriate dose. (Ch.9) → Glossary fragments — Chapter 9
Health equity
The absence of avoidable, unjust differences in health and in access to care between population groups. *(Ch 44 §44.6)* → Glossary contributions — Chapter 44
Health-technology assessment bodies
NICE in England, IQWiG in Germany, CADTH in Canada, PBAC in Australia. These publish their *reasoning* about whether a therapy is worth funding, which is the closest thing available to a public version of the decision described in `case-study-02.md`. Reading one of these appraisals end to end is the → Chapter 12 — Further Reading
Healthy adherer effect
the observation that people who take medication consistently have better outcomes than those who do not, including when the medication is placebo. (Ch.10) → Glossary fragments — Chapter 10
Helical wheel
A representation of an α-helix viewed down its axis, used to reveal whether residues segregate into hydrophobic and polar faces. *(25.2)* → Glossary contributions — Chapter 25
Hemolysis
Lysis of red blood cells, measured by incubating a peptide with erythrocytes and quantifying released hemoglobin. The standard *in vitro* readout of an AMP's toxicity toward mammalian membranes. *(25.5)* → Glossary contributions — Chapter 25
hepatorenal
syndrome
kidney failure in advanced liver disease, driven substantially by splanchnic vasodilation and the resulting fall in effective renal perfusion. Terlipressin constricts the splanchnic circulation and can thereby improve renal function where alternatives are limited and prognosis is poor. It received U → Chapter 29: The Peptide Drugs Already in Your Pharmacy
Hepatorenal syndrome
kidney failure occurring in advanced liver disease, driven substantially by splanchnic vasodilation and the resulting fall in effective renal perfusion. Terlipressin's principal modern indication. (Ch 29) → Glossary contributions — Chapter 29
a genetic disorder of episodic bradykinin-mediated deep tissue swelling, including potentially life-threatening airway involvement. Icatibant's indication. (Ch 29) → Glossary contributions — Chapter 29
Hexamer
the six-molecule zinc-coordinated complex insulin forms at storage concentrations; inactive, and must dissociate into monomers before the molecule can bind its receptor. (Ch.11) → Glossary fragments — Chapter 11
and the right proportion has to be decided in advance, in the laboratory, from preclinical data and early clinical signals, before anyone knows what the optimum is in the population that will eventually take the drug. If the ratio turns out to be wrong, you cannot adjust it. You design a new molecul → Chapter 33: Peptide Engineering — How Scientists Modify Peptides to Make Better Drugs
HIV-associated lipodystrophy
A redistribution of body fat seen in people living with HIV, characterized by peripheral subcutaneous fat loss and visceral fat accumulation. The population in which tesamorelin was tested and approved. (Ch.15) → Ch15
> **🔬 Read the Study — the denervated loop experiment** > > ```text > FIGURE 3.CS1 — "The pancreas that could not have known" [real published work] > THE STUDY Physiological experiment in anesthetized dogs. Bayliss and Starling, > University College London, 1902. Intervention: denervation of an > in → Case Study 1 — Secretin, 1902, and the Invention of the Hormone
Host defense peptide
Alternative term for an antimicrobial peptide, preferred where immunomodulatory, chemotactic, and wound-repair activities are the focus rather than direct killing. *(25.2)* → Glossary contributions — Chapter 25
How a drug's brand name entered the language
becoming a verb, a joke, a shorthand, an insult — and what happens to public understanding when a specific molecule with specific indications becomes a general word. - **The creator economy that sells these compounds** — the incentive structure behind the content you encounter, and how it decides wh → Chapter 40: Your Peptide Evidence Dossier — Putting It All Together
How long
start date, continuous or intermittent, anything that changed 3. **Why** you started — a clinical fact, not a justification 4. **What you have noticed** — including nothing; "no change at all" is real information 5. **What you want** — monitor, stop, an evidence opinion, an interaction check, a refe → Chapter 39 — Key Takeaways
how long the molecule survives
in the body
and that is what converted an interesting hormone into a drug people actually take. This is the pattern the closing section names, and this era is where it is most visible. → Appendix J — A Timeline of Peptide Science
and the chapter is built so that the two obvious moves are both wrong. Dismissing an unfamiliar literature is parochial and is a rule-4 violation (never downgrade with distaste). Accepting it because it exists abandons the standard applied everywhere else in the book. Students will want one of those → Instructor notes — Chapter 23
§18.2. Described as limited, with corneal and dermal indications having gone furthest, and as not having produced an approved product for tissue repair in a major jurisdiction. Verify current status via regulatory databases before revising; this is the claim in the chapter most likely to become stal → Bibliography notes — Chapter 18
Human equivalent dose (HED)
An animal dose divided by a species-specific correction factor. Used to set a maximum safe *starting* dose for a first-in-human study; not a tool for estimating an effective dose. *Ch 31 §31.5.* → Glossary contributions — Chapter 31
Hydrodynamic radius
The effective size a molecule presents to a filter, including its associated water shell. This, rather than molecular weight alone, governs renal filtration — and it is why PEG works. — Ch 33 §33.5 → Glossary contributions — Chapter 33 (Peptide Engineering)
Hydrolysis
the reverse of condensation: a bond broken by the addition of water. Digestive proteases hydrolyze peptide bonds, which is why most peptides cannot be swallowed. (Ch.1) → Glossary fragments — Chapter 1
Hype cycle
the predictable five-stage progression by which a real preclinical result becomes a commercial claim, losing qualifying information at each transition and requiring no dishonesty from any participant. (Ch.6) → Glossary fragments — Chapter 6
Hype outpaces evidence
for the claim as generally stated. *(Rated as of > 2026.)* > > **The one-sentence reason:** The category spans everything from a registered 503B facility using > genuine semaglutide base under inspected quality systems to material of unclear origin supplied as a > salt form without the delivery devi → ALL EVIDENCE RATINGS — harvested, do not edit by hand
Hyperplasia
An increase in the number of muscle fibers. Largely a developmental phenomenon in mammals; a substantial contributor to double-muscled animal phenotypes and essentially unavailable to adults. — *Ch 16 §16.1* → Glossary contributions — Chapter 16
Hypertrophy (muscle)
Growth of existing muscle fibers. The dominant and probably near-exclusive mode of muscle growth in adult humans. — *Ch 16 §16.1* → Glossary contributions — Chapter 16
Persistently low or absent sexual desire causing marked distress or interpersonal difficulty, not better explained by another condition, a medication or substance, or relationship circumstances. — Ch 24 §24.4 → Glossary contributions — Chapter 24
Hypoglycemia
blood glucose below the level the brain requires; insulin therapy's defining risk, progressing from tremor and confusion to seizure, coma, and death within an hour. (Ch.11) → Glossary fragments — Chapter 11
Hypoglycemia unawareness
loss of the adrenergic warning symptoms of falling blood glucose, common in long-standing type 1 diabetes and dangerous because the warning system has failed. (Ch.11) → Glossary fragments — Chapter 11
Hypogonadotropic hypogonadism
Gonadal failure secondary to inadequate upstream signaling from the hypothalamus or pituitary rather than to a defect in the gonads themselves. Normosmic forms are caused by, among other things, KISS1R loss-of-function mutations. — Ch 24 §24.7 → Glossary contributions — Chapter 24
Hyponatremia
Abnormally low blood sodium. A documented complication of high-dose oxytocin infusion, arising from oxytocin's activity at vasopressin V2 receptors at high concentration — chemistry, not impurity. Also the principal known risk of desmopressin. *(Ch 21 §21.1, §21.7, §21.8)* → Glossary contributions — Chapter 21
Hypothalamus
the brain region that integrates neural, environmental, and metabolic input and converts it into hormone release; the top tier of every endocrine axis. (Ch.3) → Glossary fragments — Chapter 3
hypothesis
the target was not causal, or was causal only in a subpopulation nobody could identify in advance, or was causal at an earlier stage of disease than the patients enrolled, or was causal and compensatory biology closed the gap. A better binder to a wrong target is a better binder to a wrong target. → Chapter 35: Peptide Discovery — From Venom to Artificial Intelligence
I
Icatibant
a synthetic decapeptide antagonist at the bradykinin B2 receptor, approved for acute attacks of hereditary angioedema; contains several non-proteinogenic residues. (Ch 29) → Glossary contributions — Chapter 29
identical dossiers
same fields, same evidence, same ratings — can reasonably choose differently, and neither is misreading the file. They differ in how they weight things the dossier does not contain: tolerance for uncertainty, the cost of the problem they are trying to solve, what happens if it goes wrong. A person m → Chapter 40: Your Peptide Evidence Dossier — Putting It All Together
identified broken step upstream
POMC is not made, or the leptin receptor cannot signal — and the drug acts **downstream** of the break, activating MC4R directly. → Answers — Chapter 13
One of six proteins that bind circulating IGF-1. Together with the acid-labile subunit they form a ternary complex that extends IGF-1's half-life from minutes to hours, restricts its distribution, and keeps it inert until released. Upward of 99% of circulating IGF-1 is bound. — *Ch 16 §16.2* → Glossary contributions — Chapter 16
A peptide of about 70 amino acids, structurally similar to proinsulin, produced largely in the liver in response to growth hormone and also locally in many tissues. Mediates most of growth hormone's growth effects and provides negative feedback to the pituitary. (Ch.14) → Ch14
IGF-1 LR3
often written "Long R3 IGF-1" — is a modified IGF-1 variant carrying a thirteen-residue N-terminal extension and a substitution at position 3. Both changes serve one purpose: **reduced binding-protein affinity and extended activity.** It slips the leash. Less of it is captured by IGFBPs, more of it → Chapter 16: IGF-1, Myostatin Inhibitors, and the Muscle-Building Peptides
IGF-1 LR3 (Long R3 IGF-1)
A modified IGF-1 variant carrying a thirteen-residue N-terminal extension and a substitution at position 3, producing reduced binding-protein affinity and extended activity. Originally developed as a cell-culture reagent for bioprocessing. Sold on the gray market; not approved anywhere; known by a c → Glossary contributions — Chapter 16
IGFBP (IGF binding protein)
A carrier protein, principally IGFBP-3, that binds circulating IGF-1 and greatly extends its circulating lifetime. This is why IGF-1 is stable enough to be measured usefully while growth hormone itself is not. (Ch.14) → Ch14
Ileal brake
the slowing of gastrointestinal transit triggered when nutrients reach the distal small intestine, mediated in part by GLP-1. (Ch.7) → Glossary fragments — Chapter 7
Immortal time bias
a bias arising from misclassifying time during which a patient could not have experienced the outcome. (Ch.10) → Glossary fragments — Chapter 10
and antibodies raised against > an administered version could in principle cross-react with a person's own follistatin. That is a > theoretical risk, stated as one: theoretical, with no monitoring, no data, and no way for an > individual to detect it. > > The point generalizes. When a product's biol → Chapter 16: IGF-1, Myostatin Inhibitors, and the Muscle-Building Peptides
A compound that alters immune function. A legitimate pharmacological category when the alteration is specified by immune arm, direction, magnitude, and population; an empty term when it is not. See *unfalsifiable claim*. [ch18 §18.3, §18.6] → Glossary contributions — Chapter 18
improved
which is what you would predict if the functional benefit of losing substantial fat mass outweighs the cost of losing some lean mass. → Answers — Chapter 8
a horse is not a person, and neither is a rat. 2. **For what?** — growth promotion is not injury recovery. 3. **Measured how?** — weight gain is not function, and no animal reports pain or wellbeing. 4. **And collected how?** — veterinary and laboratory use frequently generates no systematic outcome → Chapter 31 — Key Takeaways
In-group favoritism
Preferential treatment of members of one's own group; reported experimentally as one direction of oxytocin's context-dependent social effects, alongside increased defensiveness toward out-groups. *(Ch 21 §21.5)* → Glossary contributions — Chapter 21
INCI name
International Nomenclature of Cosmetic Ingredients; the naming system used for cosmetic ingredients, which describes modification and length rather than identifying a characterized drug substance. (Ch.1) → Glossary fragments — Chapter 1
A dense intracellular aggregate of misfolded protein formed when a host organism overexpresses a foreign protein. Convenient to isolate, but the material must be solubilized and refolded. [Ch 32 §32.5] → Glossary contributions — Chapter 32
Incretin
a gut hormone released in response to nutrients that amplifies insulin secretion; GLP-1 and GIP are the principal human incretins. (Ch.3) → Glossary fragments — Chapter 3
Incretin effect
the observation that a given blood glucose level produces substantially more insulin secretion when the glucose was taken orally than when infused intravenously. (Ch.3) → Glossary fragments — Chapter 3
statisticians and clinicians with no stake in the outcome — periodically looks at unblinded results that nobody else, including the sponsor and the investigators, is permitted to see. → Case Study 1 — The Trial That Stopped Itself
Index test
In a diagnostic accuracy study, the test being evaluated. Visual inspection of a photograph would be the index test in the study §41.3 describes and that does not exist. (Ch.41) → Glossary contributions — Chapter 41
the specific approved use of a drug as stated on its label, which is frequently narrower than the range of situations in which it is prescribed. (Ch.8) → Glossary fragments — Chapter 8
Indication expansion
the process by which a drug approved for one use accumulates evidence and subsequent approvals for others. (Ch.10) → Glossary fragments — Chapter 10
indication-specific
not a certificate about a molecule. "Approved" without an indication is an incomplete sentence. - It is **based on the evidence submitted** — so an unapproved use may be unstudied rather than rejected. - It is **jurisdiction-specific**, and agencies applying similar principles routinely reach differ → Chapter 38 — Key Takeaways
individual and unshared by default
invite volunteers, never call on someone. Second, hold the line the chapter holds: a rating is an input to a decision, not the decision, and two people with identical dossiers can reasonably choose differently. A student discovering a generous bias has not discovered that their choice was wrong. → Instructor notes — Chapter 40
Induced fit
the model in which ligand and receptor both adjust their shapes on binding, rather than fitting together as rigid complementary forms. (Ch.2) → Glossary fragments — Chapter 2
inference machinery
the five mechanisms of translational failure and the four questions — and veterinary medicine is the case material because it is where students' bad reasoning is most confident. → Instructor notes — Chapter 31
Information asymmetry
the imbalance between what a seller knows about a product and what a buyer can find out. (Ch.6) → Glossary fragments — Chapter 6
programmed cell death, which is among the body's main > defenses against a cell that has begun behaving badly. A signal that says "divide, and do not die" > is, at the level of mechanism, the kind of signal you would not choose to amplify without a reason. > > **Two: the observational association ex → Chapter 14: Growth Hormone — What It Does, How It Declines, and the Science of the "Youth Hormone"
the dose is already administered and cannot be withdrawn. Counter-regulation still operates, but it is now pushing against a fixed input it cannot influence, so glucose may keep falling. This is Chapter 3's counter-regulation argument in its sharpest form, and it is why hypoglycemia is unavoidable i → Chapter 11 — Quiz
Innate immunity
The fast, genetically encoded, non-specific arm of host defense that requires no prior exposure and generates no immunological memory. Far older and more widely distributed than adaptive immunity. *(25.2)* → Glossary contributions — Chapter 25
an insulin engineered with substitutions or modifications that alter its absorption profile and duration of action. (Ch.11) → Glossary fragments — Chapter 11
a receptor tyrosine kinase rather than a GPCR; ligand binding brings the receptor halves together, triggering autophosphorylation and a downstream cascade. (Ch.11) → Glossary fragments — Chapter 11
Insulin resistance
reduced tissue responsiveness to insulin, requiring higher concentrations for the same effect; the core defect in type 2 diabetes. (Ch.11) → Glossary fragments — Chapter 11
insulin transition
under which insulin was deemed a biological product in the United States — reclassified a century-old drug, opening the biosimilar pathway to it and changing the competitive landscape for a product that had been regulated as a conventional drug for its entire commercial life. Chapter 38 §38.2 covers → Appendix J — A Timeline of Peptide Science
Insulin-like growth factor 1 (IGF-1)
A 70-amino-acid single-chain polypeptide structurally related to proinsulin, produced largely in the liver in response to GH, mediating many of GH's anabolic effects. Acts on the IGF-1 receptor via PI3K/Akt and MAPK; promotes cell growth and inhibits apoptosis. — *Ch 16 §16.2* → Glossary contributions — Chapter 16
Penetration by winding through the lipid matrix between corneocytes; the dominant route for most substances, favoring small, moderately lipid-soluble molecules. *(Ch 30 §30.2)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Interchangeability
an additional determination beyond biosimilarity, bearing on whether a product may be substituted at the pharmacy level without prescriber involvement (Ch. 38). → Chapter 38 — Glossary fragment
Interest map
the dossier overlay introduced in this chapter: for each claim about a compound, the roles that gain if it is believed, and the identification of claims made by parties with no financial interest. → Chapter 42: The Creator Economy and the Peptide Pipeline
internal audit
Checking a dossier against itself for consistency of standard, as distinct from checking it against an external source for correctness of conclusions. Detectable without any external reference, which is what makes it possible to run on your own file. *(Ch 40 §40.3.)* → Glossary contributions — Chapter 40
A quasi-experimental design that looks for a break in an existing trend at the moment a policy or intervention took effect. One of the honest tools for population-level questions. *(Ch 44 §44.1)* → Glossary contributions — Chapter 44
Intranasal administration
Delivery via the nasal cavity. The route used in nearly all human behavioral oxytocin studies, and the subject of an unresolved controversy over central delivery. *(Ch 21 §21.6)* → Glossary contributions — Chapter 21
Intrathecal
administered directly into cerebrospinal fluid, bypassing the blood-brain barrier. The required route for ziconotide. — Ch 20 §20.9 → Glossary contributions — Chapter 20
Intrathecal administration
delivery directly into the cerebrospinal fluid, typically by catheter from an implanted pump. The required route for ziconotide, which does not cross the blood-brain barrier. *(Ch 4 introduced as a delivery route; Ch 35 clinical example)* → Glossary contributions — Chapter 35
intrathecally
directly into the cerebrospinal fluid, because it cannot reach its target any other way. Chapter 4's delivery constraints do not relent for interesting molecules. A peptide can be potent, selective, and clinically real and still require a route of administration that limits it to a narrow population → Appendix J — A Timeline of Peptide Science
Intrinsically disordered
describing a protein or region that does not adopt a single stable structure. Common in short peptides, and the regions where structure prediction confidence is systematically lowest. *(Ch 1 foreshadowed as "random coil"; Ch 35 named)* → Glossary contributions — Chapter 35
The observation, described in 1971, that the availability of good medical care tends to vary inversely with the need for it in the population served. (Ch.12) → Ch12
Investigational New Drug application (IND)
the filing that permits administration of an investigational compound to human beings. A permission to test, not an approval of anything (Ch. 38). → Chapter 38 — Glossary fragment
Ipamorelin
A pentapeptide ghrelin receptor agonist designed for selective growth hormone release. No completed outcome trials exist for the claims it is sold for. (Ch.15) → Ch15
Irradiance
power delivered per unit area at a stated distance. This varies by more than an order of magnitude across consumer products. - **Treatment area and distance**, since irradiance falls off sharply with distance. - **Whether the manufacturer publishes any of the above**, and whether anyone independent → Case Study 2 — Twelve Fields, No Peptide
the pH at which a molecule carries no net charge and is least soluble; shifting it is the mechanism by which insulin glargine precipitates at the injection site. (Ch.11) → Glossary fragments — Chapter 11
no frequency guidance, no titration, no route instruction anywhere in the chapter. - No sourcing, vendors, or purchasing guidance. No named fictional characters or private individuals; the Case Study 37.2 dossier is labeled `[constructed teaching example]` and its subject is "the learner." - Code fe → Continuity — Chapter 37 (The Peptide Evidence Table)
a peptide you can swallow that reaches systemic circulation and suppresses the immune system well enough to have made organ transplantation routine. Everything Appendix B §B.7 says about what D-substitution and N-methylation buy is visible in this one entry: D-residues that mammalian proteases canno → Appendix E — Approved Peptide Medicines by Indication
**The counterweight:** exenatide's duration was still inadequate for many patients, and the drugs that displaced it — liraglutide, semaglutide — **were** engineered. **Nature supplied the lead; chemistry supplied the drug.** Both clauses. → Chapter 35 — Key Takeaways
Item 13
students who choose (a) or (d) have read splits as hedges. Recover with the GHK-Cu example: the split is *more* precise than a single glyph. → Answer notes — Chapter 37
Item 17
the ten-versus-eight distinction is the whole item. Ten rows; two claims rated twice; eight distinct claims. Counting to eight also requires including the Ch 12 compounded-product row, which is not about the molecule — deliberate, and worth surfacing: a claim about a *product* is still a claim, and → Answer notes — Chapter 37
item 3, the comparator
and it was not obvious beforehand. The question was never "does collagen do anything." It was "does collagen do anything that protein does not." A reader who had written *more research needed* would have read the next positive trial without checking the one thing that determines whether it means any → Chapter 35: Peptide Discovery — From Venom to Artificial Intelligence
Items marked † are the hard ones
they require you to hold two positions at once, or to reason to a conclusion the chapter does not hand you. No answers are provided here; several of these have no single correct answer, and the ones that do are checkable against §23.1–§23.9. → Chapter 23 — Exercises
Items that discriminate well:
Q4 option (d) — students who think IGF-1 is unaffected by nutrition and age have memorized "IGF-1 is the stable one" without understanding why it needs age-referenced ranges. - Q8 — students who pick (a) "it's from 1990 and therefore outdated" have not understood scope; the date is not the problem. → Chapter 14 — Instructor Notes: Growth Hormone
J
Joke, as information vector
41.6 - **Joke, immunity from evaluation** — 41.6 - **Jumper, John** — ch35 **§35.8** - **Justification tax** — 41.8 → Appendix L — Index
Justification tax
This book's term for the social cost borne by people who must explain an approved prescription to strangers, colleagues, or family because the culture has coded the whole drug class as elective. Not a pharmacological cost. (Ch.41) → Glossary contributions — Chapter 41
an inhibitory GPCR opioid receptor preferred by the dynorphins. Mediates analgesia together with dysphoria and aversion rather than euphoria; produces little respiratory depression and has low abuse liability. — Ch 20 §20.3 → Glossary contributions — Chapter 20
Keep it there
this is a place where the safety guardrail (§11 of the style bible) and reader usefulness are in tension, and the resolution is descriptive rather than instructional. 6. **I did not state a specific BMI threshold** for the approved indication, only that one exists. Thresholds vary by jurisdiction an → Continuity notes — Chapter 8
The kisspeptin receptor. Loss-of-function mutations cause failure of puberty, which is the genetic evidence that kisspeptin signaling is necessary for activation of the reproductive axis. — Ch 24 §24.7 → Glossary contributions — Chapter 24
Kisspeptin
A hypothalamic peptide encoded by the *KISS1* gene, acting through KISS1R upstream of GnRH neurons and central to generating the pulsatile GnRH signal. — Ch 24 §24.7 → Glossary contributions — Chapter 24
The tripeptide lysine-proline-valine, corresponding to the C-terminal fragment of α-MSH, with reported anti-inflammatory activity in preclinical models, principally models of intestinal inflammation. Studied under its own name rather than inheriting α-MSH's citations. [ch18 §18.5] → Glossary contributions — Chapter 18
KPV / α-MSH preclinical literature
§18.5. Preclinical, concentrated in models of intestinal inflammation. Noted specifically as work conducted under KPV's own name, which is the contrast with §18.1. → Bibliography notes — Chapter 18
L
L cell
the enteroendocrine cell that produces GLP-1, concentrated in the distal small intestine and colon. (Ch.7) → Glossary fragments — Chapter 7
Label
The reviewed document accompanying an approved drug, describing the approved use, the population studied, the dosing evaluated, the adverse events observed, and required warnings. **It tells you what was submitted and approved, not what is known** (§G.6). → Appendix G — Regulatory and Legal Quick Reference
Label (approved label)
the reviewed document accompanying an approved drug describing the approved use, the population studied, dosing evaluated, adverse events observed, and required warnings. It records what was submitted and approved, not what is known (Ch. 38). → Chapter 38 — Glossary fragment
Lactam bridge
An amide bond formed between two amino acid side chains (here, an aspartate and a lysine), used to cyclize a peptide. Chemically more robust than a disulfide bond. — Ch 24 §24.1 → Glossary contributions — Chapter 24
Larazotide
An octapeptide studied for celiac disease as a tight junction regulator. Taken orally and deliberately designed **not** to be absorbed, because its target is at the apical surface of the intestinal epithelium, facing the gut lumen. A rare and instructive case in which non-absorption is the specifica → Glossary contributions — Chapter 18
Larazotide clinical program
§18.5. Human trials in celiac disease. The chapter deliberately reports no verdict. Registry entries are the right source; do not summarize published results without reading the registry entry alongside. → Bibliography notes — Chapter 18
large bacterial protein
thousands of residues, a complex multi-domain structure with enzymatic activity — and it is not a short peptide by any measure. It is in the popular imagination as the archetypal "peptide injection," and it appears in Chapter 30 alongside cosmetic peptides because that is the company it keeps in cli → Appendix E — Approved Peptide Medicines by Indication
Inherited insensitivity to growth hormone at its receptor, producing very low IGF-1 signaling for a lifetime and short stature. Studied cohorts have been reported to show remarkably low rates of diabetes and cancer. The mirror-image natural experiment to acromegaly. (Ch.14) → Ch14
Laron syndrome (GH receptor deficiency)
An inherited defect in GH receptor signaling producing very low lifetime IGF-1 and severe short stature. A long-followed cohort has been reported to show strikingly low cancer and diabetes incidence relative to unaffected relatives — the natural experiment at the low end of the growth-signaling axis → Glossary contributions — Chapter 16
Laron syndrome cohort reports
long-term follow-up of populations with inherited growth hormone receptor insensitivity, reporting strikingly low incidence of diabetes and cancer alongside other health issues. Small populations, extraordinary observations. Treat as a genuine and important signal and not as a general prescription. → Chapter 14 — Further Reading
Late 1980s–1990s
GLP-1 infusion studies in humans confirm the physiology, including in people with type 2 diabetes, where GLP-1's effect is preserved while GIP's is blunted. The therapeutic implication is now obvious and the delivery problem is now clearly the obstacle. → Case Study 1 — Forty Years of Nobody Caring
Lawful
an approved drug may be prescribed for an unapproved indication, as clinical judgment about an individual patient | **Generally prohibited** — a manufacturer may not market a drug for an unapproved use | | Why the rule sits this way | Medical practice moves faster than regulatory filings, and should → Appendix G — Regulatory and Legal Quick Reference
Lean mass
non-fat body mass, including muscle; a surrogate for strength and physical function rather than a substitute for measuring them. (Ch.8) → Glossary fragments — Chapter 8
Legal fiction
a formally maintained characterization that all parties understand does not describe the actual transaction. (Ch.6) → Glossary fragments — Chapter 6
Leptin
targeted a signal that was *already maximal*. Adding more of a message being ignored changes nothing. The failure was not redundancy exactly; it was resistance, which is redundancy's cousin: the system had already routed around the signal. → Answers — Chapter 13
Leptin resistance
reduced responsiveness to leptin despite elevated circulating levels; the state characterizing common obesity, and the reason leptin failed as a general therapy. (Ch.13) → Glossary fragments — Chapter 13
they are structural isomers, and no mass measurement can distinguish them. Chapter 34 made this point about mass spectrometry's limits; here is where it comes from. → Appendix B — The Twenty Amino Acids: A Reference
**Achieving matched weight loss is very hard.** No other intervention produces comparable weight loss reliably, so the comparator arm will likely lose less, reintroducing the confound. - **Enormous size and duration.** Cardiovascular events in a population healthy enough to randomize this way accrue → Answers — Chapter 10
Linaclotide
a 14-amino-acid guanylate cyclase-C agonist, taken orally and designed for minimal systemic absorption, approved for IBS-C and chronic idiopathic constipation. (Ch 29) → Glossary contributions — Chapter 29
Line of therapy
Where a treatment sits in a sequence: first-line, or after specified prior treatments. A load-bearing element of oncology labels. *Ch 27 §27.5, Dossier.* → Glossary contributions — Chapter 27
The chemical connector between resin and peptide chain, chosen to hold reliably through every cycle and release cleanly under defined conditions at the end. Different linkers leave different chemical groups at the C-terminus. [Ch 32 §32.1] → Glossary contributions — Chapter 32
Lipid A
The membrane-anchoring portion of lipopolysaccharide; the site modified by aminoarabinose or phosphoethanolamine in charge-based AMP resistance. *(25.3)* → Glossary contributions — Chapter 25
Breakdown of stored triglyceride in adipose tissue with release of free fatty acids. A direct growth hormone effect and the main reason fat mass falls when growth hormone is administered. (Ch.14) → Ch14
Lipopeptide
A peptide bearing a covalently attached lipid tail. Colistin, polymyxin B, and daptomycin are cyclic lipopeptides. *(25.8)* → Glossary contributions — Chapter 25
Lipopolysaccharide (LPS)
The major constituent of the Gram-negative outer leaflet. Its lipid A anchor carries phosphate groups supplying much of the surface's negative charge and serving as the polymyxin binding site. *(25.3)* → Glossary contributions — Chapter 25
List price (WAC)
The price a manufacturer publishes for a product. Public, paid by almost nobody with insurance, and the number that appears in headlines. (Ch.12) → Ch12
Listen for:
✅ Someone states that the failed chains kept growing and are still in the vessel. This is the chapter's central mechanical insight and everything else depends on it. - ✅ Someone notices it is not *one* impurity but many — up to one per position. - ⚠️ "It's waste" / "it fell apart" — the absence mode → Instructor Notes — Chapter 32
livestock research
§31.3; case study 1 rating — §31.3 ghrelin-receptor agonist, veterinary appetite stimulation — §31.1, §31.9 GnRH analogs **veterinary reproductive management** — §31.1 rating — §31.1 dossier entry — dossier insulin veterinary use in dogs and cats — §31.1 species sequence differences — §31.5 canine/p → Index entries — Chapter 31
LL-37
The human cathelicidin antimicrobial peptide. Has direct membrane-disrupting antibacterial activity *and* separate immunomodulatory properties; the two activities are measured differently and can dissociate. Appears in Ch. 18 only as a bridge; rated in Ch. 25. [ch18 §18.4] → Glossary contributions — Chapter 18
LL-37 / cathelicidin literature
§18.4. Described only in scope: direct antimicrobial activity, separate immunomodulatory functions, and the selectivity problem inherent to membrane-disrupting mechanisms. **Full citation burden belongs to Ch. 25.** Coordinate with Ch. 25's bib file before adding anything here. → Bibliography notes — Chapter 18
load-bearing
§22.5 explicitly calls itself "Chapter 2 §2.9 in its purest form." Verify §2.9 exists with that numbering and that framing. | | Flat versus pulsatile exposure | Ch 3 | §22.3 (Joint 2) | light | | Rating system; rating attaches to a claim not a molecule | Ch 5 | throughout | standard | | Area postrem → Continuity notes — Chapter 22
local
activating receptors on vagal afferent nerve endings in the gut wall a very short distance from the L cell, with the vagus then relaying the signal neurally to the hindbrain. The hormone may function more as a paracrine signal with a neural relay than as a classical endocrine one. → Chapter 7 — Quiz
canine receptor mutation, orexin-null mice, and low or undetectable CSF orexin-A in humans. One of the cleanest neuropeptide-deficiency-to-disease links known. - **Orexin receptor antagonists became approved insomnia drugs** (suvorexant and successors) — a genuinely new hypnotic class that removes a → Chapter 22 — Key Takeaways
through surgery, medical therapy, or radiation — and outcomes improve toward population norms, you have something functionally like a dose-response relationship. You have watched the outcome track the exposure in both directions. That is one of the classic criteria for inferring causation from obser → Case Study 14.2 — Acromegaly: The Experiment Nobody Designed
lyophilization
Freeze-drying; the usual final isolation step for a peptide, producing a hygroscopic powder that retains residual water. [Ch 32 §32.4] → Glossary contributions — Chapter 32
major adverse cardiovascular events; a composite endpoint typically comprising cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. (Ch.5) → Glossary fragments — Chapter 5
Magainin
An α-helical antimicrobial peptide isolated from the skin of *Xenopus laevis* and described in 1987. Historically the compound class that opened AMPs to drug development. *(25.4)* → Glossary contributions — Chapter 25
Magainins
Zasloff's characterization of magainins from *Xenopus laevis* skin, late 1980s. Supports: §35.4. - Antimicrobial peptide field reviews spanning multiple decades. Supports: §35.4's closing point about the gap between discovery and translation, and links to Chapter 25. → Bibliography notes — Chapter 35
Magnocellular neuron
Large hypothalamic neurons (paraventricular and supraoptic nuclei) that synthesize oxytocin and vasopressin and project to the posterior pituitary, firing in synchronized bursts to produce pulsatile release. *(Ch 21 §21.1, §21.2)* → Glossary contributions — Chapter 21
Making the molecule
synthesis/fermentation, purification, drying/isolation. **Making it a medicine** — formulation, aseptic fill-finish, delivery device, cold chain. **Proving it is a medicine** — QC and release testing, quality systems and regulatory compliance. **Everything before** — recovered development cost inclu → Answers — Chapter 32
manufacturers may not promote off-label use.
The asymmetry is deliberate: it **preserves clinical freedom while keeping the evidentiary burden on the party that profits from the claim.** - **Off-label is not a synonym for unsupported.** Some off-label uses rest on substantial published evidence nobody had reason to submit; others rest on almos → Chapter 38 — Key Takeaways
Many modern products are hybrids
recombinant or synthetic backbone plus defined chemical modification. The routes are stages, not rivals. → Chapter 32 — Key Takeaways
Mapping to §2.9's steps:
Naming the compound and its receptor action → **step 1** - Dose, route, duration → **steps 2 and 3** - A measurable change in a hormone level → **step 4** (evidence the machinery responded) - Persistence over the stated duration → **step 5** (the system did not fully compensate) - Improvement in a n → Answers — Chapter 3
A proposed lump-sum payment on approval of a qualifying novel antibiotic, decoupling revenue from sales volume. *(25.6)* → Glossary contributions — Chapter 25
Marketing authorization
the term used in the European Union and elsewhere for what United States practice calls an approval (Ch. 38). → Chapter 38 — Glossary fragment
MASLD
metabolic dysfunction-associated steatotic liver disease — is fat accumulation in the liver associated with metabolic dysfunction. Its inflammatory, progressive form is **MASH**. (Both were until recently called NAFLD and NASH; the terminology changed to remove the alcohol-defined negative and to na → Chapter 10: Beyond Weight Loss: GLP-1 for the Heart, Kidney, Liver, Brain, and Addiction
an analytical technique measuring the mass-to-charge ratio of ions. A peptide's exact mass follows from its composition, so a measured mass strongly constrains identity. Structurally blind to stereochemistry and to isomeric substitutions. (§34.2) → Glossary contributions — Chapter 34
Mass-to-charge ratio (m/z)
the quantity a mass spectrometer actually measures. Because peptides commonly carry multiple charges, one peptide produces a family of peaks that software deconvolutes to a single neutral mass. (§34.2) → Glossary contributions — Chapter 34
Master ratings appendix
six rating rows from this chapter need to be merged in, including the inherited GHK-Cu split (which should appear once, attributed to Ch 6 with a Ch 30 locator, not twice as separate ratings). → Continuity record — Chapter 30 (Cosmetic Peptides)
master table
The reference table in Chapter 37 §37.5 reproducing all 140 molecule-and-indication ratings issued across Chapters 2–44, organized into ten therapeutic-area blocks, with the source chapter given for each row. Chapters 37 and 40 contribute none, because they restate ratings rather than issue them. *( → Glossary contributions — Chapter 37
The melanocortin receptor expressed on melanocytes. Activation shifts pigment production toward eumelanin, darkening skin, hair, and existing moles. — Ch 24 §24.2 → Glossary contributions — Chapter 24
MC3R / MC4R
Central nervous system melanocortin receptors involved in energy balance and in sexual function. MC4R is the receptor Chapter 13 covers for appetite. — Ch 24 §24.2 → Glossary contributions — Chapter 24
the receptor at which the appetite circuit's accelerator and brake converge; the most common known monogenic contributor to obesity. (Ch.13) → Glossary fragments — Chapter 13
mcr
A family of plasmid-borne genes encoding phosphoethanolamine transferases that modify lipid A, reducing outer-membrane negative charge and conferring transferable colistin resistance. First reported 2015. *(25.3)* → Glossary contributions — Chapter 25
Mecasermin
Recombinant human IGF-1, approved for severe primary IGF-1 deficiency in children and for GH gene deletion with neutralizing antibodies to GH. Labeling carries a prominent hypoglycemia warning. — *Ch 16 §16.2* → Glossary contributions — Chapter 16
The conversion of mechanical deformation of structural proteins into biochemical signaling; the process by which mechanical loading initiates the anabolic response in muscle. — *Ch 16 §16.1* → Glossary contributions — Chapter 16
Medicalization
The process by which a human variation or difficulty comes to be described, studied, and treated as a medical condition. A description of a process, not automatically a criticism. — Ch 24 §24.4 → Glossary contributions — Chapter 24
Medullary thyroid carcinoma
a rare thyroid cancer arising from C-cells; the subject of the GLP-1 agonist class boxed warning, based on rodent findings not demonstrated in humans. (Ch.8) → Glossary fragments — Chapter 8
Melanocortin
The family of peptides derived from proopiomelanocortin, including α-MSH and ACTH, acting at the melanocortin receptors. — Ch 24 §24.1 → Glossary contributions — Chapter 24
Melanocortin receptor
A family of five G-protein-coupled receptors, MC1R through MC5R, differing chiefly in tissue distribution and therefore in physiological consequence. — Ch 24 §24.2 → Glossary contributions — Chapter 24
Melanocortin receptor pharmacology reviews
MC1R through MC5R tissue distribution and function; POMC processing yielding α-MSH, ACTH, and β-endorphin. Any standard endocrinology text covers this; the chapter makes no claim here that is contested. → Bibliography notes — Chapter 24
Melanocortin system
the hypothalamic circuit in which α-MSH activates and AgRP blocks the MC4R receptor, setting appetite; the convergence point of the leptin signal. (Ch.13) → Glossary fragments — Chapter 13
Melanocytic nevus
A mole; a benign localized proliferation of melanocytes. Changes in existing nevi are among the published case-report findings in melanotan II users. — Ch 24 §24.6 → Glossary contributions — Chapter 24
Melanotan II
An unapproved cyclic melanocortin agonist, structurally very close to bremelanotide but with greater MC1R activity, widely sold and used for cosmetic tanning. — Ch 24 §24.6 → Glossary contributions — Chapter 24
MEN2 (multiple endocrine neoplasia type 2)
an inherited syndrome carrying high medullary thyroid carcinoma risk; a contraindication to GLP-1 receptor agonist therapy. (Ch.8) → Glossary fragments — Chapter 8
Message-address
the organizing description of endogenous opioid peptide structure: a shared N-terminal Tyr-Gly-Gly-Phe motif ("message") that signals *opioid* to a receptor, plus a divergent C-terminal extension ("address") that determines receptor preference, survival time, and distribution. — Ch 20 §20.2 → Glossary contributions — Chapter 20
Meta-analyses of intranasal oxytocin in autism.
**PTSD trial literature**, including studies reporting context-specific or subgroup effects. Flag clearly in the reference annotation which findings were prespecified. - **Social anxiety literature**, including the oxytocin-plus-exposure-therapy work reporting improvement in self-appraisal without c → Bibliography notes — Chapter 21
The fall in energy expenditure following weight loss, beyond what the loss of tissue mass alone predicts. Part of the body's defense of a set point. (Ch.12) → Ch12
the observation that a period of good glycemic control appears to confer durable benefit after the period ends; named from an observational extension, and not mechanistically established. (Ch.11) → Glossary fragments — Chapter 11
then working on African clawed frogs (*Xenopus laevis*) for unrelated reasons — noticed something about the animals' recovery from surgery. Frogs returned to tanks of unsterile water healed without infection. Something in the skin was doing antimicrobial work. → Chapter 35: Peptide Discovery — From Venom to Artificial Intelligence
microbial natural products
mostly non-ribosomally synthesized compounds that soil bacteria and fungi evolved to attack each other, found by screening programs rather than designed from human immunology. They are structurally strange by peptide standards: cyclic, lipidated, glycosylated, full of non-standard residues, and shap → Appendix E — Approved Peptide Medicines by Indication
Microneedling
Physical puncture of the skin barrier with fine needles. Unambiguously effective as a delivery method, and therefore carrying risks the other approaches do not, since ingredients formulated for intact skin are introduced into channels reaching living tissue. *(Ch 30 §30.2)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
mid-1980s
removed the supply constraint | | Compounds entering human trials that reach approval | roughly **1 in 10** | → Chapter 14 — Key Takeaways
Neuroendocrine arc in which suckling or infant cues trigger pulsatile oxytocin release, causing myoepithelial contraction and milk let-down. Distinct from milk production, which is prolactin's role. A textbook illustration of Ch 3's pulsatile-versus-flat distinction. *(Ch 21 §21.2)* → Glossary contributions — Chapter 21
Minimal clinically important difference
general psychometrics literature; also instrument-specific estimation literature for sexual-function questionnaires. → Bibliography notes — Chapter 24
Minimal clinically important difference (MCID)
the smallest change in an outcome measure that patients perceive as meaningful; a statistically significant difference below the MCID is a finding about biology, not a reason to act. (Ch.17) → Glossary fragments — Chapter 17
Minimum inhibitory concentration (MIC)
The lowest concentration of an agent preventing visible bacterial growth under defined conditions. The standard measure of antibacterial potency; lower is better. *(25.5)* → Glossary contributions — Chapter 25
Misattribution
Assigning a result to a cause that did not produce it. Distinguished from non-disclosure: silence makes no claim, misattribution makes a false one and is therefore subject to ordinary evidence evaluation. (Ch.41) → Glossary contributions — Chapter 41
MK-677 (ibutamoren)
An orally active, long-acting ghrelin receptor agonist that is **not a peptide**. Reliably raises GH and IGF-1 in humans and carries a documented signal for increased blood glucose and reduced insulin sensitivity. Not approved. (Ch.15) → Ch15
individualized manufacturing as a therapeutic platform — has not yet produced a completed confirmatory trial demonstrating durable clinical benefit. Under rule 5 that judgment is date-stamped and falsifiable, and may well be wrong by the time you read it. That is a feature. **A rating you cannot ima → Chapter 26: Peptide Vaccines — Cancer Immunotherapy and Infectious Disease Prevention
modality versus product
The distinction between an intervention type with a clinical literature and a specific marketed item claiming to deliver it. Evidence attaches to specified exposures; an item that does not specify its exposure has inherited nothing. The non-molecular counterpart of the peptide/vial distinction of Ch → Glossary contributions — Chapter 40
Model organism
A species studied as a stand-in for another, chosen for tractability and therefore chosen partly for the ways it differs from what it stands in for. *Ch 31 §31.5.* → Glossary contributions — Chapter 31
moderation, keyword-based
as topic classifier, not evidence classifier → 42.5 - euphemism dialects and pressure toward imprecision → 42.5 → Index entries — Chapter 42
modified GRF(1-29) fragment without DAC
peptidase-resistant substitutions only, duration far shorter. The key reasoning: aggregation of informal reports requires that the reports be about the same thing. Here they are not, and the reports do not reliably say which molecule is involved, so pooling them mixes two pharmacologies. This is why → Chapter 15 — Worked Solutions
monitoring
what supervision adds → 39.9; unavailable for undisclosed exposure → 39.2 - **moral framing, as obstacle to disclosure** → 39.2 → Index entries — Chapter 39
Monitoring (reinforced)
baseline and interval measurement aimed at detecting specific foreseeable harms, plus a defined response pathway. Genuinely valuable; entirely unavailable for an undisclosed exposure; and not a substitute for evidence about whether something works. *Defined Ch 19 §19.7; applied Ch 39 §39.2, §39.9.* → Glossary contributions — Chapter 39
severe, early-onset obesity caused by a single gene defect, identifiable by molecular diagnosis. (Ch.13) → Glossary fragments — Chapter 13
Monograph
a pharmacopeial document specifying what a substance must be and what it must meet, including required tests, methods, and acceptance criteria. Defines the specification; does not address how the material was made. (§34.10) → Glossary contributions — Chapter 34
Monoisotopic mass
a molecule's mass calculated using the most abundant isotope of each element. Distinct from **average mass**, which uses natural abundance-weighted isotopic averages; the two diverge as molecules get larger. (§34.2) → Glossary contributions — Chapter 34
Monopsony
A market with a single dominant buyer; the buyer-side mirror of monopoly. The mechanism by which national health systems obtain lower drug prices. (Ch.12) → Ch12
Most peptide receptors are GPCRs
seven-transmembrane proteins, roughly 800 of them in humans, the target of about a third of all approved drugs. Cascade: peptide → receptor shape change → G protein → effector enzyme → second messenger (usually cAMP) → kinases → cellular response → termination. → Chapter 2 — Key Takeaways
Most 🔬 becomes ❌.
**A 🔬 entry must name the readout that would move it.** If you cannot name one, it is not a frontier entry — it is an enthusiasm. - **A 🔬 entry must carry a date.** An undated entry cannot age, and an entry that cannot age can never be found stale. - **A 🔬 entry may never be upgraded by news.** Not → Chapter 36 — Key Takeaways
Motivated reasoning
reasoning shaped by a preferred conclusion; invisible from inside, and indistinguishable from hope when experienced. (Ch.6) → Glossary fragments — Chapter 6
mRNA display
a cell-free selection technology in which a peptide is covalently linked to its own messenger RNA through a chemical adaptor, permitting libraries far larger than can be transformed into cells. *(Ch 35)* → Glossary contributions — Chapter 35
Mu receptor (μ, OPRM1)
the inhibitory GPCR opioid receptor responsible for the analgesia, euphoria, respiratory depression, constipation, itch, miosis, tolerance, and dependence associated with clinical opioids. The target of morphine and of nearly every clinical opioid analgesic. — Ch 20 §20.3 → Glossary contributions — Chapter 20
the two reasons the ranking is what it is. **Deduct if the student ranks by p-value magnitude**; the smallest p-value here belongs to the least trustworthy finding, which is exactly the trap. → Practical Evaluation Exam — Open Book
must preserve the unresolved status
do not let Ch 9 resolve it. The "agonist behaving like an antagonist via desensitization" possibility in particular must stay labeled as unestablished. 2. **§7.7's "food noise" callout deliberately holds two positions at once** — genuine and important patient observation, and evidence of a kind Chap → Continuity notes — Chapter 7
Myonuclear domain
The volume of cytoplasm governed by a single nucleus within a multinucleated muscle fiber. The concept underlying why substantial fiber growth appears to require added nuclei. — *Ch 16 §16.1* → Glossary contributions — Chapter 16
Myostatin
a negative regulator of skeletal muscle mass signaling through the activin type II receptors; blocking myostatin or those receptors increases muscle mass in animal models (Chapter 16), which is the rationale behind the agents in §36.6. → Chapter 36 — Glossary Contributions
Myostatin (GDF-8)
A TGF-β superfamily member produced and secreted by skeletal muscle that acts back on muscle as a negative regulator of growth — a brake. Signals via ActRIIB, a type I receptor, and Smad2/3. Loss of function produces marked hypertrophy in mice, cattle, dogs, and rare human cases. — *Ch 16 §16.3* → Glossary contributions — Chapter 16
Myostatin (GDF-8) is a negative regulator
a brake — signaling through ActRIIB and Smad2/3. - Natural loss of function is documented in **mice, cattle (double-muscled breeds), dogs, and rare human cases**. This is real and striking, and it is the best-supported part of the story. - **A developmental knockout is not adult blockade.** The anim → Chapter 16 — Key Takeaways
N
N-methylation
addition of a methyl group to a peptide backbone amide nitrogen. Reduces protease recognition and removes a hydrogen-bond donor, substantially increasing membrane permeability. Central to cyclosporine's oral activity. (Ch 29; see also Ch 33) → Glossary contributions — Chapter 29
n-of-1
an observation in a single individual; compelling as narrative and near-worthless as evidence of efficacy, because a single uncontrolled case cannot distinguish treatment from natural recovery, expectation, or regression to the mean. (Ch.6) → Glossary fragments — Chapter 6
N-terminus
the end of a peptide chain bearing a free amino group. Sequences are written and numbered from here by universal convention. (Ch.1) → Glossary fragments — Chapter 1
Naloxone
a short-acting competitive opioid receptor antagonist. Used clinically to reverse overdose and experimentally as the standard probe for whether an effect is opioid-mediated. — Ch 20 §20.1 → Glossary contributions — Chapter 20
narcolepsy with cataplexy, caused by loss of orexin-producing neurons, most likely by an autoimmune process in genetically susceptible people. Low or undetectable CSF orexin-A is a diagnostic criterion. *(Ch 22)* → Glossary contributions — Chapter 22
Nasal glucagon
a dry powder delivered into the nostril, absorbed across the nasal mucosa and notably *not* requiring the recipient to inhale, which matters when the recipient is unconscious — reached the market, as did → Chapter 29: The Peptide Drugs Already in Your Pharmacy
National regulator equivalents outside the US
the European Medicines Agency, the UK MHRA, Health Canada, the TGA in Australia. Indications, thresholds, and availability differ by jurisdiction, and §12.6's refusal to state BMI numbers is the direct consequence. Use the regulator for the country you live in. → Chapter 12 — Further Reading
native chemical ligation
A method, introduced in the mid-1990s, for joining two unprotected peptide fragments selectively in water at a specific junction. Extended chemical synthesis into territory previously reachable only by recombinant means. [Ch 32 §32.6] → Glossary contributions — Chapter 32
a peptide released by cardiac muscle in response to stretch, promoting sodium and water excretion and vasodilation; ANP and BNP are the principal ones. (Ch.3) → Glossary fragments — Chapter 3
Natriuretic peptide resistance
the observation that in established heart failure, circulating natriuretic peptide levels are markedly elevated while the physiological effect is blunted. Contributing mechanisms include receptor downregulation, increased clearance, and impaired precursor processing. [Ch 28] → Glossary contributions — Chapter 28
Natriuretic peptide-guided prevention
using the biomarker to find people at risk of developing heart failure and intervening early — has some encouraging randomized evidence and nothing like the weight behind the diagnostic claim. ⚠️ at best, and note that it is a *fifth* distinct claim about the same measurement. → Chapter 28: Natriuretic Peptides — The Heart Failure Biomarkers That Became Treatments
Natural experiment
A situation in which something approximating random assignment occurred by circumstance rather than by design, permitting causal inference without a randomized trial. Sits above observational correlation and below a randomized trial on the evidence ladder. *(Ch 5; Ch 44 §44.1)* → Glossary contributions — Chapter 44
most injuries heal and most acute conditions resolve. The question is never "did it improve" but "did it improve faster than it would have," and an individual has no access to the counterfactual. → Answers — Chapter 6
elevated IGF-1 inhibits GH release and raises somatostatin. (ii) **Receptor downregulation** — persistent stimulation often reduces receptor number or responsiveness. For the compounds in this chapter, neither has been characterized over realistic durations of use; tesamorelin and MK-677 have the lo → Chapter 15 — Worked Solutions
an ectopeptidase that degrades enkephalins among other peptides; the principal "enkephalinase" target for dual-enkephalinase-inhibitor drug programs and the mechanistic rationale invoked by DL-phenylalanine supplements. — Ch 20 §20.8 → Glossary contributions — Chapter 20
Nesiritide
recombinant human BNP, administered by infusion. Approved for acute decompensated heart failure on hemodynamic and symptomatic grounds; a large randomized outcome trial did not demonstrate benefit on death or rehospitalization. [Ch 28] → Glossary contributions — Chapter 28
Net price
What a health plan actually pays for a drug after confidential rebates and fees are applied. Not public. (Ch.12) → Ch12
Net protein balance
The running difference between muscle protein synthesis and muscle protein breakdown. Positive balance integrated over weeks and months produces hypertrophy. — *Ch 16 §16.1* → Glossary contributions — Chapter 16
NETTER-1
Strosberg J, et al. "Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors." *New England Journal of Medicine*, 2017. Read the eligibility criteria before the results, then read the results, then re-read the criteria. Follow up with the long-term overall survival analysis, which is where → Chapter 27 — Further Reading
The view that variations in neurological development, including autism, are differences rather than diseases, and that framing them as conditions to be cured misdescribes both the people and the goal. *(Ch 21 §21.7)* → Glossary contributions — Chapter 21
Neuroendocrine tumor (NET)
A tumor arising from hormone-producing cells, most often in the gut, pancreas, or lung. Frequently overexpresses somatostatin receptors. *Ch 27 §27.4.* → Glossary contributions — Chapter 27
a signaling molecule that changes how a neuron responds to other signals rather than directly exciting or inhibiting it; most neuropeptides act this way. (Ch.2) → Glossary fragments — Chapter 2
a short amino acid chain used as a signaling molecule between neurons, acting on G-protein-coupled receptors over seconds to minutes rather than milliseconds. *(Ch 22; prepared in Ch 2)* → Glossary contributions — Chapter 22
Neuropeptide Y (NPY)
a 36-residue peptide, among the most abundant neuropeptides in the mammalian brain, and the most potent known stimulator of food intake when administered centrally in animals. Named for the tyrosine residues bracketing it (Y in the one-letter code). *(Ch 22; connects to Ch 13)* → Glossary contributions — Chapter 22
Neurotransmitter
a signaling molecule released across a synapse that directly excites or inhibits the receiving neuron. (Ch.2) → Glossary fragments — Chapter 2
and the evidence the learner did not consult is multiple adequately powered randomized placebo-controlled trials with blinded assessment, consistent and large effects, and decades of post-approval use. - **Entry 12:** Semax rated down because of its country of origin. The book's ⚠️ is not an endorse → Case Study 37.2 — Auditing a Drift
never downgrade with distaste
and it is worth a full-credit example when someone gets it right. A ✅ on a claim found in an advertisement is a sophisticated submission, not a naive one. → Rubric — Single Claim Evaluation
Never upgrade a rating because something is banned
and it is the reason the book's split on this row exists at all: the surrogate claim is supportable and the outcome claim is not. - **Entry 8:** "it's been used in horses for years." This is a claim form, and it is rated in the master table: *"this compound has been used in animals for years, theref → Case Study 37.2 — Auditing a Drift
New Drug Application (NDA)
the United States application type for a drug, including peptides of 40 or fewer amino acids (Ch. 38). → Chapter 38 — Glossary fragment
NK1 receptor
the tachykinin GPCR preferred by substance P. Target of an antagonist class that failed as analgesics and antidepressants and succeeded as antiemetics. *(Ch 22)* → Glossary contributions — Chapter 22
No
Ch 15 | | (b) lowers LDL cholesterol | LDL-C | cardiovascular events | **Largely yes** — a substantial randomized literature supports it | | (c) increases lean body mass | DXA lean mass | strength, function, independence | **No** — Ch 16 shows these dissociate | | (d) reduces an inflammatory marker → Answers — Chapter 5
specifically, no vehicle control — identified | 1.5 | | Rating ❌, tagged evidence-absent | 1 | | Falsification condition specified as a trial design, ideally naming the **vehicle control** | 0.5 | → Practical Evaluation Exam — Open Book
No dishonesty is required.
**This is a specific instance of broader replication difficulties in social and behavioral science** — and also a specific instance of that problem being corrected, through preregistration, multi-lab collaboration, and larger samples. Cite both halves. → Chapter 21 Key Takeaways — Oxytocin and Vasopressin
No dosing, protocols, sourcing, or vendors
including for botulinum toxin. The safety callout states that units are product-specific and non-interchangeable **without giving any units**. - **No brand of cosmetic product or company named.** Ingredient trade names (Matrixyl, Argireline) are used because the INCI discussion requires them; "Botox → Continuity record — Chapter 30 (Cosmetic Peptides)
no natural
counterpart
sequences that do not appear in any organism and never have. Some of these binders hit their intended targets with high affinity on the first pass, without the rounds of laboratory optimization that every previous route required. → Chapter 35: Peptide Discovery — From Venom to Artificial Intelligence
but a substance must **qualify as a dietary ingredient** to be sold in it, and regulators have taken the position that certain peptides, **BPC-157 among them**, do not. - Compounds have also been placed on lists identifying **significant safety risks** for compounding use. - **"Sold as a supplement" → Chapter 38 — Key Takeaways
no private individual is named anywhere
not a celebrity, influencer, forum poster, or patient. Claims are characterized by type. Social claims are rated with the same discipline as pharmacological ones, and several earn 🔬 or ❌ because confident social prediction has a much weaker evidence base than confident pharmacology.* → Master Outline — Understanding Peptides
No specific shortage-resolution dates
stated as "declared resolved during that period," with timing described as contested. - **No fabricated statute numbers, effective dates, regulation citations, or court outcomes.** Where a fact is date-anchored (March 2020; 2022 List; DSHEA 1994; 503B created 2013; nesiritide 2001 and 2011) it is a → Chapter 38 — Continuity notes
Nobel 1923
**recombinant human insulin approved 1982** — first recombinant drug - porcine differs at 1 residue, bovine at 3 (Tier 2, **new** — add to canon if Ch 32 needs it) - **DCCT reported 1993** (Tier 1, **new to canon**) → Continuity notes — Chapter 11
Nocebo
the mirror of the placebo phenomenon, in which negative expectation worsens symptoms. In pain, nocebo hyperalgesia has been linked to signaling systems other than the opioid system. — Ch 20 §20.7 → Glossary contributions — Chapter 20
Nociceptin / orphanin FQ
a 17-residue peptide structurally related to the opioid peptides but beginning Phe-Gly-Gly-Phe rather than Tyr-Gly-Gly-Phe. Acts at the NOP receptor; not blocked by naloxone. — Ch 20 §20.2 → Glossary contributions — Chapter 20
Nociception
the neural detection and transmission of potentially damaging stimuli. Distinct from pain, which is the conscious experience produced downstream of it. — Ch 20 §20.4 → Glossary contributions — Chapter 20
Prohibited-List category covering any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Captures most research peptides by definition, without naming them. — Ch 19 §19.9 → Glossary contributions — Chapter 19
a design asking whether a treatment is not meaningfully worse than its comparator, rather than whether it is better. (Ch.9) → Glossary fragments — Chapter 9
Non-proteinogenic
Not encoded by the genetic code, and therefore not incorporable by ribosomal protein synthesis. A single non-proteinogenic residue determines a drug's entire manufacturing route. — Ch 33 §33.2 → Glossary contributions — Chapter 33 (Peptide Engineering)
Nonapeptide
A peptide nine amino acids long. Oxytocin and vasopressin are the canonical examples; both are nonapeptides differing at only two of the nine positions. *(Ch 21 §21.1)* → Glossary contributions — Chapter 21
none of it is present by construction
and non-disclosure to the clinicians who *are* involved is itself a safety failure. - **Highest uncertainty, lowest oversight — and the two share a cause.** The regulatory absence that makes a compound available is the same absence that means nobody generated safety data or wrote monitoring guidance → Chapter 43 — Key Takeaways
§23.6 explains that rating it would ratify the misclassification the section exists to correct. Do not "fix" this by adding it. → Continuity — Chapter 23
Proposed movement of molecules from the nasal cavity into the brain along olfactory and trigeminal nerve pathways, through perineural and perivascular spaces, bypassing the blood-brain barrier. Real as a route; disputed in quantitative contribution for oxytocin in humans. *(Ch 21 §21.6; Ch 22)* → Glossary contributions — Chapter 21
was developed from bradykinin-potentiating peptides found in pit viper venom, working through the peptide teprotide to a small molecule that could be taken orally. It is the first major **peptidomimetic**: a demonstration that a peptide can be a lead rather than a destination, and that the useful th → Appendix J — A Timeline of Peptide Science
not a peptide drug
nothing peptide-shaped was administered. But it is unambiguously a **peptide-antigen vaccine**: the therapeutic message is a peptide sequence, and only the delivery differs. The designer chose amino acids. The vial contained nucleotides. The immune system read amino acids. → Chapter 26: Peptide Vaccines — Cancer Immunotherapy and Infectious Disease Prevention
Not a peptide: MK-677 (ibutamoren)
a small, orally active, non-peptide ghrelin receptor agonist. The distinction changes expectations because it is not made of peptide bonds, so digestive proteases have nothing to cut; it is orally active and long-acting, which makes it easier to obtain and easier to take continuously. → Chapter 15 — Worked Solutions
not about the molecules
duration, population, comparator, endpoint, or funder — and estimate how much of the apparent difference it could account for. → Chapter 9 — Exercises
you can do both, most countries are doing some of both, and the trade-off between them is not a quantity anyone measures. No trial has "primarily" as an endpoint. No dataset has a column for it. Someone who tells you the evidence settles this question has smuggled a value judgment inside an empirica → Chapter 37: The Peptide Evidence Table — Every Rating in One Place
NOT RATED
this claim falls outside the system's competence. If forced, 🔬. > **Reason:** It is a prediction about aggregate future human behavior, not a claim about a > population and an endpoint, and there is no body of evidence that bears on it in the way trial > evidence bears on a pharmacological claim. > → ALL EVIDENCE RATINGS — harvested, do not edit by hand
not uniformly distributed across positions
it concentrates at the one or two hard couplings. That in turn means an analytical method must be shown to resolve the *specific* deletions a given process generates, not deletions in general. → Answers — Chapter 32
Notes for the ratings index:
Two of the four are **claim-form / technology ratings rather than molecule ratings**. The claim-form one is prefixed `Claim form —` per convention. The AlphaFold-as-research-tool rating is explicitly scoped in its "what would change it" line to a research tool and *not* a therapeutic claim, to preve → Continuity — Chapter 35
Notes on the table.
**Week 3 gets two sessions.** One on vocabulary — population, endpoint, comparator, design, duration, replication — and one on application. If your calendar has a flexible session anywhere, spend it here. - **Week 4's field-12 collection is not busywork.** You are holding a fixed record of what each → Syllabus — One-Semester Survey
nothing
about the evidence
a product in this category may be well studied or not studied at all, and the disclaimer is silent between those. (1) **Deduct if the student treats the disclaimer as a downgrade signal**: that is the Rule 4 error and the mirror image of treating approval as a ✅. → Practical Evaluation Exam — Open Book
the fields where you recorded what the evidence actually shows and the verdict you drew from it, with its falsifier (Appendix C has the blank workbook). For each of the four sources, record the departure. → Chapter 41: Ozempic Enters the Language
NPR-A / NPR-B / NPR-C
the natriuretic peptide receptors. NPR-A binds ANP and BNP; NPR-B binds CNP; both are guanylyl cyclases. NPR-C binds all three, does not signal, and internalizes them for degradation — a clearance receptor. [Ch 28] → Glossary contributions — Chapter 28
the 76-amino-acid N-terminal fragment released when proBNP is cleaved. Biologically inactive, longer-lived than BNP, and more stable in the specimen, which makes it the more practical measurement. **Not a neprilysin substrate**, which is why it remains interpretable in patients on an ARNI. [Ch 28] → Glossary contributions — Chapter 28
NT-proBNP is
more stable
in the blood and in the specimen — which makes the useless half of the molecule the more useful measurement. → Chapter 28 — Key Takeaways
Nucleus tractus solitarius (NTS)
the hindbrain nucleus that receives vagal sensory input and integrates it with circulating signals. (Ch.7) → Glossary fragments — Chapter 7
null revision
A dated dossier revision recording that news arrived and the rating did not move. More informative than a revision recording a change, because it is evidence that the standard held under pressure. *(Ch 40 §40.5.)* → Glossary contributions — Chapter 40
Number needed to treat (NNT)
how many people must receive a treatment for one additional person to benefit; the most honest single number in medicine. (Ch.5) → Glossary fragments — Chapter 5
nutrients in the gut
not in response to circulating GLP-1 levels. **That is why agonists don't suppress endogenous production.** → Chapter 7 — Key Takeaways
O
ob/ob mouse
the leptin-deficient mouse strain whose study led to leptin's identification; a model of leptin deficiency rather than of common obesity. (Ch.13) → Glossary fragments — Chapter 13
Obesity ↓
the dangerous one, because it is the only one that undermines the test's rule-out strength. Atrial fibrillation ↑, sometimes markedly. → Chapter 28 — Key Takeaways
Covering skin to reduce water loss. Hydrates the stratum corneum, increases penetration of many substances, and independently improves the appearance of fine lines. *(Ch 30 §30.2)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
prescribing an approved drug outside its approved indication, population, or route. Legal, common, often appropriate, and not a statement about evidence strength. → Chapter 39: Talking to Your Doctor About Peptides
Off-label (reinforced)
prescribing an approved drug for an indication, population, or route not covered by its approved labeling. Legal, common, and frequently appropriate — and not a statement about the strength of the evidence for that particular use. *Defined Ch 38 §38.5; applied Ch 39 §39.8.* → Glossary contributions — Chapter 39
Off-label prescribing
a licensed prescriber's use of an approved drug for an unapproved indication; lawful in the United States and many other jurisdictions, and silent on the state of the evidence (Ch. 38). → Chapter 38 — Glossary fragment
Off-label promotion
a manufacturer's marketing of a drug for an unapproved use; generally prohibited. The asymmetry with prescribing is deliberate (Ch. 38). → Chapter 38 — Glossary fragment
Off-label use
Prescribing an approved drug outside its approved indication, population, dose, or route. Legal in the US, common, often the standard of care, and it shifts evidentiary responsibility to the prescriber. Not the same as unapproved. (Ch.12) → Ch12
Reviews comparing antibody-drug conjugates with peptide-drug conjugates on penetration, half-life, payload capacity, and manufacture. Read these as trade-off analyses rather than as advocacy. - The regulatory history of melphalan flufenamide — accelerated approval, confirmatory data, withdrawal — is → Chapter 27 — Further Reading
Reviews of ¹⁷⁷Lu dosimetry and renal protection. The amino acid co-infusion is a nice worked example of engineering around a known biodistribution problem. - Literature on ⁶⁸Ga-dotatate and PSMA PET imaging agents, which is where the diagnostic half of the theranostic pair lives. - Reviews of alpha- → Chapter 27 — Further Reading
On somatostatin analogs and neuroendocrine tumors.
Review articles on somatostatin receptor subtypes (SSTR1–5) and their differential expression across tumor types. This is the material that explains why receptor-targeted approaches work in some neuroendocrine tumors and not others. - Literature on carcinoid syndrome management, including carcinoid → Chapter 27 — Further Reading
On the endocrine history.
Charles Huggins' 1966 Nobel Lecture, *Endocrine-Induced Regression of Cancers*, is short, free, and still one of the clearest statements of the idea that a cancer can depend on its host's hormones. - The 1977 Nobel Prize materials for Roger Guillemin and Andrew Schally cover the isolation of GnRH an → Chapter 27 — Further Reading
on top of standard care
which is the ethically necessary design and also > the honest one, since the practical question was never "nesiritide or nothing" but "does adding > this help?" > > **Endpoints.** Co-primary: change in self-reported dyspnea at 6 and 24 hours, and the composite of > rehospitalization for heart failur → Chapter 28: Natriuretic Peptides — The Heart Failure Biomarkers That Became Treatments
operating not across wildly different uses but *within a single indication area.* If a molecule can require two separate ratings for two claims about the same tumor in the same patient, the idea that a molecule has a rating should be finished. It does not. **The unit of evaluation is the claim, alwa → Appendix H — Twenty Worked Evidence Evaluations
One pharmacokinetic profile
both receptors are engaged in the same temporal pattern always, rather than two drugs with different half-lives and peaks producing a ratio that drifts. **A fixed activity ratio** — determined by the molecule's structure and unchangeable without making a different molecule, whereas two drugs can be → Chapter 9 — Quiz
One rule, opposite outcomes, and it predicts both
which is what makes it worth carrying into Part III, where several compounds are marketed as replacements and are in fact overrides. → Chapter 11 — Quiz
`GHK`, `HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG` — are used for anything longer than a handful of residues and for everything computational. A thirty-residue peptide in hyphenated three-letter code occupies most of a line and resists visual comparison; as a one-letter string it can be aligned against anothe → Appendix I — Peptide Nomenclature and How to Read a Sequence
Opioid-induced hyperalgesia
increased pain sensitivity arising from sustained opioid exposure, associated with the facilitatory arm of descending modulation. — Ch 20 §20.4 → Glossary contributions — Chapter 20
two peptides, orexin-A and orexin-B, produced from a single precursor by lateral hypothalamic neurons and acting at OX1R and OX2R to stabilize wakefulness. Two names because two groups reported them independently in 1998. *(Ch 22)* → Glossary contributions — Chapter 22
Orforglipron
an investigational oral small-molecule GLP-1 receptor agonist; notable for not being a peptide, and therefore escaping the delivery and manufacturing constraints of the peptide agonists. (Ch.9) → Glossary fragments — Chapter 9
Orphan compound
a molecule that cannot be profitably developed because it is unpatentable, cheap, or off-patent, regardless of scientific merit; the structural reason many answerable questions stay unanswered. (Ch.17; concept introduced Ch.5) → Glossary fragments — Chapter 17
Orphan designation
A status a regulator may grant to a product intended for a rare disease, carrying development incentives. Criteria, incentives, and the definition of "rare" differ between jurisdictions. **A designation is not an approval.** → Appendix G — Regulatory and Legal Quick Reference
Orphan drug frameworks exist precisely for this
offering extended exclusivity, fee reductions, and development incentives in exchange for pursuing conditions that would otherwise be commercially irrational. → Case Study 2 — The Drug for a Few Dozen People
Orthogonal methods
analytical methods whose separation or detection principles are independent, so a species hidden from one is unlikely to be hidden from the other. The practical answer to co-elution. (§34.3) → Glossary contributions — Chapter 34
Out-of-pocket cost
What a covered patient actually pays at the counter, determined by plan design rather than by the drug's price. (Ch.12) → Ch12
Outcome switching
reporting a secondary measure as though it were the trial's question, after the pre-specified primary endpoint disappointed. (Ch.5) → Glossary fragments — Chapter 5
Outweighed
the least informative, because it predicts nothing and cannot be distinguished from the others by any experiment. → Answers — Chapter 9
Overall survival (OS)
Time until death from any cause. The hardest endpoint in oncology, and one that many approvals do not certify. *Ch 27 §27.4–27.5.* → Glossary contributions — Chapter 27
override
and what that predicts about discontinuation - ✅ what each insulin analog was built to solve - ✅ the pricing controversy, without defending anyone or overstating - ❌ **not yet:** whether the same story is running again. **Chapter 12.** → Chapter 11 — Key Takeaways
Oxytocin
A nonapeptide hormone synthesized in the hypothalamus and released from the posterior pituitary. Causes uterine contraction and milk ejection; also acts as a neuromodulator within the brain. An approved obstetric medicine and the subject of the "love hormone" nickname this book rates ❌. *(Ch 21 §21. → Glossary contributions — Chapter 21
Oxytocin assay methodology literature
the extraction vs. non-extraction immunoassay discrepancy. - **PET ligand development for the oxytocin receptor** — for the "what would resolve it" passage. → Bibliography notes — Chapter 21
Oxytocin receptor (OXTR)
The single known human receptor for oxytocin; a G-protein-coupled receptor. Myometrial expression rises sharply toward term, which is why the same hormone concentration has very different effects at twenty and forty weeks. *(Ch 21 §21.1, §21.2)* → Glossary contributions — Chapter 21
P
P-value
the probability of observing a result at least this extreme if the treatment had no effect; below 0.05 is conventionally called statistically significant. (Ch.5) → Glossary fragments — Chapter 5
A durable selective social attachment between two adults. Measured in voles as partner preference. Not interchangeable with human romantic love; the shared label was supplied by us. *(Ch 21 §21.3)* → Glossary contributions — Chapter 21
A five-residue fragment of type I procollagen carrying an attached 16-carbon fatty acid; roughly 800 daltons; marketed under the ingredient trade name Matrixyl. *(Ch 30 §30.3)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Palmitoylation
Attachment of a 16-carbon fatty acid to a peptide, increasing lipid solubility. In cosmetics a **delivery** modification aimed at barrier crossing; related acylation strategies in pharmaceuticals target half-life. *(Ch 30 §30.3; cf. Ch 33)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Panning
the selection step of a display experiment: washing a library over an immobilized target, discarding non-binders, and recovering what remains. Wash stringency sets selection pressure. *(Ch 35)* → Glossary contributions — Chapter 35
Parabiosis
an experimental technique joining the circulations of two animals, used in the 1960s–70s to infer the existence of a circulating satiety factor and of resistance to it. (Ch.13) → Glossary fragments — Chapter 13
a claim of a type that circulates widely, rewritten so that it belongs to no particular person or seller. For each: identify what is true in it, identify precisely where it fails, and write a two-sentence replacement that is accurate and that the original speaker could read without feeling insulted. → Chapter 17 — Exercises
the part of the book that turns from molecules to society, and rates claims about language, media, sport, work, food systems, and stigma. Every molecule claim in Part I through Part VII got a tier. The refusals appear only, and all together, at the point where the questions stop being about what a c → Appendix A — The Master Peptide Evidence Table
Partial agonist
a ligand that activates a receptor submaximally at any dose; it acts as an activator when alone and as an inhibitor in the presence of a full agonist. (Ch.2) → Glossary fragments — Chapter 2
Toll-like receptors and their relatives — that detect molecular signatures of pathogens and tissue damage: bacterial cell wall components, double-stranded RNA, unmethylated bacterial DNA motifs. When those receptors fire, the presenting cell matures: it migrates to the draining lymph node, upregulat → Chapter 26: Peptide Vaccines — Cancer Immunotherapy and Infectious Disease Prevention
Payer churn
The movement of individuals between insurers, plans, and programs over time. Its structural consequence is that the entity funding a decade of preventive therapy is frequently not the entity that would have paid for the event that therapy prevented. *(Ch 44 §44.3)* → Glossary contributions — Chapter 44
PDE5 inhibitor
A class of small-molecule drugs (sildenafil and relatives) acting peripherally to sustain genital blood flow by preventing the breakdown of cyclic GMP in vascular smooth muscle. Acts downstream of arousal and cannot initiate it. — Ch 24 §24.3 → Glossary contributions — Chapter 24
PEGylation
Covalent attachment of polyethylene glycol chains to a therapeutic molecule. The polymer's large hydration shell raises hydrodynamic radius and reduces renal clearance; it also shields the backbone from proteases. Largely displaced by lipidation for peptides. — Ch 33 §33.5 → Glossary contributions — Chapter 33 (Peptide Engineering)
Penetration enhancer
A formulation ingredient that increases absorption, typically by disrupting the stratum corneum lipid matrix. The benefit and the cost are the same physical event. *(Ch 30 §30.2)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
conventionally, a chain of roughly 2–50 amino acids joined by peptide bonds. The upper boundary is a convention, not a chemical distinction. (Ch.1) → Glossary fragments — Chapter 1
Peptide bond
the covalent amide link between the carboxyl group of one amino acid and the amino group of the next, formed by a condensation reaction that releases water. (Ch.1) → Glossary fragments — Chapter 1
Peptide content
The fraction of a lyophilized product's total mass that is actually peptide, as distinct from bound water and counterions. Distinct from purity, and frequently not stated. — Ch 19 §19.3 → Glossary contributions — Chapter 19
phage display, mRNA display — as the discovery engine behind modern macrocycle and constrained-peptide programs. This is where "how did anyone find that sequence" gets answered. → Chapter 33 — Further Reading
Peptide engineering
The deliberate chemical modification of a peptide to change its pharmacokinetic, physicochemical, or selectivity properties, generally without changing what the molecule does at its receptor. — Ch 33, throughout → Glossary contributions — Chapter 33 (Peptide Engineering)
Peptide Evidence Dossier
a personal, twelve-field reference on the peptides *you* care about, built one field per chapter | | **5 learning paths** | 💊 GLP-1 · 🏋️ Performance · 🔬 Science · 💄 Cosmetic · 🏥 Clinical | | **An instructor companion** | syllabi, rubrics, exams, and per-chapter teaching notes and discussion guides | → Understanding Peptides
Peptide receptor radionuclide therapy (PRRT)
Therapy in which a receptor-targeting peptide, joined to a chelator and loaded with a radionuclide, delivers radiation to receptor-expressing tumor cells. The peptide is a delivery address rather than a therapeutic agent. *Ch 27 §27.5.* → Glossary contributions — Chapter 27
Peptide YY (PYY)
a peptide released from intestinal L cells after meals that reduces subsequent food intake; extensively pursued as a target without producing an approved drug. (Ch.13) → Glossary fragments — Chapter 13
Peptide-drug conjugate
a construct joining a targeting peptide, a linker, and a payload, in which the peptide's job is not to have an effect but to arrive somewhere specific; its receptor selectivity is the delivery address. → Chapter 36 — Glossary Contributions
Peptide-drug conjugate (PDC)
A targeting peptide joined by a linker to a cytotoxic payload; the antibody-drug conjugate principle with a smaller carrier. *Ch 27 §27.7.* Cross-ref: Ch 36. → Glossary contributions — Chapter 27
Peptidomimetic
A non-peptide or partly non-peptide molecule designed to reproduce a peptide's functional architecture while escaping its liabilities. *(25.7)* → Glossary contributions — Chapter 25
the period surrounding a procedure, including preparation, the procedure itself, and recovery. The setting in which undisclosed exposures cause some of their most concrete harm. *Ch 39 §39.2.* → Glossary contributions — Chapter 39
Periaqueductal gray (PAG)
a midbrain region central to descending pain modulation. Receives input from hypothalamus, amygdala, and prefrontal cortex — the anatomical route by which context, threat appraisal, and expectation reach the pain system. — Ch 20 §20.4 → Glossary contributions — Chapter 20
Permeation enhancer
an excipient that transiently promotes absorption of a poorly absorbed drug across a membrane; SNAC in oral semaglutide is the principal example. (Ch.4) → Glossary fragments — Chapter 4
attachment style, borderline personality features, early adversity — including the finding that participants high in attachment anxiety recalled maternal care less positively after oxytocin. - **The social salience framing review** ("context and person matter"), which is the chapter's principal sour → Bibliography notes — Chapter 21
Personal import exemption
A provision in some jurisdictions permitting an individual to import limited quantities of a medicine for personal use. Existence, scope, and conditions vary widely and change. — Ch 19 §19.9 → Glossary contributions — Chapter 19
Phage display
a selection technology in which peptide variants are displayed on the surface of bacteriophage that carry the encoding DNA inside the same particle. Pioneered by George Smith in the mid-1980s and developed for antibodies by Greg Winter; a share of the 2018 Nobel Prize in Chemistry. *(Ch 35)* → Glossary contributions — Chapter 35
pharmacists
as underused resource → 39.5; scope and limits → 39.5 - **population question** → 39.4 (question 1); *see also* Ch 5 - **prescription** — as clinical judgment, not evidence → 39.8; rated ❌ → 39.8 - **procedures with sedation** — breadth of → 39.2 → Index entries — Chapter 39
an officially recognized compendium of drug standards, such as the United States Pharmacopeia or the European Pharmacopoeia. Publishes monographs and general chapters. (§34.10) → Glossary contributions — Chapter 34
pharmacopeial monograph
A published public standard for a specific substance listing required tests, methods, and acceptance limits. Naming one converts a vague quality claim into a specific and falsifiable one. [Ch 32 §32.4] → Glossary contributions — Chapter 32
Pharmacovigilance
The systematic collection, analysis, and action on safety information about medicines in use. Requires a reporting pathway to exist. — Ch 19 §19.8 → Glossary contributions — Chapter 19
Pharmacovigilance methodology
disproportionality analysis, signal detection, and the known limitations of spontaneous reporting systems. Worth reading precisely because it establishes how weak these systems are *even when they exist*, which sharpens rather than softens §19.8's argument. → Chapter 19 Further Reading — The Gray Market
An intermediary that negotiates drug prices and manages formularies on behalf of health plans. (Ch.12) → Ch12
Phase 1
first-in-human study, usually small and often in healthy volunteers, assessing safety, tolerability, and pharmacokinetics. Generally not designed to demonstrate that the drug helps anyone. → Chapter 36 — Glossary Contributions
Phase 2
mid-stage trial assessing efficacy signals and dose at modest sample size, usually on surrogate endpoints; systematically more favorable than the phase 3 that follows, which is phase 2 optimism (Chapter 9). → Chapter 36 — Glossary Contributions
Phase 2 optimism
the systematic tendency for Phase 2 effect sizes to exceed the Phase 3 results that follow, arising from small samples, best-dose selection, favorable populations, shorter durations, and regression to the mean; requires no misconduct by anyone. (Ch.9) → Glossary fragments — Chapter 9
Phase 3
the large, adequately powered confirmatory trial regulators rely on, where most of the cost sits and most surprises happen. → Chapter 36 — Glossary Contributions
Phase 4
study and monitoring after approval, including post-marketing surveillance and any confirmatory trials required as a condition of approval (Ch. 38). → Chapter 38 — Glossary fragment
the first stage of human testing, assessing safety and pharmacokinetics in a small number of participants. (Ch.5) → Glossary fragments — Chapter 5
Phase I trial
the first study of a compound in humans, typically dose-escalation in healthy volunteers, producing pharmacokinetics and systematically collected safety data. None exists for BPC-157 in the published literature. (Ch.17) → Glossary fragments — Chapter 17
Phase II
the stage testing for an efficacy signal and dose-response in dozens to a few hundred participants; results are systematically more optimistic than subsequent Phase III findings. (Ch.5) → Glossary fragments — Chapter 5
Phase III
the definitive efficacy stage, in hundreds to tens of thousands of participants in the target population. (Ch.5) → Glossary fragments — Chapter 5
Phase IV
post-marketing surveillance, detecting rare harms and real-world effects after approval. (Ch.5) → Glossary fragments — Chapter 5
The component of visible skin aging caused by ultraviolet exposure, as distinct from intrinsic chronological aging. The dominant driver of what people dislike about aging skin. *(Ch 30 §30.1)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Physical dependence
a state in which the body has adapted to a drug's presence such that abrupt cessation produces a withdrawal syndrome. Occurs in essentially anyone maintained on sustained opioid therapy, including patients using medication appropriately. Not addiction, not a diagnosis, and not a statement about anyo → Glossary contributions — Chapter 20
Pick one compound from your dossier
ideally one with a large public presence, because the exercise needs material. For that compound, build an **interest map**: not a new field, but an overlay on the entry you already have. → Chapter 42: The Creator Economy and the Peptide Pipeline
Pick your top dossier entry
the one you would actually raise in an appointment. 2. **Write out Field 11 verbatim**, without improving it. 3. **Convert it to a question** using the pattern above. 4. **Read it aloud.** If you would not be comfortable asking it, or it sounds like an argument, rewrite it. The test: could a clinici → Chapter 39: Talking to Your Doctor About Peptides
PIONEER
oral semaglutide. Established that an orally administered peptide could produce clinically meaningful glycemic control, at roughly 1% bioavailability with a strict fasting protocol. → Answers — Chapter 8
Pipeline
the set of compounds a field has in development, at various stages; readable only with the phase, estimand, dose, population, endpoint, and source of each announcement attached. (Ch.9) → Glossary fragments — Chapter 9
Pituitary
the small gland at the base of the brain that releases tropic hormones into the general circulation in response to hypothalamic signals. (Ch.3) → Glossary fragments — Chapter 3
pain relief produced by an inert intervention together with the expectation of benefit. Substantially reduced by opioid receptor antagonism, establishing that it is at least partly mediated by endogenous opioid release. — Ch 20 §20.7 → Glossary contributions — Chapter 20
Advocacy for or against a compound that isn't grounded in a change to the evidence base - Testimonials, personal experience, or n-of-1 reports as support for a claim - Dosing information, protocols, sources, or anything that reads as a how-to - Precise statistics without a source - Rewrites that sof → Contributing to Understanding Peptides
Plecanatide
a guanylate cyclase-C agonist structurally related to the natural ligand uroguanylin, approved for chronic idiopathic constipation and IBS-C. (Ch 29) → Glossary contributions — Chapter 29
a molecule activating three or more receptors; retatrutide, targeting GLP-1, GIP, and glucagon receptors, is an example. (Ch.9) → Glossary fragments — Chapter 9
cyclic lipopeptide antibiotics used as last-line agents against resistant gram-negative organisms. (Ch 25, expanded Ch 29) → Glossary contributions — Chapter 29
Polypeptide
a long amino acid chain; used either as a synonym for protein or for a chain that has not folded into a functional structure. (Ch.1) → Glossary fragments — Chapter 1
the precursor protein cleaved to produce α-MSH and other peptides; loss-of-function variants cause severe early-onset obesity. (Ch.13) → Glossary fragments — Chapter 13
POMC neurons
*stimulated* by leptin. POMC is cleaved to **α-MSH**, which **activates MC4R** and reduces hunger. - **AgRP/NPY neurons** — *inhibited* by leptin. They release **AgRP**, which **blocks MC4R** and increases hunger. → Answers — Chapter 13
The audit check that requires every Field 6 row to name both a population and an endpoint. *(Ch 40 §40.3, Check 2.)* → Glossary contributions — Chapter 40
population, endpoint, comparator, size
**Ask about it, do not present it** — and do this because it is true, not because it works better - An eight-minute appointment cannot absorb a literature review. Book a longer one and say why - **Pharmacists are underused** and often have more minutes than a physician → Chapter 39 — Key Takeaways
Population-level effect
An outcome that emerges only at the scale of a whole population — a shift in market demand, a change in a social norm. Not measurable by trials of individuals, because the effect does not exist at the level of an individual. *(Ch 44 §44.1)* → Glossary contributions — Chapter 44
the short dedicated vascular connection between hypothalamus and pituitary, delivering releasing hormones at high local concentration without systemic exposure. (Ch.3) → Glossary fragments — Chapter 3
Study and monitoring after approval, including any confirmatory trials required as a condition of it. It exists because Phase 3 trials are not large or long enough to characterize rare or long-latency effects. **Never truly finished.** → Appendix G — Regulatory and Legal Quick Reference
Posterior pituitary
The neural lobe of the pituitary; not a synthesizing gland but the release site for the axon terminals of hypothalamic magnocellular neurons. Functionally an extension of the brain that secretes into blood. *(Ch 21 §21.1)* → Glossary contributions — Chapter 21
Postpartum hemorrhage
Excessive bleeding after delivery, frequently from uterine atony; a leading cause of maternal death globally and a principal indication for oxytocin. *(Ch 21 §21.2)* → Glossary contributions — Chapter 21
describing a trial large enough that a real effect of the anticipated size would be detected; an underpowered trial finding nothing has told you little. (Ch.5) → Glossary fragments — Chapter 5
PP-fold
the compact hairpin structure shared by NPY, PYY, and pancreatic polypeptide: an extended N-terminal segment folded against a C-terminal alpha helix. *(Ch 22)* → Glossary contributions — Chapter 22
Socially monogamous North American rodent whose contrast with closely related non-monogamous species established the link between oxytocin/vasopressin receptor distribution and social behavior. Socially monogamous, **not** sexually exclusive. *(Ch 21 §21.3)* → Glossary contributions — Chapter 21
Pramlintide
a synthetic amylin analog, engineered because native human amylin aggregates; approved as an adjunct to mealtime insulin. (Ch.13) → Glossary fragments — Chapter 13
a threshold that the interim result must cross. The boundary is deliberately more stringent than the final analysis would be, precisely because looking at data repeatedly increases the chance of seeing something striking by accident. → Case Study 1 — The Trial That Stopped Itself
precedent in the same mechanistic class
not the story but the track record of approved drugs working that way. A mechanism with drugs already on the market is evidence. A mechanism with a beautiful diagram is not. → Chapter 36 — Worked Answers
development conducted before a compound has been given to a human for the indication in question: cells, tissue, animals. Not a synonym for "almost in trials"; it is a different category of knowledge. → Chapter 36 — Glossary Contributions
Preclinical evidence
research conducted before human testing: cell culture, tissue, and animal studies. It generates candidates and cannot adjudicate them. (Ch.17) → Glossary fragments — Chapter 17
The degree to which interventions effective in an animal model prove effective in humans. The only form of validity that licenses animal-to-human inference, and the least often established. *Ch 31 §31.5.* → Glossary contributions — Chapter 31
High-performance liquid chromatography run at a scale intended to collect purified material rather than to measure it. The workhorse purification method for synthetic peptides; always trades purity against recovery. [Ch 32 §32.4] → Glossary contributions — Chapter 32
Publicly specifying hypotheses, outcomes, and analyses before data collection, so that analytic flexibility cannot manufacture a finding. *(Ch 21 §21.4)* → Glossary contributions — Chapter 21
prespecified functional and
> clinical endpoints
measured strength, gait speed, disability, falls, fractures, > hospitalization, independent living, cardiovascular events, malignancy, mortality — demonstrating > benefit that outweighs the observed harms. That trial is entirely possible to run. It has not been > run, and the reasons it has not are → ALL EVIDENCE RATINGS — harvested, do not edit by hand
prespecified functional primary endpoint
a walk test, a timed task, a validated functional scale — showing a clinically meaningful difference sustained over time. Toward ❌: the accumulation of adequately powered trials showing the mass-function dissociation is robust, which would move this class from "not yet demonstrated" into the same ca → Appendix H — Twenty Worked Evidence Evaluations
Primary afferent
a first-order sensory neuron carrying information from the periphery into the central nervous system. Small-diameter unmyelinated C fibers carry slow, burning, poorly localized pain and contain most of the spinal cord's substance P. *(Ch 22)* → Glossary contributions — Chapter 22
Primary endpoint
the pre-specified main outcome a trial is designed and powered to detect; changing it after the fact is outcome switching. (Ch.5) → Glossary fragments — Chapter 5
Primary nocturnal enuresis
bedwetting in children — is the one that surprises people. The rationale is partly that some affected children have a blunted overnight rise in vasopressin and therefore produce more urine overnight than their bladder can hold. It is an approved indication with genuine randomized evidence behind it, → Chapter 29: The Peptide Drugs Already in Your Pharmacy
misfolded proteins that induce normal proteins to misfold in the same way, propagating through nervous tissue. Prions are not living organisms. They have no genetic material. And critically, they are **extraordinarily resistant to the sterilization methods that kill bacteria and viruses** — heat, ra → Case Study 2 — Cadaver Growth Hormone
Prior authorization
A requirement that a prescriber submit documentation and obtain approval before a plan will pay for a drug. A legitimate stewardship tool that also functions as a non-random attrition filter. (Ch.12) → Ch12
the sequence of operations that turns a patient's tumor into a product made for that patient and nobody else — and about how to read the evidence such a procedure generates. → Case Study 26.1 — From Biopsy to Injection
Process simulation (media fill)
running an entire aseptic filling operation using growth medium in place of product and incubating every filled unit. Because every unit is examined, the sampling limitation of end-product sterility testing does not apply; this is how a process demonstrates that it reliably yields sterile units. (Ca → Glossary contributions — Chapter 34
Procollagen
The precursor form of collagen, carrying propeptide extensions cleaved during maturation. Palmitoyl pentapeptide-4 derives from a type I procollagen propeptide region. *(Ch 30 §30.3)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
the precursor protein processed differently in different tissues to yield glucagon in pancreatic alpha cells and GLP-1 in intestinal L cells. (Ch.7) → Glossary fragments — Chapter 7
Progression-free survival (PFS)
Time until the disease is shown to grow or the patient dies. Not the same as overall survival; the two are routinely conflated. *Ch 27 §27.4.* → Glossary contributions — Chapter 27
Prohibited List
WADA's annually updated list of prohibited substances and methods, organized into categories (Ch. 38). → Chapter 38 — Glossary fragment
Prohibited substance list
A sporting or racing authority's list of substances barred from competition. A risk-management document reflecting uncertainty, welfare, competitive integrity, and regulatory status — not a finding of efficacy. *Ch 31 §31.2.* → Glossary contributions — Chapter 31
proinsulin
Insulin's single-chain precursor, in which a connecting segment (the C-peptide) holds the future A and B chains together so that folding brings the correct cysteines into proximity. Removed enzymatically after folding. The segment's entire function is to make folding easy and then leave. [Ch 32 §32. → Glossary contributions — Chapter 32
for the *direction*. The **timeline and magnitude > are not predictable and should be treated as unrated.** > **Why:** The pattern of price decline following competitive entry holds across many drug classes > and is a well-understood consequence of market structure, which is enough to support the di → ALL EVIDENCE RATINGS — harvested, do not edit by hand
PROOF
Prevent Recurrence Of Osteoporotic Fractures — a multi-year randomized placebo-controlled study of nasal salmon calcitonin with several active dose arms. It reported a statistically significant reduction in new vertebral fractures in one dose arm relative to placebo. → Case Study 2 — How a Drug Class Shrinks Without a Villain
proopiomelanocortin
POMC — which you have already met in Chapter 13 as the source of the appetite-suppressing signal in the hypothalamus. The same precursor yields α-MSH, ACTH, and β-endorphin, depending on where it is processed and by which enzymes. This is one precursor doing several unrelated jobs, and it is the fir → Chapter 24: PT-141 (Bremelanotide) and the Sexual Function Peptides
Proopiomelanocortin (POMC)
a single precursor protein processed, in a tissue-specific manner, into β-endorphin, ACTH, α-MSH, β-lipotropin, γ-MSH, and CLIP. The clearest example in the book of one gene serving unrelated physiologies. — Ch 20 §20.2 → Glossary contributions — Chapter 20
an enzyme that cleaves peptide bonds. Also called a peptidase. Pepsin, trypsin, and chymotrypsin are examples. (Ch.1) → Glossary fragments — Chapter 1
protecting group
A chemical cap on a reactive group that renders it temporarily inert and can be removed later under conditions leaving everything else intact. The whole art of peptide synthesis is arranging that exactly one pair of groups can react at any moment. [Ch 32 §32.2] → Glossary contributions — Chapter 32
Protein
conventionally, a chain of roughly 50 or more amino acids, usually folded into a defined functional structure. (Ch.1) → Glossary fragments — Chapter 1
protein folding problem
predicting a protein's three-dimensional structure from its amino acid sequence alone — was one of the defining open problems in molecular biology. The information is clearly there in the sequence, since proteins fold reliably on their own, but extracting it computationally defeated an enormous amou → Chapter 35: Peptide Discovery — From Venom to Artificial Intelligence
ProteinMPNN
a computational method for the sequence-design half of de novo design: given a desired backbone, choose an amino acid sequence that will fold into it. *(Ch 35)* → Glossary contributions — Chapter 35
Proteolysis
enzymatic breakdown of peptide bonds, carried out by proteases and peptidases. The default fate of any peptide in the body. (Ch.1) → Glossary fragments — Chapter 1
the bias arising when early, undiagnosed disease influences which treatment a patient receives. (Ch.10) → Glossary fragments — Chapter 10
Protoporphyrin IX
The heme precursor that accumulates in erythropoietic protoporphyria; it absorbs visible light and generates reactive species in surrounding tissue. — Ch 24 §24.5 → Glossary contributions — Chapter 24
Provocation study
a human experiment in which administering a suspected causal agent reproduces the clinical event of interest in the population that has the condition. The study type that separated CGRP from substance P. *(Ch 22)* → Glossary contributions — Chapter 22
PRRT
peptide receptor radionuclide therapy, the approved existence proof for the conjugate architecture: a somatostatin-analog targeting peptide, a chelator caging a metal ion, and a therapeutic radioisotope (Chapter 27). → Chapter 36 — Glossary Contributions
PSMA (prostate-specific membrane antigen)
A transmembrane enzyme highly expressed on most prostate cancer cells; used as both an imaging and a therapeutic target. Despite the name, not a secreted marker like PSA. *Ch 27 §27.6.* → Glossary contributions — Chapter 27
parathyroid hormone-related protein, a separate gene product from PTH that acts at the same receptor; the parent of abaloparatide. (Ch 29) → Glossary contributions — Chapter 29
Publication bias
the tendency for positive results to be published and negative ones not to be, systematically distorting the apparent evidence base without any individual paper being fraudulent. (Ch.5) → Glossary fragments — Chapter 5
Publication filtering
The process by which a published literature becomes an unrepresentative sample of the work actually performed. Especially severe in animal research, which is largely unregistered, leaving no denominator against which completeness can be assessed. The fifth and most-forgotten of Ch. 5 §5.3's five tra → Glossary contributions — Chapter 18
the primary index for everything in this chapter. Two searches worth running as an exercise rather than just reading about: `Rudman growth hormone men over 60` will return the 1990 *New England Journal of Medicine* paper and, more usefully, the enormous downstream citation trail. `growth hormone hea → Chapter 14 — Further Reading
pulmonary capillary wedge pressure
a catheter-derived measurement of left-sided filling pressure, and about as objective a number as cardiology produces. It is not a questionnaire, not a subjective assessment, not a proxy invented by a marketing department. It is a pressure, measured in millimeters of mercury, in a chamber of the hea → Case Study 28.1 — Nesiritide: Approved on Surrogates, Answered by Outcomes
Pulsatile secretion
Release of a hormone in discrete bursts rather than continuously. Growth hormone secretion is strongly pulsatile and predominantly nocturnal, falling to near-undetectable levels between bursts, which is why a single random measurement is nearly uninterpretable. (Ch.14) → Ch14
Pulsatility
release of a hormone in discrete bursts rather than continuously, where the temporal pattern itself carries information. (Ch.3) → Glossary fragments — Chapter 3
purity by peak area
The product peak's integrated area as a percentage of total integrated peak area in a chromatogram. A ratio among detected species. Does not establish identity, does not include non-absorbing components, and cannot see what co-elutes. [Ch 32 §32.4; Ch 34] → Glossary contributions — Chapter 32
PYY
added one satiety signal to a system that already had several. Redundancy absorbed it. The effect in infusion studies was modest and short-lived, and nausea was dose-limiting. → Answers — Chapter 13
Q
Qualifier loss
9.CS1 - **Quality of life outcomes** — 8.6 - **Quaternary structure** — 1.4 → Appendix L — Index
Quaternary structure
the assembly of two or more separate folded chains into a functional unit; insulin's storage hexamer is an example. (Ch.1) → Glossary fragments — Chapter 1
Quiz
22 items, key included. Items 11, 13, 15, 19, and 20 are the discriminating ones; a student who gets those five right has the chapter. Item 19 distinguishes the two failure modes (overclaiming from case reports and dismissing them entirely) — worth reviewing aloud whichever way the class splits. - * → Instructor notes — Chapter 24
R
R group
the variable side chain attached to an amino acid's alpha carbon; the only part that differs among the twenty, and therefore the source of all chemical variety in peptides. (Ch.1) → Glossary fragments — Chapter 1
the hormonal system that raises blood pressure and promotes sodium retention. The natriuretic peptide system is its physiological counterweight, and in established heart failure the RAAS predominates. [Ch 28] → Glossary contributions — Chapter 28
racemization
Inversion of a residue's three-dimensional configuration during activation, producing a mirror-image residue: identical mass, different molecule. [Ch 32 §32.2] → Glossary contributions — Chapter 32
Radioligand therapy
The general category PRRT belongs to: a targeting ligand of any chemical class carrying a therapeutic radionuclide. *Ch 27 §27.6.* → Glossary contributions — Chapter 27
Radionuclide
A radioactive isotope; in therapy, chosen for emissions that damage cells over very short distances. *Ch 27 §27.5.* → Glossary contributions — Chapter 27
Random coil
a region of peptide with no regular repeating secondary structure. Many short peptides are largely coil in solution and adopt a defined shape only on binding. (Ch.1) → Glossary fragments — Chapter 1
Randomization
assigning trial participants to arms by chance, which makes the groups comparable in every respect including characteristics nobody measured. (Ch.5) → Glossary fragments — Chapter 5
the stage of a process that determines its overall speed. Improving any other stage does not speed up the whole. *(Ch 35)* → Glossary contributions — Chapter 35
rating discipline
❌ as a statement about evidence → 39.6; rule 1 (claims not molecules) → Dossier §; rule 3 (never upgrade with mechanism) → CS 39.2; rule 4 (never downgrade with distaste) → Dossier § - **repeated game, conversation as** → 39.10 - **reporting back** → 39.10 - **repair move ("what would change your mi → Index entries — Chapter 39
rating drift
The movement of a rating over time as evidence accumulates. For a ⚠️ resting on a single early result the commoner direction is downward, because larger, longer, better-blinded studies regress early effects. Two entries in the master table (intranasal oxytocin for autism; calcitonin for fracture ris → Glossary contributions — Chapter 37
Rating rule 3: never upgrade with mechanism.
The finding arguably *undermines* casual cross-species inference, since its whole content is that closely related species differ enough in receptor placement to behave oppositely. → Chapter 21 Key Takeaways — Oxytocin and Vasopressin
Rating rule 4.
Entry 3's margins: *"honestly a very elegant mechanism"* and *"training partner... recovered well."* That is a rating moved by mechanism plausibility and by a single anecdote. **Rating rule 3**, plus Chapter 6's testimonial dynamic operating on someone the reader knows. → Case Study 1 — Auditing a Finished Dossier
rating rule 6: one molecule, many ratings
and rule 1, that a rating attaches to a claim with a population and an endpoint, never to a molecule. Intravenous oxytocin for postpartum hemorrhage in an obstetric setting and intranasal oxytocin for social functioning in healthy adults are different interventions, different populations, and differ → Chapter 21 Quiz — Oxytocin and Vasopressin
designing a molecule from knowledge of the target, its physiology, or its structure, rather than finding one by search or selection. *(Ch 33 introduced; Ch 35 as one of four routes)* → Glossary contributions — Chapter 35
read a drug label as evidence
indication, population, line of > therapy, and what the approval actually certifies. It is the single most underrated research skill > available to a non-specialist, and the information is free. > > Chapter 28 adds a distinction that will save you from a common error: **the same peptide in two > rol → Part V — Peptides in Medicine
Reading a certificate of analysis
the six things to check and the four things it cannot tell you · 34.8 What independent testing programs have found · 34.9 Why analysis is not a substitute for oversight · 34.10 Pharmacopeial standards and GMP → Master Outline — Understanding Peptides
Rebate
A payment from a manufacturer to a plan or pharmacy benefit manager in exchange for formulary placement. Lowers net price for insurers; does nothing for the uninsured. (Ch.12) → Ch12
The removal or correction of a product already on the market; like withdrawal and label revision, one of the mechanisms by which an approval turns out not to be permanent. → Appendix G — Regulatory and Legal Quick Reference
a protein that recognizes a specific ligand and changes its behavior in response, converting an external signal into an internal one. (Ch.2) → Glossary fragments — Chapter 2
reduction in the number of receptors on a cell surface following sustained stimulation, occurring over hours to days. (Ch.2) → Glossary fragments — Chapter 2
the property of a ligand that acts preferentially at one receptor subtype over another. The single design change underlying desmopressin's clinical profile. (Ch 29; formalized Ch 33) → Glossary contributions — Chapter 29
active transport of cargo across the blood-brain barrier by an endothelial receptor such as the transferrin receptor, exploited by attaching a therapeutic to a ligand for it so that it rides across as a passenger. → Chapter 36 — Glossary Contributions
Recombinant
Produced by genetically engineered cells rather than extracted from tissue. Recombinant growth hormone replaced cadaver-derived material in the mid-1980s and removed the supply constraint that had defined the entire field. (Ch.14) → Ch14
Recombinant DNA
the technique of inserting a gene into a host organism to produce a protein; human insulin, approved in 1982, was the first drug produced this way. (Ch.11) → Glossary fragments — Chapter 11
recombinant DNA production
Inserting the gene for a desired peptide into a host organism, growing that organism at scale, and harvesting the product. Human insulin, 1982, was the first approved recombinant drug. [Ch 32 §32.5; Ch 11] → Glossary contributions — Chapter 32
the automated process matching content to viewers in service of an engagement objective. It cannot rank by evidential quality because evidential quality is not a feature of the content. → Chapter 42: The Creator Economy and the Peptide Pipeline
Redundancy
the presence of multiple overlapping signals serving one function, such that loss of any single signal is largely compensated; the structural reason single-target appetite drugs underperform. (Ch.13) → Glossary fragments — Chapter 13
Reference standard
The independent method that establishes the truth against which an index test is judged. Its unavailability outside a research setting is what makes visual identification of drug use untestable. (Ch.41) → Glossary contributions — Chapter 41
referenced, not
retold
ch3 (pulsatile vs sustained) — cited in ch20 §20.6, §20.8 - ch4 (five barriers, oral delivery) — cited in ch20 §20.8 - ch5 (rating rules) — cited in ch20 §20.1, §20.7, §20.8 - ch13 (α-MSH, POMC, three-joint test) — cited in ch20 §20.2, §20.8 - ch21 (oxytocin/vasopressin) — forward reference in ch20 → Index entries — Chapter 20
Referenced, not rebuilt
one compressed list, then straight to the new argument. The A/B distinction is preserved and given its own paragraph plus a twelve-row table, because it is the distinction readers collapse. Vial B is explicitly *not* called counterfeit. | | **Ch 19** | Sterility vs endotoxin formulation | §34.5 | Qu → Continuity — Chapter 34
refolding
The process step in which an unfolded or misfolded chain is coaxed into its correct three-dimensional structure, including correct disulfide pairing. In recombinant production of disulfide-containing molecules, this rather than expression is usually the hard part. [Ch 32 §32.5] → Glossary contributions — Chapter 32
Regioselectivity
The property of a chemical reaction occurring at one specific site rather than several. Semaglutide's Lys34→Arg substitution creates regioselectivity by construction. — Ch 33 §33.8 → Glossary contributions — Chapter 33 (Peptide Engineering)
Registry entry
does the registered primary endpoint match the published one? *(3 min)* 2. **Methods, four questions** — who, what, against what, measured how. *(4 min)* 3. **Primary endpoint result with its confidence interval.** Ignore the abstract's adjectives. *(2 min)* 4. **Absolute numbers.** Convert any rela → Appendix D — Reading a Clinical Trial: A Field Guide
Regression to the mean
people begin treatments when they feel worst, and extreme states are followed on average by less extreme ones regardless of intervention. Arithmetic, not psychology. → Answers — Chapter 6
what attaches to which seller → 42.7 - why the gaps follow from what is being sold → 42.7 - enforcement velocity vs content velocity → 42.7 - jurisdictional ceiling effect → 42.7 - full architecture → *see* Chapter 38 → Index entries — Chapter 42
Regulatory divergence
The situation in which regulators in different jurisdictions reach different conclusions on largely the same evidence. Characteristically indicates evidence sitting in the genuinely contestable middle rather than error by either party. [ch18 §18.3] → Glossary contributions — Chapter 18
Regulatory enforcement records
warning letters, import alerts, and published inspection findings from national authorities. Public primary sources for what inspectors find in practice. Tier 3. - **Publication bias literature**, general. Supports §34.8's fourth reason. Any standard treatment is adequate; no peptide-specific source → Bibliography — Chapter 34
Regulatory patchwork
the situation in which agencies applying broadly similar principles reach different conclusions about the same molecule, because of differing evidence standards, sponsor filing decisions, medical context, or timing (Ch. 38). → Chapter 38 — Glossary fragment
regulatory product label
the FDA prescribing information in the United States, the EMA summary of product characteristics in Europe. Labels are public, free, and contain the indication, the studied population, the trial results, and the complete adverse-effect table. For a chapter like this one, the label is worth more than → Chapter 24 — Further Reading
Regulatory status documents
national regulators publish current positions on unapproved substances and on bulk substances permitted in compounded preparations; anti-doping authorities publish an annual prohibited list under which any pharmacological substance without current approval for human therapeutic use is prohibited at → Appendix N — Bibliography and Further Reading
Ch 1 §1.2 disulfide bonds; §1.3 peptides-are-food; §1.4 random coil / fold-on-binding (this is load-bearing for §35.8 limitation 2). - Ch 2 receptor engagement ≠ functional outcome; class B GPCR family. - Ch 3 pulsatile endogenous signal vs. flat exogenous exposure (used in §35.5's inherited-selecti → Continuity — Chapter 35
Related substances
Impurities structurally similar to the intended peptide, arising during synthesis; the hardest class of impurity to remove and to detect. — Ch 19 §19.3 (expanded Ch 32) → Glossary contributions — Chapter 19
Relative risk reduction
the proportional reduction in risk, expressed as a ratio; systematically more impressive-sounding than the absolute figure. (Ch.5) → Glossary fragments — Chapter 5
Releasing hormone
a hypothalamic peptide that travels via the portal circulation to stimulate pituitary hormone release; CRH, TRH, GnRH, and GHRH are the four principal ones. (Ch.3) → Glossary fragments — Chapter 3
Repair move: "What would change your mind?"
informative in all three of its usual answers. One bad conversation is not a pattern, and do not shop until you find agreement. → Chapter 39 — Key Takeaways
Repeated interaction
a relationship in which the same two parties engage many times, so that each encounter's value depends on the accumulated history. The correct model of a clinical relationship, and the reason accuracy compounds. *Ch 39 §39.10.* → Glossary contributions — Chapter 39
repertoire
millions of distinct T-cell and B-cell clones, each generated by randomized genetic recombination, each specific for something you will probably never meet. Some tiny number happen to be specific for what is in the vaccine. Vaccination finds them, wakes them, multiplies them, and leaves behind a → Chapter 26: Peptide Vaccines — Cancer Immunotherapy and Infectious Disease Prevention
Replacement versus override
The distinction between supplying a hormone that is absent and adding to one being produced normally. Replacement predicts durable benefit; overriding an intact system predicts adaptation, including feedback suppression of endogenous production. (Ch.14) → Ch14
replaces an absent signal
the beta cells are destroyed, there is no intact system being overridden, no counter-regulation is provoked, and the effect persists indefinitely. → Answers — Chapter 8
Replication
Independent repetition of a study to determine whether its finding holds. A published result is a hypothesis with data attached; a replicated result is knowledge. *(Ch 21 §21.4)* → Glossary contributions — Chapter 21
Replication in a second tumor type or setting
what distinguishes a platform from a single lucky application. - Regulatory approval, which imports independent expert review of the full dataset. - Evidence that benefit is **not confined** to high-mutational-burden tumors and favorable HLA backgrounds — or clear characterization of exactly which p → Chapter 26: Peptide Vaccines — Cancer Immunotherapy and Infectious Disease Prevention
Required elements:
2023: American Society of Anesthesiologists guidance on preoperative management of patients on GLP-1 receptor agonists - Subsequent multi-society clinical practice guidance developed jointly across anesthesiology, gastroenterology, bariatric surgery, and related societies, moving toward individualiz → Bibliography notes — Chapter 39
Research chemical
a compound sold labeled "for research use only" or "not for human consumption," a formulation that avoids drug regulation and liability while permitting a market in human use. (Ch.6) → Glossary fragments — Chapter 6
Research use only
a seller's disclaimer stating that a product is not for human consumption. A liability posture, not a regulatory category conferred by any agency (Ch. 38). → Chapter 38 — Glossary fragment
Research use only (RUO)
A designation placing a substance outside the regulatory definition of a drug by attaching no therapeutic claim. It describes what was *not* done to the material rather than what the material is. — Ch 19 §19.2 (introduced Ch 6 §6.4) → Glossary contributions — Chapter 19
Residual payer
The party left holding the undiscounted price because they sit outside the rebate structure. In US drug pricing, typically the uninsured patient. (Ch.12) → Ch12
Residual solvent
Solvent remaining from synthesis or purification, controlled to defined limits in pharmaceutical products and typically unverified elsewhere. — Ch 19 §19.3 → Glossary contributions — Chapter 19
Residue
an amino acid once incorporated into a chain, so called because it is what remains after the condensation reaction released water. (Ch.1) → Glossary fragments — Chapter 1
Residue mass
the mass a residue contributes to a peptide chain — is the free amino acid mass minus 18.02 Da, because forming each peptide bond releases one molecule of water (Chapter 1, §1.3). → Appendix B — The Twenty Amino Acids: A Reference
Residue tolerance
The maximum permissible concentration of a drug or its metabolites in edible tissue, from which a withdrawal period is derived. *Ch 31 §31.7.* → Glossary contributions — Chapter 31
resin (solid support)
The insoluble polymer beads to which a growing chain is anchored during solid-phase synthesis. Typically swellable, so that chemistry occurs throughout a porous interior rather than only on an outer surface. [Ch 32 §32.1] → Glossary contributions — Chapter 32
Response factor
the relationship between the mass of a compound and the detector signal it produces. Because response factors differ between compounds, peak area is not proportional to mass across different species. (§34.3) → Glossary contributions — Chapter 34
Restoration with improved glycemia
testable and under-tested. It predicts that GIP agonism should contribute little early and more later, which is a measurable prediction. → Answers — Chapter 9
internalization and residence time long enough for the isotope to deposit its dose. Accept also: adequate tumor-to-background ratio, acceptable normal-tissue biodistribution. → Answer notes — Chapter 27
the time at which a component emerges from a chromatography column. A property of the compound *and* the method, not of the compound alone. (§34.3) → Glossary contributions — Chapter 34
reversal
a peptide that looked promising and failed, or one that looked marginal and became standard care, or one whose approved use and popular use are completely different things. → Part V — Peptides in Medicine
a computational method that generates plausible protein backbones, including backbones shaped to bind a specified target surface. *(Ch 35)* → Glossary contributions — Chapter 35
Ribosome display
a cell-free selection technology in which translation is stalled so that the finished peptide, the ribosome, and the encoding mRNA remain associated as a single complex. *(Ch 35)* → Glossary contributions — Chapter 35
Caltech commencement address, 1974; reprinted in *Surely You're Joking, Mr. Feynman!* Quoted in §23.7: "The first principle is that you must not fool yourself — and you are the easiest person to fool." - **Corneliu Giurgea** — coined *nootropic*, early 1970s; developer of piracetam. Cited in §23.1 f → Bibliography notes — Chapter 23
right for the wrong reasons
A rating that matches what the evidence supports but was produced by a method that does not generalize (distaste, mechanism appeal, anecdote). Invisible from inside a single entry; detected only by the same-evidence test, which shows the same method producing a different answer on comparable evidenc → Glossary contributions — Chapter 40
the brainstem relay of the descending pain-modulatory pathway, containing cell populations that both inhibit and facilitate spinal pain transmission. — Ch 20 §20.4 → Glossary contributions — Chapter 20
Rudman
replicated.
Measured **strength and functional capacity did not convincingly improve.** The surrogate moved and the outcome did not follow. - **Adverse effects were substantially more common in treated participants** — soft tissue edema, arthralgia, carpal tunnel syndrome, gynecomastia in men, and impaired gluc → Chapter 14: Growth Hormone — What It Does, How It Declines, and the Science of the "Youth Hormone"
rule 6: one molecule, many ratings
and more sharply than any other case in the book, because the two ratings are at opposite ends of the scale for the same protein. Leptin for → Chapter 13 — Quiz
Rules explicitly exercised in this chapter:
Rule 1 (rating attaches to a claim with population and endpoint) — throughout. - Rule 3 (never upgrade with mechanism) — §26.2 note and §26.10 point 5. **This chapter is the book's strongest demonstration of rule 3.** If Ch 2 §2.9 is ever revised, this chapter's callback must be revised with it. - R → Continuity record — Chapter 26 (Peptide Vaccines)
S
S0
non-approved substances — is a statement that no regulatory authority has approved it for human therapeutic use, and that it is therefore prohibited in sport at all times. It is not a finding that the compound works, and it is not a finding that it is dangerous. Chapter 38 discusses the S0 category → Appendix J — A Timeline of Peptide Science
S0 (Non-Approved Substances)
the WADA category prohibiting at all times any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. A rule about a property rather than a list of names (Ch. 38). → Chapter 38 — Glossary fragment
S0 — Non-Approved Substances
The WADA category prohibiting, **at all times**, any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. **A rule about a property, not a list of names** (§G.9). → Appendix G — Regulatory and Legal Quick Reference
Salmon calcitonin
a fish peptide — is more potent in humans than human calcitonin is, a lovely inversion of everything this chapter has been saying: sometimes the species difference is the *gift*. Venoms in particular are peptide libraries refined by selection for exactly the receptor specificity drug designers spend → Chapter 31: Peptides in Veterinary Medicine — Where Some "Human" Peptides Were First Used
Salt form
A drug substance paired with a counter-ion. Semaglutide sodium and semaglutide acetate are not the same substance as semaglutide base, and their safety and effectiveness had not been established. (Ch.12) → Ch12
salt or ester form
altered solubility and pharmacokinetics, so exposure differs from the studied product; **concentration** — the documented failure mode, where a person accustomed to a pen's units miscalculates a vial's volume; **delivery device** — substituting a syringe for a metered pen transfers the metering job → Chapter 38 — Answers to selected exercises
same-evidence test
The audit check that identifies two entries with comparable evidence bases carrying different ratings, and requires the difference to be justified by design, population, or endpoint. Where no such justification exists, one of the two ratings was produced by something other than evidence. *(Ch 40 §40 → Glossary contributions — Chapter 40
Age-related loss of muscle mass and function. Contemporary consensus definitions lead with low muscle strength, use low mass or quality as confirmatory, and grade severity by physical performance. No drug is approved for it. — *Ch 16 §16.7* → Glossary contributions — Chapter 16
Sarcopenic obesity
the combination of excess adiposity with low muscle mass, typically in older adults; the population in which lean mass loss during weight reduction is of greatest concern and least studied. (Ch.8) → Glossary fragments — Chapter 8
Satellite cell
A resident muscle stem cell lying beneath the fiber's basal lamina that activates in response to loading and damage, proliferates, and fuses into existing fibers, supplying additional nuclei. — *Ch 16 §16.1* → Glossary contributions — Chapter 16
Satiety
the state of fullness that suppresses further eating between meals, as distinct from satiation, which ends a given meal. (Ch.7) → Glossary fragments — Chapter 7
Satisfying sexual events
the chapter states the endpoint was examined and did not separate from placebo. Verify. 4. **Bremelanotide molecular weight** — chapter says "roughly 1,025 Da," consistent with Chapter 1's size spectrum figure. Keep the two consistent if either is revised. 5. **Structural relationship between bremel → Bibliography notes — Chapter 24
Saturable transport system
a carrier-mediated route across the blood-brain barrier available to a small number of specific peptides (insulin, leptin). Saturable means raising blood levels past a point does not raise brain levels proportionally. A property of specific molecules, not of peptides generally. *(Ch 22)* → Glossary contributions — Chapter 22
Second messenger
a small intracellular molecule that carries a signal onward after the first messenger has bound outside the cell. (Ch.2) → Glossary fragments — Chapter 2
Second-order effect
A consequence that follows from the *response* to a thing rather than from the thing itself. Shortage spillover, hardened coverage arguments, and the justification tax are second-order effects of cultural framing, not of pharmacology. (Ch.41) → Glossary contributions — Chapter 41
Secondary structure
local, regular folding of the peptide backbone held together by hydrogen bonds, principally the alpha helix and the beta sheet. (Ch.1) → Glossary fragments — Chapter 1
Secretin
a 27-amino-acid peptide hormone, the first hormone ever identified (Bayliss and Starling, 1902), now used as a diagnostic agent for pancreatic exocrine function. (Ch 3 for the history; Ch 29 for the drug) → Glossary contributions — Chapter 29
sedation
retained gastric contents and → 39.2 - **shared decision-making** → 39.4 - **STEP 1 and STEP 2 trials** — population difference → 39.4 (🔬 callout); *see also* Ch 8 - **stopping rule** → 39.4 (question 5); absence of, as a finding → 39.4, CS 39.2 - **structural pressures on the encounter** → 39.1 - * → Index entries — Chapter 39
cardiovascular outcomes in adults with established cardiovascular disease and overweight or obesity **without** diabetes. Roughly 17,000 participants over about three years: a 20% relative reduction in MACE, roughly 8% to 6.5% absolute, about 1.5 percentage points. → Answers — Chapter 8
SELECT measured the outcome directly
cardiovascular death, myocardial infarction, and stroke, in a population without diabetes, over about three years. That converts the claim from "improves a risk factor" to "reduces events," which is categorically stronger and which cannot be undermined by the historical failure mode. → Answers — Chapter 8
selection
you are seeing the reports that got made and shared, drawn from an unknown denominator, with no comparison group and no account of what would have happened anyway. Chapter 9's Phase 2 optimism and Chapter 10's interim-stopping discussion are the same mechanism operating on professionals with statist → Appendix F — Red Flags: Evaluating a Peptide Information Source
Selection effect
distortion produced not by false statements but by which statements get made at all. Creators who find a product disappointing usually publish nothing, so the visible distribution of opinion is not the distribution of opinion. → Chapter 42: The Creator Economy and the Peptide Pipeline
The degree to which a compound engages its intended receptor and not others. Ipamorelin was designed for selectivity at GHS-R with less of the appetite, cortisol, and prolactin activity associated with GHRP-6. A statement about receptors, not about safety. (Ch.15) → Ch15
Selectivity index
The ratio of the concentration harming host cells to the concentration killing bacteria. This field's therapeutic window, and the metric on which most AMP candidates fail. *(25.5)* → Glossary contributions — Chapter 25
semaglutide
came from laboratories, not from deserts. They started from the human sequence, applied the lizard's trick deliberately by substituting the residue at the cleavage site, and then added something no organism supplied: a fatty acid chain, attached through a linker, that binds circulating albumin and h → Case Study 35.1 — The Gila Monster and the Engineers
Semaglutide injection (Ozempic or Wegovy)
note how few administration constraints there are - **Semaglutide tablets (Rybelsus)** — note the fasting window, the water volume, the waiting period - **Exenatide (Byetta)** — note the twice-daily schedule and the meal timing → Chapter 4 — Further Reading
semaglutide salt forms
semaglutide sodium or semaglutide acetate — rather than the semaglutide base used in the approved products. These are not the same substance, their safety and efficacy had not been established, and their use fell outside what the compounding provisions permit. → Case Study 2 — Compounded Semaglutide
Semaglutide's backbone is 31 residues
the drug side. Tirzepatide at 39 sits two residues from the line. - The line counts **residues, not daltons**. Modified peptides can carry large non-amino-acid mass without moving toward it. - **How a molecule is classified shapes what happens after exclusivity ends** — which connects the line to Ch → Chapter 38 — Key Takeaways
obesity, eating disorders, body image, sexual function, aging, fertility, mental health, terminal illness — are written clinically, respectfully, and without moral framing. Obesity is discussed as a chronic condition with biological drivers, and the book presents the full range of legitimate perspec → Style & Continuity Bible — Understanding Peptides
Sensitive topics
obesity, eating disorders, body image, sexual function, aging, mental health — are written clinically and without moral framing. Never present weight loss as a moral achievement, and never write as though wanting help is a character flaw. - **No named fictional characters.** The running threads are → Contributing to Understanding Peptides
the teaching device in Case Study 1: five progressively less accurate one-sentence descriptions of the same study, used to locate the exact step at which a claim stops being licensed. (Ch.17) → Glossary fragments — Chapter 17
Separate the three risk categories
risk at studied use, risk at unstudied use, and risk from preparation quality — and explain why the third is independent of efficacy. 4. **Explain what a certificate of analysis can and cannot establish** about the vial in front of them. 5. **Explain why regulatory status is not evidence**, in both → Syllabus — Professional Development Short Course
Sequence
the order of amino acids in a chain, written N-terminus to C-terminus; equivalently, primary structure. (Ch.1) → Glossary fragments — Chapter 1
Sermorelin
GHRH(1-29), the unmodified active fragment of GHRH. Formerly marketed for diagnostic and pediatric growth hormone deficiency uses and withdrawn from the US market for commercial reasons; now sold for claims it was never tested against. (Ch.15) → Ch15
Session A
§24.1–24.3 plus case study 1. Origin story, receptor map, and the central/peripheral distinction. Ends on a clean mechanistic note. - **Session B** — §24.4–24.8 plus case study 2 and the dossier. Approval, effect size, the medicalization debate, melanotan II, kisspeptin, ratings. → Instructor notes — Chapter 24
an 8-amino-acid cyclic MC4R agonist approved for obesity due to specified rare genetic deficiencies in the leptin–melanocortin pathway; works by acting downstream of the broken step. (Ch.13) → Glossary fragments — Chapter 13
Setmelanotide labeling
the source for the statement that an approved MC4R agonist causes skin hyperpigmentation and darkening of nevi. Cross-referenced to Chapter 13, which owns setmelanotide. → Bibliography notes — Chapter 24
See *directional bias*. Fingerprint: rating ⚠️ or ❌ where the evidence supports ✅, on evidence not actually examined because the packaging suggested what to expect. *(New in Ch 37 §37.10.)* → Glossary contributions — Chapter 37
Severe hypoglycemia
blood glucose low enough to cause confusion, seizure, or loss of consciousness — is the acute emergency of insulin treatment (Chapter 11 §11.4). It frightens parents of children with type 1 diabetes, and it ends careers, driving licenses, and independent living for adults who experience it repeatedl → Chapter 29: The Peptide Drugs Already in Your Pharmacy
Severe primary IGF-1 deficiency
A rare condition in which IGF-1 production fails despite normal or elevated GH, most often from a defect in GH receptor signaling. Mecasermin's approved indication. — *Ch 16 §16.2* → Glossary contributions — Chapter 16
Shared decision-making
an approach in which clinician and patient combine clinical evidence with the patient's values and circumstances to reach a decision together. The five questions of §39.4 function as its patient-side toolkit. *Ch 39 §39.4.* → Glossary contributions — Chapter 39
Short
typically **12 to 50 residues**, squarely inside the peptide size range of Chapter 1, with all the consequences that follow: chemically synthesizable, rapidly cleared, digested if swallowed. **Cationic** — most carry a **net positive charge** at physiological pH, from an abundance of the basic side → Chapter 25: Antimicrobial Peptides — The Natural Weapons That Could Solve Antibiotic Resistance
A peptide proposed to act as a message to fibroblasts prompting matrix synthesis, typically by mimicking a collagen breakdown fragment. **Distinct from** the molecular-biology meaning of "signal peptide," which denotes a protein-trafficking sequence. Flag this collision wherever both senses could be → Glossary contributions — Chapter 30 (Cosmetic Peptides)
modeling the refusal is more valuable than any figure would be, and it is a compressed version of the whole book's method. → Instructor notes — Chapter 43
Smad2 / Smad3
Intracellular signal transducers phosphorylated downstream of the myostatin receptor complex; they translocate to the nucleus and suppress the transcriptional program of muscle growth. — *Ch 16 §16.3* → Glossary contributions — Chapter 16
a low-molecular-weight non-peptide compound that activates a receptor normally addressed by a peptide, absorbed from the gut as a matter of course and made by conventional organic chemistry. Orforglipron is the GLP-1 receptor example. → Chapter 36 — Glossary Contributions
Smart insulin
investigational glucose-responsive insulin whose activity would vary with surrounding glucose concentration, restoring the glucose-dependence that insulin lacks. (Ch.11) → Glossary fragments — Chapter 11
SNAC
sodium N-[8-(2-hydroxybenzoyl)amino] caprylate, the absorption enhancer in oral semaglutide; it transiently raises local pH to reduce pepsin activity and promotes absorption across the gastric epithelium. Not a peptide and not the drug. → Chapter 36 — Glossary Contributions
A reference assembled at one moment, valid as a description of that moment and progressively less valid thereafter. Chapter 37 is one and says so in its first section. *(New in Ch 37 §37.1.)* → Glossary contributions — Chapter 37
SNARE complex
The protein assembly, including SNAP-25, syntaxin, and synaptobrevin, that drives fusion of neurotransmitter vesicles with the nerve terminal membrane. Target of both botulinum toxin and acetyl hexapeptide-8, by different chemistry and very different routes. *(Ch 30 §30.5)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
So investigators use instruments
questionnaires with defined items, tested for internal > consistency, test-retest reliability, and correlation with clinician assessment. This is a real > methodological achievement and it makes trials possible in a domain with no blood test. > > **What it costs you is interpretability.** When a tri → Chapter 24: PT-141 (Bremelanotide) and the Sexual Function Peptides
Social fact
Something that is true because a group treats it as true, independent of any external measurement. "This drug is everywhere" can be a social fact while actual prevalence remains unknown to everyone asserting it. (Ch.41) → Glossary contributions — Chapter 41
Social salience hypothesis
The leading current account of oxytocin's central effects: that it amplifies the salience of social cues rather than producing affiliation, so context determines the direction of the behavioral effect. The molecule supplies the gain; the situation supplies the sign. *(Ch 21 §21.5)* → Glossary contributions — Chapter 21
solid-phase peptide synthesis (SPPS)
Merrifield's 1963 method, in which a peptide chain is assembled while anchored to an insoluble support so that excess reagents and byproducts can be washed away at every step rather than separated chromatographically. Nobel Prize in Chemistry, 1984. [Ch 32 §32.1; Ch 1 §1.7] → Glossary contributions — Chapter 32
Soluble guanylate cyclase
the cytoplasmic, nitric-oxide-responsive enzyme that produces cGMP. A separate enzyme from the receptor-linked particulate cyclases, converging on the same second messenger. The target of vericiguat. [Ch 28] → Glossary contributions — Chapter 28
Somatopause
The age-related decline in growth hormone secretion and IGF-1, commonly cited as roughly 14% per decade after about age 30. The term's analogy to menopause is rhetorical rather than physiological, since the decline is gradual, partial, and never reaches zero. (Ch.14) → Ch14
Somatostatin
an inhibitory peptide that brakes growth hormone release and suppresses several pancreatic and gastrointestinal hormones; the basis of an approved oncology drug class. (Ch.3) → Glossary fragments — Chapter 3
Somatostatin analog
An engineered, stabilized relative of somatostatin (octreotide, lanreotide) used to suppress hormone secretion and, in neuroendocrine tumors, to slow progression. *Ch 27 §27.4.* Cross-ref: Ch 3 §3.3, Ch 14, Ch 33. → Glossary contributions — Chapter 27
Somatostatin receptor (SSTR)
A family of five receptor subtypes; SSTR2 is the principal target of octreotide and lanreotide and the address exploited by PRRT. *Ch 27 §27.4–27.5.* → Glossary contributions — Chapter 27
Somatotroph
The cell type in the anterior pituitary that produces and secretes growth hormone. (Ch.14) → Ch14
Somatotropin
The generic pharmaceutical name for growth hormone; the `-tropin` stem denotes a pituitary-hormone-like molecule. (Ch.14) → Ch14
The short chemical bridge between a peptide and an attached lipid or polymer, providing distance and flexibility so the conjugate can bind albumin without obstructing the receptor-binding face. — Ch 33 §33.4 → Glossary contributions — Chapter 33 (Peptide Engineering)
Specific force
Force produced per unit of muscle cross-sectional area; a measure of muscle quality rather than quantity. Reported to be reduced in myostatin-null animals — bigger muscle, weaker per gram. — *Ch 16 §16.3* → Glossary contributions — Chapter 16
The written set of tests, methods, and acceptance criteria a batch must meet. Research specifications and pharmaceutical specifications differ in kind, not merely in strictness. — Ch 19 §19.1 → Glossary contributions — Chapter 19
Speculation economy
The set of incentives that makes public guessing about individuals' medical treatment cheap to produce, highly engaging, socially defensible, and never resolved — with the cost falling entirely on the subject. (Ch.41) → Glossary contributions — Chapter 41
split rating
A rating carrying two glyphs separated by a slash (⚠️/❌, ✅/⚠️, ⚠️/🔬) because the evidence supports a modest version of a claim but not its strong version, or supports it in one sub-population but not another, or has moved between tiers over time. Ten appear in this book. A split is a finding, not a → Glossary contributions — Chapter 37
The threshold required before assigning a given rating. The audit's premise is that a threshold must be the same across entries to be a standard at all. *(Ch 40 §40.3.)* → Glossary contributions — Chapter 40
Stapled peptide
A peptide whose alpha helix is locked in its bound conformation by a hydrocarbon crosslink between two side chains, typically at positions *i* and *i*+4 or *i* and *i*+7. — Ch 33 §33.3 → Glossary contributions — Chapter 33 (Peptide Engineering)
State any peptide claim in evaluable form
with a population and an endpoint — and explain why a claim stated without those is not evaluable. 2. **Apply the four-tier rating (✅ ⚠️ ❌ 🔬) to a claim they have never seen before**, with a date and a falsification condition. *This is the outcome the course exists for.* 3. **Describe an evidence ba → Syllabus — One-Semester Survey
deliberately, so the constructed dossier cannot be mistaken for a data source. - Case Study 2 contains **no numeric claims whatsoever**. Its evidence discussion is qualitative and hedged throughout, and all ratings are labeled as the worked example's own and dated. → Continuity — Chapter 40
Statistical significance
the conventional threshold at which a result is unlikely to be chance; it says nothing about whether the effect is large or important. (Ch.5) → Glossary fragments — Chapter 5
statistically significant and modest
fractions of a point on multi-point scales, against a substantial placebo response. The number of **satisfying sexual events did not separate from placebo.** - **Nausea is common** — a large minority of participants. For a drug taken in anticipation of sexual activity, that is a meaningful practical → Chapter 24 — Key Takeaways
Steady state
the stable drug concentration reached after approximately four to five half-lives of regular dosing. (Ch.4) → Glossary fragments — Chapter 4
stem
a fixed syllable, almost always at the end of the name, that encodes the compound's class. The prefix that comes before the stem is chosen to be distinctive and pronounceable and carries no information; the stem carries the meaning. → Appendix I — Peptide Nomenclature and How to Read a Sequence
Stem (drug naming)
the shared suffix or infix in a generic drug name that identifies its class, assigned under international nomenclature conventions: `-tide` for peptides, `-mab` for monoclonal antibodies, `-relin` and `-relix` for releasing-hormone agonists and antagonists. (Ch.1) → Glossary fragments — Chapter 1
STEP
semaglutide 2.4 mg in weight management. About **−15%** from baseline at 68 weeks in adults with overweight or obesity **without** diabetes versus roughly −2.4% on placebo; about **−10%** in adults **with** type 2 diabetes. Both arms received lifestyle intervention. → Answers — Chapter 8
STEP 1
semaglutide 2.4 mg weekly, adults with overweight/obesity **without** diabetes, ~**−15%** from baseline at 68 weeks vs ~**−2.4%** placebo, both arms receiving lifestyle intervention. - **STEP 2** — same dose, adults **with** type 2 diabetes, ~**−10%**. - **SELECT** — adults with **established cardio → Chapter 12 — Continuity Record
Step therapy
A requirement that a less expensive option be tried and fail before a more expensive one is covered. (Ch.12) → Ch12
stepwise yield
The fraction of chains that are correct, full-length product after *n* couplings at efficiency *e*, equal to *eⁿ*. The single most useful piece of arithmetic in Part VI. [Ch 32 §32.3] → Glossary contributions — Chapter 32
Sterility
Absence of viable organisms, achieved by a validated process (terminal sterilization or aseptic processing) and verified by a specific test. Not conferred by dryness. — Ch 19 §19.3 → Glossary contributions — Chapter 19
Stigma
Social devaluation attached to a characteristic or condition. Treated in this book as a health variable rather than a matter of manners: associated with avoidance of medical care, disordered eating, psychological harm, and documented differences in clinical treatment. *(Ch 44 §44.4)* → Glossary contributions — Chapter 44
Stimulation test
a diagnostic procedure in which a provoking agent is administered and the resulting hormonal response measured, to assess whether a gland is capable of responding. (Ch 29) → Glossary contributions — Chapter 29
Stop it and the deficiency is still there
which makes it chronic > therapy in exactly the sense Chapter 8 §8.9 defined, and which raises the same access questions > Chapter 12 raises, for a population too small to have any market power. > > **What "genetic obesity" overstates:** the approval covers *specified* deficiencies. Many people with → Case Study 2 — The Drug for a Few Dozen People
Stopped early for efficacy
termination of a trial when an interim analysis crosses a pre-specified benefit boundary; ethically motivated, and associated with systematically overestimated effect magnitudes. (Ch.10) → Glossary fragments — Chapter 10
Stopping rule
a condition, defined in advance, under which an intervention will be discontinued. Should contain a symptom that means stop immediately, a finding that means stop and reassess, and a date at which no benefit means stop. The clinical analogue of a trial's pre-specified interim stopping criteria. **Mu → Glossary contributions — Chapter 39
supplying exogenous natriuretic peptide in acute heart failure. Limit: both tested acute decompensation with short follow-up; neither excludes a different phase of illness, a different population, or a differently engineered molecule. → Answers and marking notes — Chapter 28
Stratum corneum
The outermost layer of the epidermis: dead, keratin-filled corneocytes embedded in a lipid matrix, roughly 10–20 µm thick. Its evolved function is to keep substances out and water in. The organizing obstacle of Chapter 30. *(Ch 30 §30.2)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Stretching
using less than the prescribed dose to make a vial last longer - **Skipping** — omitting doses, particularly mealtime doses - **Delaying** refills until money is available - **Substituting** to older, cheaper formulations without clinical supervision - **Choosing between** insulin and other necessit → Case Study 2 — Rationing
Strict liability (anti-doping)
The principle that an athlete is responsible for any prohibited substance found in their body, regardless of intent or of what a product's label claimed. — Ch 19 §19.9 → Glossary contributions — Chapter 19
Strong clinical evidence
for this population. > > **Why:** SELECT: roughly 17,000 participants, about three years, pre-specified hard endpoint, a 20% > relative reduction (hazard ratio about 0.80), roughly 8% to 6.5% absolute — about 1.5 percentage > points. SUSTAIN 6 provides supporting evidence in type 2 diabetes. > > **W → ALL EVIDENCE RATINGS — harvested, do not edit by hand
Strong evidence
for this *mechanistic* claim. > > **Why:** Receptor identity, binding, and downstream signaling have been characterized > extensively in cell and animal systems and are consistent across laboratories. > > **What would change it:** Very little; this is settled science. > > **And note what it does not → ALL EVIDENCE RATINGS — harvested, do not edit by hand
strongest and rarest
it asserts evidence exists and is negative — and that the follow-up is *which trial?* That "I don't know" says nothing about the state of the field. That "we don't know" is a real and common state of the world, and that saying it costs the clinician something. → Instructor Notes — Chapter 39: Talking to Your Doctor About Peptides
A change to environments, systems, prices, regulations, or access rather than to individual bodies. The alternative frame to medicalization, and not mutually exclusive with it. *(Ch 12; Ch 44 §44.5)* → Glossary contributions — Chapter 44
A dossier field that is empty because no answer could exist, as distinct from one empty because the answer was not sought. Field 7 for a dietary pattern is structurally empty — no regulator approves eating patterns — and carries no information, whereas an empty Field 7 for a drug is highly informati → Glossary contributions — Chapter 40
Structure-based design
designing or optimizing a ligand using the three-dimensional structure of its target's binding site. *(Ch 35)* → Glossary contributions — Chapter 35
Structure/function claim
A claim that a product affects the structure or any function of the body. Making one converts a cosmetic into a drug requiring approval, which is why cosmetic marketing says "the appearance of" instead. *(Ch 30 §30.7)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
Sub-claims that must be separately supported:
Slowed gastric emptying contributes to satiety and to attenuation of the post-meal glucose rise - Shorter-acting agents in the class produce more pronounced slowing than long-acting agents - Partial adaptation (tachyphylaxis of the gastric effect) with continued exposure to some agents - Substantial → Bibliography notes — Chapter 39
Subcutaneous
injected into the fat layer beneath the skin, from which absorption occurs over hours; the default route for peptide drugs. (Ch.4) → Glossary fragments — Chapter 4
A payment model in which a health system pays a fixed sum for access to an antibiotic regardless of quantity used. *(25.6)* → Glossary contributions — Chapter 25
Substance P
an 11-residue tachykinin, Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2, released from small-diameter primary afferent neurons under sustained noxious stimulation and acting principally at the NK1 receptor. Named in 1931 for the dried "powder" preparation from which it was identified. *(Ch 22)* → Glossary contributions — Chapter 22
Sunscreen regulatory category by jurisdiction
OTC drug in the United States; cosmetic in the European Union, Japan, and many other markets. **[VERIFY current status; this has been subject to proposed change.]** Used in: §30.7. → Bibliography working file — Chapter 30 (Cosmetic Peptides)
the reduction in endogenous hormone production that follows supplying that hormone from outside; expected physiology rather than a malfunction. (Ch.3) → Glossary fragments — Chapter 3
SURMOUNT
obesity. Supported approval for weight management in 2023 (Zepbound). → Answers — Chapter 9
SURPASS
type 2 diabetes. Supported approval for glycemic control in 2022 (Mounjaro). → Answers — Chapter 9
SURPASS-2: direction only
"greater A1C reduction and greater weight loss at all three doses." No decimals anywhere. - **Retatrutide: ~−24% at 48 weeks, Phase 2** — **"Phase 2" appears with the figure every time.** - tirzepatide 39 aa, ~4,800 Da (canon §2.1) - approvals 2022 (T2D) / 2023 (weight) - nine in ten compounds enter → Continuity notes — Chapter 9
Surrogate endpoint
a measurement believed to predict a clinically important outcome, used because it is faster or cheaper to measure than the outcome itself. (Ch.5) → Glossary fragments — Chapter 5
Surrogate endpoint (reinforced)
a measurement that stands in for an outcome people care about. Frequently what an optimization-oriented practice is actually treating, because a surrogate is measurable at every visit and an outcome is not. *Defined Ch 16; question 2 of Ch 39 §39.4.* → Glossary contributions — Chapter 39
measurements standing in for outcomes we care about, on the assumption that moving them moves the outcomes. Chapter 5 is entirely about why that assumption fails often enough to be dangerous. Nobody wants lean mass for its own sake. People want to be strong, to climb stairs, to not fall, to not brea → Chapter 14: Growth Hormone — What It Does, How It Declines, and the Science of the "Youth Hormone"
the structural one. Those for whom something happened post; those for whom nothing happened mostly do not write about the absence of an event. The visible sample is filtered before any reader arrives. → Answers — Chapter 6
Survivorship bias
the distortion produced when only cases reaching a particular outcome are visible; in testimonial records, the structural reason positive experiences dominate before any reader arrives. (Ch.6) → Glossary fragments — Chapter 6
Survivorship is
structural
it operates on the *record you see* rather than on the person reporting, filtering the visible sample for positive outcomes before you arrive. It is the same problem as publication bias, operating on testimonials, and it is the one you cannot correct for by being a careful reader of any individual p → Chapter 6 — Quiz
SUSTAIN
semaglutide in type 2 diabetes. Established substantial A1C reduction against placebo and active comparators, weight loss as a secondary finding, and — in SUSTAIN 6, a cardiovascular outcomes trial — a statistically significant *reduction* in major adverse cardiovascular events in a study designed o → Answers — Chapter 8
The observation that angiogenesis, proliferation, and cell survival — the three mechanisms in nearly every pro-healing promotional story — are also the three processes a tumor requires. No causal link to human cancer is established for the compounds in Ch. 18, and the question is also unstudied. [ch → Glossary contributions — Chapter 18
synthesized it
built the molecule from scratch and showed that the synthetic material had the biological activity of the natural one. That was **the first chemical synthesis of a peptide hormone**, and it earned the **Nobel Prize in Chemistry in 1955**. It matters for two reasons. First, it established the proof o → Chapter 21: Oxytocin and Vasopressin — The "Love Hormones": What They Actually Do
the fraction of an administered dose that reaches systemic circulation intact. Usually the objective of peptide delivery engineering; deliberately minimized for linaclotide. (Ch 4, reframed Ch 29) → Glossary contributions — Chapter 29
T
Tachykinin
the peptide family including substance P, neurokinin A, and neurokinin B, sharing the C-terminal signature motif Phe-X-Gly-Leu-Met-NH2. *(Ch 22)* → Glossary contributions — Chapter 22
isolating an ion, fragmenting it, and measuring the fragment masses. Because peptides fragment preferentially at the peptide bond, the mass differences between consecutive fragments reveal the sequence. (§34.2) → Glossary contributions — Chapter 34
Tape stripping
Sequential removal of stratum corneum layers with adhesive tape to measure compound distribution. Frequently reported as evidence of "penetration" when it demonstrates only arrival in the layer that is about to be shed. *(Ch 30 §30.2)* → Glossary contributions — Chapter 30 (Cosmetic Peptides)
target
CGRP antibodies and gepants (this chapter) - peptide as **delivery address** — radioligand therapy (**Chapter 27 must pick this up by name**) - peptide as **effector raised indirectly** — neprilysin inhibition (**Chapter 28 must pick this up by name**) → Continuity notes — Chapter 22
Target versus drug
the distinction between the molecule a therapy acts on and the molecule the therapy is made of. A peptide can be the target of an antibody or small molecule (Ch 22), a delivery address for a payload (Ch 27), or an effector raised indirectly by inhibiting its degradation (Ch 28). *(Ch 22)* → Glossary contributions — Chapter 22
TB-500
A laboratory code for a compound marketed as a short synthetic fragment of thymosin β4, commonly described as corresponding to the actin-binding region. **Not the same molecule as thymosin β4**, despite the two names being used interchangeably throughout the consumer market. Never assigned a generic → Glossary contributions — Chapter 18
TB-500 human literature
§18.2, §18.8. Stated as: no completed randomized controlled human trials in the published literature as of this writing. Phrased as a description of a search result and date-stamped per Rule 5. Recheck at every revision; this is the load-bearing fact under the ❌. → Bibliography notes — Chapter 18
Teichoic acid
Anionic polymers threading the Gram-positive cell wall; a major contributor to Gram-positive surface negative charge and a site of D-alanylation in AMP resistance. *(25.3)* → Glossary contributions — Chapter 25
telehealth
access benefits → 42.2 - volume incentives → 42.2 - vertical integration of advertising, prescribing, dispensing → 42.2 - diagnostic question ("what would make them decline?") → 42.2 - rated ⚠️ → 42.2 → Index entries — Chapter 42
Tendinopathy
the preferred term for chronic tendon disorders, adopted in place of "tendinitis" because these conditions typically show degenerative change, disorganized collagen, and often abnormal neovascularization, with relatively little classic inflammation. (Ch.17) → Glossary fragments — Chapter 17
Teprotide
a bradykinin-potentiating peptide from *Bothrops jararaca* venom developed as an injectable ACE inhibitor. It worked and was impractical; the direct precursor to captopril. *(Ch 35)* → Glossary contributions — Chapter 35
Teriparatide
recombinant PTH(1–34), an approved anabolic bone agent for severe osteoporosis and high fracture risk, given by daily subcutaneous injection. (Ch 29) → Glossary contributions — Chapter 29
Terlipressin
a longer-acting vasopressin analog with relative V1 preference, used in esophageal variceal bleeding and, more notably, in hepatorenal syndrome. (Ch 29) → Glossary contributions — Chapter 29
A stabilized GHRH analog, and the only compound in Chapter 15 with a regulatory approval: reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. (Ch.15) → Ch15
Testimonial
a personal account of benefit from a treatment; subject to regression to the mean, natural history, expectation, co-intervention, and survivorship filtering. (Ch.6) → Glossary fragments — Chapter 6
A large group of secreted signaling proteins sharing receptors and downstream machinery, including myostatin, activin A, GDF-11, and the bone morphogenetic proteins. Its shared architecture is the source of the specificity problem in myostatin drug design. — *Ch 16 §16.3* → Glossary contributions — Chapter 16
That is precisely the design brief of a drug.
**Venom peptides are selective because indiscriminate venom is metabolically wasteful.** Venom is expensive and slow to regenerate; specificity is cheap and effective. - Many are disulfide-stapled and protease-resistant, arriving pre-solved for the stability problem Chapter 33 attacks by design. **S → Chapter 35 — Key Takeaways
That is the danger signal working
a local innate immune response, which is > the thing that converts an injected antigen into durable memory. Reactogenicity and immunogenicity > are linked, which is why the most effective adjuvants are often the least pleasant. > > Three real cautions. > > **The safety bar depends entirely on the se → Chapter 26: Peptide Vaccines — Cancer Immunotherapy and Infectious Disease Prevention
The "false belief" move at the end of case study 2
retracing the five steps on the assumption that the enhancement does not work — is the chapter's strongest single passage and is deliberately placed in a case study rather than the chapter so that §43.5 does not become overlong. It is also signposted in §43.5 so a reader who skips case studies still → Continuity — Chapter 43
The 1978 Lancet study population
postoperative dental pain following third-molar extraction. 6. **Siebers et al. 2021** — author, year, journal, and that the antagonist used was an opioid antagonist. Chapter text hedges to "an opioid receptor antagonist"; keep the hedge unless verified. 7. **Boecker 2008 sample size** — chapter say → Bibliography contributions — Chapter 20
The alternative to abstraction was
invention.
The institutional interest can be entirely legitimate. **The coercion problem does not require bad motives, which is why it cannot be fixed by improving motives.** → Chapter 43 — Key Takeaways
The book does not resolve it
the weights are values, not findings. But note that **the argument is far stronger as a safety argument than as a fairness argument, and is almost always deployed as the latter.** → Chapter 43 — Key Takeaways
The BPC-157 evidence gap
**this is where it becomes a formal rating.** §5.3's Figure 5.4 is the composite animal study, §5.12 is the ❌. **Ch 17 owns the full treatment and must build on this rather than restate it.** - **The Ozempic conversation** — advanced implicitly: §5.12's ✅ and its explicit "what this does NOT cover" → Continuity notes — Chapter 5
THE CLAIM AS USUALLY ENCOUNTERED
how a reader actually meets it, in the wild: the phrasing on > the label, in the video, in the thread, at the dinner table. Not a tidied-up version. > > **THE CLAIM, RESTATED PRECISELY** — population, endpoint, comparator, timeframe. The four questions > from Appendix D §D.2, applied to the claim ra → Appendix H — Twenty Worked Evidence Evaluations
The claim types paraphrased throughout
the clinic email, the website copy, the training-partner report. These are composites written to be representative. No real advertisement, person, or post is quoted anywhere in this chapter, by design. → Chapter 15 — Further Reading
the clinician conversation / disclosure
owned by **Ch 39**. §17.9 gives it one paragraph and one sentence of actionable advice; Ch 39 owns the how. → Continuity notes — Chapter 17
the coercion question
when a choice becomes an expectation · 43.6 the level-playing-field argument, examined · 43.7 safety without a physician · 43.8 who bears the risk and who captures the benefit · 43.9 what would make enhancement defensible → Master Outline — Understanding Peptides
the comparison, not the ingredient
fiber has real benefits, and a blanket dismissal would be wrong and would hand the argument away. → Chapter 13 — Key Takeaways
A neuropeptide with a perfect mechanism and no route in is a **research tool**, not a drug candidate. - Three exceptions make the rest legible: **circumventricular organs** (area postrema, Chapter 7); **saturable transport systems** for a few specific peptides (insulin, leptin — a property of those → Chapter 22 — Key Takeaways
The definition of approval
"a regulator's judgment that, for a specified indication and population, the evidence submitted shows the benefits outweigh the risks," plus the label. Three properties: indication-specific, submission-dependent, jurisdiction-specific. - **The forty-amino-acid line** — US; >40 residues in a specific → Chapter 38 — Continuity notes
The details and
timing were contested
through litigation, through disputed determinations, and through disagreement about what "resolved" meant in practice for patients who still could not fill prescriptions. Chapters 12 and 38 lay out the structure of the dispute. → Appendix J — A Timeline of Peptide Science
The dismissal
*"no approved drug after forty years, doesn't work"* — is wrong on the evidence, since absence of an approval is not evidence of failure and §25.6 supplies a large non-scientific reason approvals may be missing. It also cannot be updated: someone who has concluded "doesn't work" has no reason to loo → Chapter 25: Antimicrobial Peptides — The Natural Weapons That Could Solve Antibiotic Resistance
The Evidence Dossier project
this chapter fills **Field 4 (Route and Delivery)**. The dossier section demonstrates with a deliberately paired contrast: botulinum toxin (injected, ✅) against acetyl hexapeptide-8 (topical, ❌), same target, opposite ratings. Students are instructed that a molecule with both a topical and an inject → Continuity record — Chapter 30 (Cosmetic Peptides)
the accelerator/brake schematic, drawn to make the somatostatin point visible. Simplified; ghrelin and the GH secretagogue receptor are deliberately omitted and arrive in Chapter 15. - **The deficiency-versus-aging comparison table (§14.4)** — assembled to state the anti-aging argument at its strong → Chapter 14 — Further Reading
a substantial observational literature associating higher circulating IGF-1 with incidence of several cancers, prostate, breast, and colorectal among the most frequently reported. Read at least one of these papers' limitations sections rather than only the abstract; the authors are generally far mor → Chapter 14 — Further Reading
the field's best cautionary tale about mechanism · 22.6 Orexin/hypocretin, narcolepsy, and the antagonists that became insomnia drugs · 22.7 CGRP and the migraine drugs that finally worked · 22.8 The blood-brain barrier as the field's central obstacle · 22.9 What CGRP's success teaches that substanc → Master Outline — Understanding Peptides
the 1977 Nobel Prize in Physiology or Medicine was awarded in part for work on the peptide hormones of the hypothalamus, the line of research that identified the hypothalamic releasing and inhibiting factors. The Nobel lectures and presentation speeches are freely available and are unusually readabl → Chapter 14 — Further Reading
The origin story
"an exact fragment of a protein found naturally in the human body." Origin carries no evidentiary weight (dossier field 2). Letting it raise the rating is the error field 2 exists to quarantine; several compounds rated ❌ in this book are exact fragments of human proteins, and one of the best-support → Midterm Exam — Parts I–III
The Ozempic conversation
advanced via §9.5's "which is better" decomposition, which is the question a reader's friend actually asks. **Ch 39 should reuse the six-part decomposition.** - **The semaglutide engineering story** — referenced only. - **New material Ch 9 contributes:** - **§9.4 is the estimand's permanent home.** → Continuity notes — Chapter 9
and whether it was stated at all. Frequently it is not, or appears only in a parenthesis. - **The estimand** — almost never named outside the trial publication itself. - **The dose** — often present, often as "up to." - **The population** — usually present in general terms ("adults with obesity") an → Answers — Chapter 9
The population lesson
STEP 1 versus STEP 2. Students must never again quote a trial figure without its population. 2. **The relative/absolute discipline** — SELECT, worked in both framings with an NNT. 3. **The chronic-therapy reframe** — weight returns, this is not a failure, and the expectation that it should be perman → Instructor material — Chapter 8
Metabolic dysfunction and insulin resistance are associated with Alzheimer's risk, to the point that the phrase "type 3 diabetes" has circulated - GLP-1 receptors are present in the brain - Preclinical work reports neuroprotective effects in animal models - Epidemiological analyses have reported low → Chapter 10: Beyond Weight Loss: GLP-1 for the Heart, Kidney, Liver, Brain, and Addiction
it is a correct number answering a question the student did not ask. There is no lie to catch, which makes this harder to teach than outright deception. Students are not being fooled; they are being handed the wrong denominator and never told there was one. → Where Students Get Stuck
The remainder is deletion sequences
chains that missed a coupling and then accepted the next residue, leaving an internal gap. - A 29-residue impurity in a 30-residue product has nearly identical charge, hydrophobicity, and retention time. **Very hard to separate and easy to miss.** This is the link to Chapter 34 and to Chapter 19. - → Chapter 32 — Key Takeaways
The results:
Dyspnea improved slightly more with nesiritide. The difference did not meet the prespecified threshold for statistical significance. - The 30-day composite of death or rehospitalization was essentially identical between groups. - Hypotension was more common with nesiritide. - The mortality and renal → Case Study 28.1 — Nesiritide: Approved on Surrogates, Answered by Outcomes
The Rudman study (1990)
what it showed and the three things it did not measure · 14.6 The anti-aging industry that a 12-person study built · 14.7 Risks: joint pain, edema, carpal tunnel, insulin resistance, and the cancer question stated carefully · 14.8 Acromegaly as the natural experiment · 14.9 Two ratings for one molec → Master Outline — Understanding Peptides
The selection mechanism worked in Case Study 1
a drug with a true 20% effect whose interim looks scatter to 31% — is a **constructed illustration** of a real statistical phenomenon. The numbers are invented to demonstrate the logic and describe no actual trial. - The four-explanations diagram, the biopsy-endpoint comparison table, the ten-claim → Bibliography fragments — Chapter 10
The semaglutide anchor
three modifications, 2 minutes to 7 days · 4.6 Bioavailability and why the oral tablet contains so much more drug · 4.7 Immunogenicity: when the body makes antibodies against the drug · 4.8 Why peptide drugs are expensive — the honest cost stack · 4.9 What the delivery problem means for every gray-m → Master Outline — Understanding Peptides
The semaglutide engineering story
introduced in outline only (§1.4, §1.7): the position-8 substitution as an example of sequence change serving a pharmacokinetic goal. Full three-modification treatment is reserved for Ch 4 and Ch 33. **Ch 1 deliberately does not enumerate all three.** - **The BPC-157 evidence gap** — introduced as a → Continuity notes — Chapter 1
The six quality failure modes
identity, purity, content, sterility, endotoxin, residuals — as *independent* questions requiring separate tests. Chapter 32 owns the synthesis chemistry behind purity; Chapter 34 owns what analysis can establish. Neither should re-enumerate the six. 2. **Endotoxin vs sterility.** The formulation "s → Continuity — Chapter 19 (The Gray Market)
The steps skipped are 6 and 7
whether an outcome a person notices improves, and whether benefit exceeds harm. The claim argues steps 1 through 3 convincingly and asserts 6 and 7 without data. → Chapter 3 — Quiz
pose it, let them work, then neoantigens (§26.5) | 35 | | 6 | mRNA as message not drug (§26.6) | 10 | | 7 | Status, attribution, and how to read a trial report (§26.7) | 20 | | 8 | Therapeutic vs prophylactic; the failure record (§26.8) | 20 | | 9 | Allergy as the inverted case (§26.9) | 10 | | 10 | → Instructor notes — Chapter 26: Peptide Vaccines
The translational-failure literature
a substantial body of work on the poor predictive value of preclinical results for human outcomes, indexed under terms such as *translational failure*, *preclinical reproducibility*, and *animal-to-human translation*. Supports §17.5 generally. - **The tendinopathy literature** — the shift from "tend → Bibliography fragments — Chapter 17
20.9% and 22.5% are the same trial · 9.5 Head-to-head: what SURPASS-2 does and does not establish · 9.6 Retatrutide and triple agonism — a Phase 2 result that reads like a Phase 3 · 9.7 CagriSema and the amylin combination · 9.8 Orforglipron and the small-molecule threat to peptides · 9.9 The pipeli → Master Outline — Understanding Peptides
The visible
changes
less fat, more lean mass, a different look in the mirror. And what is unmeasured in that setting? Cardiac structure. Glucose trend. Everything that acromegaly says is where the damage actually accumulates. → Case Study 14.2 — Acromegaly: The Experiment Nobody Designed
and watch students discover that most of the proposed fixes require the reader to do more work, which is exactly what does not happen at scale. → Instructor material — Chapter 5
Theranostic
A targeting system usable for both diagnosis and therapy by exchanging the radionuclide, enabling imaging-confirmed target presence before treatment. *Ch 27 §27.6.* → Glossary contributions — Chapter 27
Therapeutic antibody
weeks. Too large for renal filtration, and antibodies are recycled by a dedicated salvage pathway. 2. **Semaglutide** — about a week. Engineered specifically for this: DPP-4 resistance plus albumin binding via a fatty acid chain. 3. **Aspirin** — hours for the parent molecule (its effect on platelet → Answers — Chapter 1
Therapeutic relationship
the ongoing clinical relationship itself, whose diagnostic value comes substantially from accumulated context: the patient's own baselines, their patterns of describing symptoms, and what has already been tried. *Ch 39 §39.10.* → Glossary contributions — Chapter 39
Therapeutic use exemption
a process by which an athlete may be permitted to use an otherwise prohibited substance for a documented medical need, subject to the relevant organization's requirements (Ch. 38). → Chapter 38 — Glossary fragment
Therapeutic window
The range between an effective and a harmful exposure. The general concept of which the selectivity index is the AMP-specific instance. *(25.5)* → Glossary contributions — Chapter 25
nobody has defined the outcome measure for "a drug name entering the language," and the plausible candidates all embed a value judgment. **There is no placebo**, because there is no version of the society that did not get the drug, running alongside for comparison. → Chapter 40: Your Peptide Evidence Dossier — Putting It All Together
These may not be the
same signal
a candidate explanation for why the drug effect so exceeds anything physiology produces. → Chapter 7 — Key Takeaways
but draws one line that is in its lane: **silence and misattribution are not the same act.** Silence makes no claim. Attributing results to a cause that was not the cause is an efficacy claim, and efficacy claims get evaluated. → Chapter 41 — Key Takeaways
this chapter issues no ratings of
its own
every rating was decided in the chapter that owned the claim — and that Chapters 37 and 40 are the only two contributing none to the count, because they restate rather than issue. It ties forward to §37.10: the dossier comparison is only worth making if neither column was written while looking at th → Continuity — Chapter 37 (The Peptide Evidence Table)
This does not violate rule 2
❌ still describes the evidence. It is just that here the evidence > includes harm reports, and the rating summarizes all of it. It also does not violate rule 4: the > rating is not a downgrade for distaste. Cosmetic tanning is a perfectly legitimate thing to want. > The rating would be identical if → Chapter 24: PT-141 (Bremelanotide) and the Sexual Function Peptides
This is deliberate and should be preserved
they are the two entries most likely to be wrong by the time anyone reads this. 3. **Case Study 2 rates an inference rather than a compound.** This is a format extension. It works pedagogically and Ch 37 needs to decide whether to carry it. **Flagged as an editorial choice, not an error.** 4. **§9.5 → Continuity notes — Chapter 9
This label must not be edited out.
**Currency escaped** — `\$90`-style escaping not required in this chapter; the only monetary reference is "on the order of a billion dollars," written in words. - **American spelling** throughout. Note: "program" does **not** appear; "program" used consistently, including for clinical development pr → Continuity — Chapter 25
identity, purity, and content — that ordinary usage collapses into one. Identity asks what it is. Purity asks what fraction of the detected material is the target. Content asks how many milligrams are actually present. A vial can be 98% pure and contain considerably less peptide than its label state → Chapter 34: Peptide Analysis and Quality Control — How Anyone Knows What's Actually in the Vial
Three-letter codes separated by hyphens
`Gly-His-Lys`, `Ala-Aib-Glu` — are used for short peptides and anywhere a human being needs to read the residues rather than scan the string. They are unambiguous, they accommodate non-standard residues without special pleading (`Aib` needs no explanation; there is no single letter for it), and they → Appendix I — Peptide Nomenclature and How to Read a Sequence
Thymosin alpha-1 (Tα1)
A 28-amino-acid peptide derived from prothymosin alpha, with immunomodulatory activity. Approved in a number of countries for defined indications — notably hepatitis B, and as an immune adjuvant in some jurisdictions — and not FDA-approved in the United States. Structurally and functionally unrelate → Glossary contributions — Chapter 18
Thymosin alpha-1 clinical literature
§18.3. Described as including randomized human trials in chronic hepatitis B, in sepsis, and in immune support during cancer treatment; heterogeneous in design, population, endpoint, and quality; contested effect sizes. This is the chapter's most evidentially substantial claim and the one a reviser → Bibliography notes — Chapter 18
Thymosin alpha-1 is a different molecule entirely
28 amino acids, derived from prothymosin alpha, immunomodulatory. The shared word "thymosin" is a historical accident of isolation, not a family resemblance that predicts anything. → Chapter 18 — Key Takeaways
Thymosin alpha-1 regulatory status
§18.3, Case Study 18.1. Approved in a number of countries, notably for hepatitis B and as an immune adjuvant in some jurisdictions; not FDA-approved in the United States. Deliberately phrased without a country count. Checkable via national regulatory registers. → Bibliography notes — Chapter 18
A 43-amino-acid endogenous human peptide, present in essentially all human cell types and in extracellular fluid. Binds G-actin and buffers the cellular pool available for actin polymerization, thereby participating in cell motility and tissue repair. Subject of a substantial animal repair literatur → Glossary contributions — Chapter 18
Thymosin β4 preclinical repair literature
§18.1, §18.2. Described as spanning dermal wound healing, cardiac repair after injury, and corneal healing; conducted by academic laboratories; published in peer-reviewed journals; sustained over time. **No count given, deliberately** (§18.2's publication-filtering argument makes any count unverifia → Bibliography notes — Chapter 18
thyroid C cells
the same cells at the center of Chapter 8's rodent tumor discussion, a coincidence worth noticing. Its classical role is to lower blood calcium, largely by inhibiting osteoclasts. In the standard endocrine diagram it is parathyroid hormone's opposite number: PTH raises calcium, calcitonin lowers it. → Chapter 29: The Peptide Drugs Already in Your Pharmacy
Tier 1
Evans, I., Thornton, H., Chalmers, I., and McPherson, K. *Testing Treatments: Better Research for Better Healthcare.* Pinter & Martin. Freely available online via the James Lind Library. - Goldacre, B. *Bad Science.* Fourth Estate, 2008. - Goldacre, B. *Bad Pharma: How Drug Companies Mislead Doctors → Bibliography — Chapter 37
Tier 2
Guyatt, G., Rennie, D., Meade, M. O., and Cook, D. J., eds. *Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice.* American Medical Association / McGraw Hill. - Guyatt, G. H., et al. The GRADE methodology series. *Journal of Clinical Epidemiology*, from 2011. (Mult → Bibliography — Chapter 37
Tier 3
PubMed (U.S. National Library of Medicine). Database, cited as a resource. - World Anti-Doping Agency, *Prohibited List*, category S0. Cited for its structure; the substantive discussion is Chapter 38's. - United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) monographs. Cited as do → Bibliography — Chapter 37
Tight junction
The protein complex sealing the space between adjacent epithelial cells; a major determinant of what passes between the gut lumen and the bloodstream. The proposed target of larazotide. [ch18 §18.5] → Glossary contributions — Chapter 18
both on the drug side, the second with two residues to spare. When exclusivity ends, the route open to competitors is the generic route, not the biosimilar route. → Appendix G — Regulatory and Legal Quick Reference
Tirzepatide is a unimolecular dual agonist
39 amino acids, ~4,800 Da, activating both the **GIP** and **GLP-1** receptors with a ratio fixed by its structure. Its sequence is based on **GIP**, not GLP-1. → Chapter 9 — Key Takeaways
Titration
stepwise increase of a dose over time, usually to allow tolerance to side effects to develop before reaching the target dose. (Ch.4) → Glossary fragments — Chapter 4
Banting, Best, Macleod, and Collip — who took a pancreatic extract from an idea to a dying child in under two years, and then sold the patent for a dollar. Every peptide drug that followed is standing on that. Chapter 11 tries to do it justice. → Acknowledgments
Sustained, non-pulsatile receptor stimulation. For some axes it produces a categorically different result from pulsatile stimulation, up to and including suppression. (Ch.15) → Ch15
Topline results
a sponsor-selected summary of headline numbers released ahead of full data, without the tables that would let a reader check them. Frequently accurate, never sufficient, and not a publication. → Chapter 36 — Glossary Contributions
Toroidal pore model
A mechanism in which lipid headgroups bend inward with the inserting peptides, so the pore is lined by both peptide and lipid. *(25.3)* → Glossary contributions — Chapter 25
toxicity
membrane-disrupting mechanisms are often insufficiently selective between bacterial and human membranes; **stability** — peptides are degraded by the proteases that exist to degrade peptides; and **manufacturing cost** — producing peptides at the scale and price point antibiotics require is a genuin → Appendix H — Twenty Worked Evidence Evaluations
Track material
💊 GLP-1: §36.3–§36.6, with §36.6 read twice. 🏋️ Performance: §36.6, and note this is the one place in the book where a muscle question is genuinely open rather than settled against the marketing. 🔬 Science: straight through. 💄 Cosmetic: a light chapter, but §36.2 applies unmodified to ingredient cla → Chapter 36 — Instructor Notes
Tracking parameter
an identifier appended to a link that attributes a resulting action to a specific creator. The mechanism by which affiliate payment is calculated, and often the only visible sign that an arrangement exists. → Chapter 42: The Creator Economy and the Peptide Pipeline
an experimental injury created by surgically cutting a structure such as a tendon, ligament, or nerve; acute, complete, standardized, with a known time zero, and therefore structurally unlike most human overuse injuries. (Ch.17) → Glossary fragments — Chapter 17
What survives after the specific content of the book is forgotten: the reflex of asking of any claim *for whom, measured how, compared to what, and how would we know if it were false.* *(Ch 40 §40.8, Conclusion; Appendix C.7.)* → Glossary contributions — Chapter 40
the distance between a result in a laboratory model and a result in human patients, crossed only by human trials; the reason roughly nine in ten compounds entering human trials never reach approval. (Ch.17) → Glossary fragments — Chapter 17
Trial registration
the public filing of a clinical trial's design before enrollment begins. Registered, run, completed, results-posted, and peer-reviewed publication are five distinct states, and only the last settles anything. (Ch.17) → Glossary fragments — Chapter 17
the sensory ganglion serving the face and meninges. It lies outside the blood-brain barrier, which is why peripherally administered CGRP therapies reach their target. *(Ch 22)* → Glossary contributions — Chapter 22
A chain that stopped growing at some intermediate length. Easier to separate than a deletion sequence because it differs from the product in more properties. [Ch 32 §32.3] → Glossary contributions — Chapter 32
available for extra credit, for student-led sessions, for reading over a break, and for the students who get interested and want more. **Say which is which on day one.** A survey that pretends to be comprehensive teaches students that they have seen the field, which is the one impression this book i → Syllabus — One-Semester Survey
Two Semester I set pieces worth protecting:
**Week 10's mirror session.** Chapters 8 and 17 are the same twelve fields, the same procedure, and opposite results. Teach 17 explicitly as a re-run of 8. The contrast is the course's spine and it is wasted if the two are separated by a term. - **Week 13's mechanism audit.** Students hand in field → Syllabus — Two-Semester Sequence
Two Semester II set pieces worth protecting:
**Week 21's field-12 rewrite.** Chapter 35 turns "what would change my mind" from a sentiment into a specification — *the study*, with a population, an endpoint, a comparator, a duration, and a rough size. Grading the rewrite against the week-4 original shows students exactly how much their standard → Syllabus — Two-Semester Sequence
Two structural rules:
**Criterion 3 cannot be scored Exemplary from silence.** A student may only be credited for changing their mind if the revision was visible — spoken, posted, or written in a dossier revision note. Tell students this explicitly, because otherwise the quiet revisers are penalized for discretion and th → Rubric — Participation and Discussion
Type 1 diabetes
autoimmune destruction of pancreatic beta cells producing absolute insulin deficiency; insulin therapy is required for survival. (Ch.11) → Glossary fragments — Chapter 11
Type 2 diabetes
insulin resistance accompanied by progressive beta cell dysfunction; insulin is one treatment option among several, typically later in the course. (Ch.11) → Glossary fragments — Chapter 11
A claim compatible with every possible observation, and therefore incapable of being supported by any of them. "Immune modulation," as usually stated, is this field's canonical example: it specifies no direction, no immune arm, no measurable endpoint, and no population. The correct response is a req → Glossary contributions — Chapter 18
Unimolecular dual agonist
a single molecule that activates two different receptors, with an activity ratio fixed by its structure and unchangeable without redesigning the molecule. (Ch.9) → Glossary fragments — Chapter 9
A Field 6 row assigning a symbol without naming the population and endpoint it applies to. It rates a molecule rather than a claim, which rating rule 1 forbids. The most common defect in reader dossiers, and one that clusters on the claims a reader considers settled. *(Ch 40 §40.3, Case Study 1 Defe → Glossary contributions — Chapter 40
unquantified
which is not the same as small. And risk is only ever weighed against benefit; for the performance claim, the benefit side of the ledger is empty. → Chapter 16 — Key Takeaways
untested
it could still turn out to be true. | BPC-157 (Ch 17), TB-500 (Ch 18), most of Part III | | **❌ evidence present and negative** | Adequate trials **were** run, in the right population, on a hard endpoint, and the answer was no. | Nesiritide for outcomes in acute decompensated HF (Ch 28), NT-proBNP-g → Continuity Ledger — Understanding Peptides
untreated
not placebo | | Blinding | Not blinded in the modern sense; everyone knew group assignment | | Duration | Six months | | Primary measurements | Body composition — lean body mass, adipose tissue mass — plus skin thickness and bone density measures | | Not measured | Strength, physical function, endur → Case Study 14.1 — Twelve Men: Reading Rudman 1990 as a Paper
Failure of the uterus to contract adequately after delivery, leaving placental-bed vessels uncompressed. The proximate cause of most postpartum hemorrhage. *(Ch 21 §21.2)* → Glossary contributions — Chapter 21
Uterotonic
An agent causing uterine contraction. Oxytocin is a first-line uterotonic worldwide for postpartum hemorrhage. *(Ch 21 §21.2)* → Glossary contributions — Chapter 21
V
V1
a non-adrenergic pathway that adds tone alongside norepinephrine. VASST and VANISH support an adjunct role; a general mortality benefit has not been convincingly demonstrated. - Vasopressin was used in hospitals for decades as an unapproved marketed drug and only received formal FDA approval in the → Chapter 29 Key Takeaways — The Peptide Drugs Already in Your Pharmacy
Vasopressin receptor on vascular smooth muscle and in the brain; mediates vasoconstriction and is central to the vole pair-bonding literature. A V1a antagonist was carried into large autism trials without delivering on primary endpoints. *(Ch 21 §21.8)* → Glossary contributions — Chapter 21
V1b receptor
Vasopressin receptor in the anterior pituitary; contributes to ACTH release, linking vasopressin into the stress axis. *(Ch 21 §21.8)* → Glossary contributions — Chapter 21
V2 receptor
Renal collecting-duct vasopressin receptor; drives aquaporin-2 insertion and water reabsorption. Desmopressin is V2-selective. Oxytocin engages V2 at high concentration, which is the basis of oxytocin-associated hyponatremia. *(Ch 21 §21.1, §21.8)* → Glossary contributions — Chapter 21
Vagal afferent
a sensory nerve fiber carrying information from the gut and hepatic portal region to the brain, providing a route by which a peptide's signal reaches the central nervous system without the peptide itself doing so. → Chapter 36 — Glossary Contributions
Vagus nerve
the major nerve carrying sensory information from the gut to the hindbrain; its afferent endings in the gut wall carry GLP-1 receptors. (Ch.7) → Glossary fragments — Chapter 7
valid
veterinarian-client-patient relationship
meaning the veterinarian has actually assumed responsibility for the animal, has seen it, and is available for follow-up. - The animal's health must be threatened, or suffering or death may result from failure to treat. - There must be **no approved animal drug** labeled for the intended use that is → Chapter 31: Peptides in Veterinary Medicine — Where Some "Human" Peptides Were First Used
Valid veterinarian-client-patient relationship
The condition that a veterinarian has assumed responsibility for an animal, knows it well enough to make a diagnosis, and is available for follow-up. A precondition of lawful extra-label use. *Ch 31 §31.7.* → Glossary contributions — Chapter 31
Validated instrument
A questionnaire whose measurement properties (internal consistency, test-retest reliability, correlation with clinician assessment) have been formally established, used as a trial endpoint where no objective measure exists. — Ch 24 §24.4 → Glossary contributions — Chapter 24
validated instruments
a desire domain score and a distress measure specifically concerning low desire. On both, the bremelanotide groups improved more than placebo, and the differences reached statistical significance. The differences were also small in absolute terms: fractions of a point on scales spanning several poin → Chapter 24: PT-141 (Bremelanotide) and the Sexual Function Peptides
values question
A claim whose load-bearing terms encode a judgment about what ought to be valued rather than a measurable state of the world. Words like *should*, *owes*, and *primarily* are the usual markers. Three of the four NOT RATED entries are values questions. *(New in Ch 37 §37.4; compare Ch 41, Ch 43, Ch 4 → Glossary contributions — Chapter 37
values questions
in the last, the load-bearing word is **"primarily,"** which encodes a judgment about how a society allocates attention between two approaches that are not mutually exclusive. The Ch 44 stigma claim is declined for a different reason: its outcome is genuinely not forecastable directionally, and rati → Continuity Ledger — Understanding Peptides
Vancomycin
a glycopeptide antibiotic, a mainstay against methicillin-resistant *Staphylococcus aureus*; given intravenously for systemic infection and orally, without absorption, for *Clostridioides difficile*. (Ch 25, expanded Ch 29) → Glossary contributions — Chapter 29
Vancomycin is a glycopeptide antibiotic
a heavily modified, cross-linked peptide core with sugars attached. In clinical use since the 1950s, a mainstay against methicillin-resistant *Staphylococcus aureus*, and on the World Health Organization's Model List of Essential Medicines. It is given intravenously for systemic infection precisely → Chapter 29: The Peptide Drugs Already in Your Pharmacy
VANISH
vasopressin versus norepinephrine as initial vasopressor in septic shock. `[VERIFY — full citation and primary endpoint result.]` → Bibliography working notes — Chapter 29
A nonapeptide hormone; the body's principal water-conservation signal, also called antidiuretic hormone. Acts at V1a, V1b, and V2 receptors. Differs from oxytocin at positions 3 and 8. *(Ch 21 §21.1, §21.8)* → Glossary contributions — Chapter 21
Vasopressin in vasodilatory/septic shock
critical care guidelines and the major trial literature. - **The V1a antagonist clinical development program in autism.** The chapter says the program did not deliver on primary endpoints; cite the primary trial reports. Do not add numbers. → Bibliography notes — Chapter 21
Vasopressor
a drug that raises blood pressure by increasing vascular tone. Vasopressin is a peptide vasopressor acting through a non-adrenergic pathway. (Ch 29) → Glossary contributions — Chapter 29
a peptide component of an animal venom: typically short, often stabilized by multiple disulfide bonds, and usually selective for a specific ion channel or receptor. *(Ch 35)* → Glossary contributions — Chapter 35
verdict-to-question conversion
**(reprise)** Rewriting a Field 11 verdict as a question a clinician could answer. Operational test: is the answer in the room? A verdict that resists conversion was probably a feeling. *(Introduced Ch 39; audited Ch 40 §40.7.)* → Glossary contributions — Chapter 40
Vericiguat
a small-molecule stimulator of soluble guanylate cyclase, approved for heart failure with reduced ejection fraction following a recent worsening event. Not a peptide. [Ch 28] → Glossary contributions — Chapter 28
no chain of custody, no assay (Ch 34) - **Make an unapproved compound safe by supervising it** — supervision adds monitoring, interaction checking, and a response pathway, and adds *no evidence* - **Generate the missing trial** - **Tell you what will happen to you individually** — only what happened → Chapter 39 — Key Takeaways
version history
A series of dated snapshots of a dossier. Its value is the trajectory rather than the old content: it reveals the direction of past errors, which a single snapshot cannot. *(Ch 40 §40.5.)* → Glossary contributions — Chapter 40
Vertical integration
the combination of advertising, prescribing, and dispensing within a single commercial entity, which removes the checks that arose from three parties having different interests. → Chapter 42: The Creator Economy and the Peptide Pipeline
Very welcome:
**Corrections with a source.** A trial result we got wrong, a regulatory status that has changed, a molecule we described inaccurately. Include what the correct statement is and how you know. - **Evidence updates.** Trials read out and approvals happen. A chapter that says "as of this writing, no co → Contributing to Understanding Peptides
Veterinary pharmacopeia
The body of drugs approved and used in veterinary medicine, including a substantial set of peptide medicines with labeled species and indications. *Ch 31 §31.1.* → Glossary contributions — Chapter 31
Veterinary/equine use
§18.1, Dossier. Real and documented; **owned by Ch. 31.** Chapter 18 flags it and hands off in the same sentence. Coordinate before expanding. → Bibliography notes — Chapter 18
Vial A
a pharmaceutical product dispensed by a licensed pharmacy. - **Vial B** — genuine research-grade material, honestly labeled, accompanied by a real certificate, and never released or intended for human use. - **Vial C** — an online vendor's product of unverifiable provenance. - **Vial D** — mislabele → Chapter 34: Peptide Analysis and Quality Control — How Anyone Knows What's Actually in the Vial
Visceral adipose tissue
Fat stored around the abdominal organs, distinct from subcutaneous fat and more strongly associated with metabolic and cardiovascular risk. The endpoint of tesamorelin's approved indication. (Ch.15) → Ch15
Volume transmission
diffusion of a released signaling molecule beyond its synapse onto cells that were never postsynaptic to it. Possible for neuropeptides because they have no reuptake transporters. *(Ch 22)* → Glossary contributions — Chapter 22
Vosoritide
a CNP analog engineered for a usable half-life, approved for achondroplasia on an endpoint of annualized growth velocity. [Ch 28] → Glossary contributions — Chapter 28
the category for substances not approved for human therapeutic use by any government health authority — effective from the **2022** List. This is worth stating precisely because it is so often deployed as an argument. It is a **regulatory fact entirely independent of the evidence rating.** S0 is not → Appendix H — Twenty Worked Evidence Evaluations
Wall stress
the mechanical tension in the heart muscle wall, rising with chamber pressure and chamber radius. The physiological stimulus for natriuretic peptide release. [Ch 28] → Glossary contributions — Chapter 28
Washout period
a mandated interval between stopping one drug and starting another, imposed where overlapping pharmacology creates risk. Required when switching between an ACE inhibitor and an ARNI, because of compounded bradykinin accumulation. [Ch 28] → Glossary contributions — Chapter 28
Week 11 (29, 30)
move both to optional. Cosmetic peptides survive well as a single 📊 rating exercise using Appendix A; the pharmacy chapter survives as an Appendix E handout. 2. **Chapter 24** — cut from week 10, leaving 21 alone. Keep 21; oxytocin is where the mechanism-vs-outcome lesson is most vivid for a general → Syllabus — One-Semester Survey
Week 17 (27, 28)
compress to a single session using the 📊 callouts and Appendix A rows. 2. **Week 26 (41, 42)** — compress to one session. Keep 43 and 44; the enhancement and society chapters carry the argument that Part VIII exists to make. 3. **Week 19 (31, 32)** — move Chapter 31 to optional reading and teach 32 → Syllabus — Two-Semester Sequence
well-specified open question
A statement of what is not known, precise enough to name the population, endpoint, comparator, and duration that would resolve it. The honest final position for most compounds readers arrive with, and a result rather than a failure, because it can be checked against a future publication while a vagu → Glossary contributions — Chapter 40
what is conspicuously absent
and in field 4, the delivery constraint. c) Field 2, since natural origin supports the claim. d) Nothing; the class is not worth tracking. → Final Exam — Cumulative
What is still not established
worth saying, so the answer does not overcorrect: long-term safety, performance outside the enrolled population, effect size relative to cost and burden, and anything about subgroups the trial was not powered to resolve. → Chapter 36 — Worked Answers
What it does not:
**Which mass convention was used.** Monoisotopic or average? For a peptide of this size the two differ by roughly a dalton, which is more than the difference between some substitutions (§34.2's 🧬 callout). The document does not say. - **What the expected value was.** "Conforms" is a conclusion. The → Case Study 34.1 — Reading a Certificate of Analysis, Line by Line
what lean mass
contains
fluid, connective tissue, organ mass, glycogen and its water — so the scan is not measuring contractile muscle in the first place. Second, **the inferential chain** — mass to strength to mobility to falls to independence, each link an assumption. The best students also reach the wrinkle: an agent ac → Chapter 36 — Instructor Notes
What this does not settle:
**Population.** Trial populations skew younger and healthier than the people most vulnerable to lean mass loss. In an older adult with low baseline muscle, the arithmetic could easily run the other way. - **Duration.** Function measured over 68 weeks says little about function after ten years of con → Answers — Chapter 8
what you wrote in field 12 in week three
specifically, whether the finding you named as the thing that would move it has actually occurred. Not against the latest headline. You are guarding against **rating drift**: the upgrade may have been driven by an information stream selected for good news rather than by the readout you specified. Fu → Final Exam — Cumulative
not "the immune system" 2. **Measured how** — a named assay with a known reference range 3. **In which direction** — stated in advance; not "modulate," "balance," or "optimize" 4. **In what population** — healthy adults, chronic infection, post-transplant, and autoimmune have opposite therapeutic go → Chapter 18 — Key Takeaways
Which locates the cause.
> **⚠️ Hype Check — the two bad versions of this story** > > **Version one: "greedy pharmaceutical companies are killing diabetics."** > Emotionally satisfying and analytically weak. It cannot explain why the same companies' products cost > far less in other countries, which is the fact that most ne → Case Study 2 — Rationing
Which of the three questions does this answer
identity, purity, or content? 2. **Percent of what, measured how, seen by which detector?** 3. **What is this a claim about — a sample, or the object in front of me?** → Chapter 34 — Key Takeaways
while present
but not to reset the set point, which is why weight > returns on stopping. > > **Two honest caveats:** this explanation is partly retrospective — it fits what happened without > having predicted it — and it does not explain the *magnitude* of the drug effect. → Chapter 13 — Key Takeaways
current edition, for oxytocin's inclusion. Also covers carbetocin (heat-stable formulation). - **Major obstetric society guidance on labor induction/augmentation and on the management of postpartum hemorrhage.** Use these for the ✅ rating's evidentiary basis. Prefer guidance documents over individua → Bibliography notes — Chapter 21
the standard reference. The chapters on anterior pituitary physiology, growth hormone and IGF-1 action, growth hormone deficiency in children and adults, and acromegaly cover essentially everything in this chapter at greater depth and with full citation. If you read one thing from Tier 1 at length, → Chapter 14 — Further Reading
Winner's curse (in study reporting)
The systematic inflation of published effect sizes that occurs when small studies of small true effects only clear significance when noise happens to favor the hypothesis. *(Ch 21 §21.4)* → Glossary contributions — Chapter 21
Withdrawal period
The interval that must elapse after treating a food-producing animal before its meat, milk, or eggs may enter the human food supply. Derived from residue depletion data against an established tolerance. Has no analogue in human medicine. *Ch 31 §31.7.* → Glossary contributions — Chapter 31
without
degrading receptor binding
a clause that deserves to be read as a piece of luck as much as a piece of skill. Position 8 happened to be a position the enzyme needed and the receptor did not care much about. That is not the usual situation. The usual situation is the one at the end of §33.1, where enzyme and receptor recognitio → Chapter 33: Peptide Engineering — How Scientists Modify Peptides to Make Better Drugs
without diabetes
canon wording used exactly - **STEP 2**: ~−10% at 68 weeks in adults **with** type 2 diabetes — used in the population-swap warning - **SELECT**: 20% relative MACE reduction, HR ~0.80, ~8% → ~6.5% absolute over ~3 years, ~1.5 percentage points, ~17,000 participants — **both relative and absolute sta → Continuity notes — Chapter 5
the organization that publishes the Prohibited List adopted by anti-doping organizations and sporting federations (Ch. 38). → Chapter 38 — Glossary fragment
worse
a problem caused by liars can be solved by catching liars, while a problem caused by aligned incentives and format constraints cannot. Push on what that implies about solutions: if nobody is doing anything wrong, what exactly do you regulate? → Instructor material — Chapter 6
The structural defect by which a payer in a market with membership churn funds prevention whose payoff will accrue to a competitor, and therefore systematically underfunds it. (Ch.12) → Ch12
Y
Y receptor
the GPCR family (Y1, Y2, Y4, Y5 in humans) through which NPY, peptide YY, and pancreatic polypeptide act. Y1 and Y5 are associated with feeding; Y2 is largely a presynaptic autoreceptor reducing NPY release. Different subtypes produce opposing effects on appetite. *(Ch 22; connects to Ch 13)* → Glossary contributions — Chapter 22
current good manufacturing practice | | Federal inspection | Limited | Yes | | Distribution | To the identified patient | May distribute to healthcare facilities | | **Premarket review of safety or efficacy** | **NO** | **NO** | → Appendix G — Regulatory and Legal Quick Reference
**The adjuvant is not an optional additive — for peptide vaccines it is frequently the entire difference between a response and nothing**, and adjuvant choice determines what *kind* of response you get. - Location beats dose: the response is made in the draining lymph node. And a persistent depot ca → Chapter 26 — Key Takeaways
a synthetic 25-residue peptide equivalent to a cone snail venom peptide, held by three disulfide bonds. Blocks N-type voltage-gated calcium channels; **not** an opioid. Approved for severe chronic pain where other therapies are inadequate, and administrable only intrathecally. — Ch 20 §20.9 → Glossary contributions — Chapter 20
Ziconotide / ω-conotoxin MVIIA
Characterization of ω-conotoxin MVIIA from *Conus magus*; N-type voltage-gated calcium channel blockade. - Ziconotide prescribing information and clinical literature. Supports: §35.4 intrathecal route, approved indication in severe chronic pain, therapeutic window, adverse effect profile. - **Chapte → Bibliography notes — Chapter 35
Zwitterionic
Carrying both a positive and a negative charge and therefore net neutral. Describes the phospholipids dominating the outer leaflet of mammalian plasma membranes. *(25.5)* → Glossary contributions — Chapter 25
a 31-residue endogenous opioid peptide derived from proopiomelanocortin, with high affinity for mu and delta receptors. The molecule popularly, and usually incorrectly, invoked as "endorphins." — Ch 20 §20.1 → Glossary contributions — Chapter 20
Ω
ω-Conotoxin MVIIA
the conotoxin from *Conus magus* that blocks N-type voltage-gated calcium channels; the natural counterpart of ziconotide. *(Ch 35)* → Glossary contributions — Chapter 35